Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors

ABSTRACT

The present invention provides methods for inhibiting Fyn kinase, using 5-3-pyridin-2-amine, 6-3-imidazo[1,2-a] pyrazine, 6-3-imidazo[1,2-b] pyridazine, N-(5-imidazo [2,1-b][1,3,4] thiadiazol-2-yl)-amine, 4-3-1H-pyrazolo[3,4-b] pyridine, and N-(3-imidazo [1,2-b] pyridazin-6-yl) amine compounds and methods of treatment, prevention, inhibition or amelioration of diseases and conditions associated with Fyn kinase using such compounds.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Patent Application No. 62/216,349 filed Sep. 9, 2015, the contents of which are incorporated herein in their entirety.

FIELD OF THE INVENTION

The present invention relates to methods for inhibiting, regulating or modulating the activity of Fyn kinase, using compounds or pharmaceutical compositions containing such compounds and methods of treatment using the compounds or compositions to treat diabetes, pre-diabetes, metabolic conditions, immune disorders, cancer and neurodegenerative disorders such as Multiple Sclerosis, Alzheimer's and Parkinson's disease.

BACKGROUND OF THE INVENTION

Fyn kinase, a cytoplasmic Src family tyrosine kinase, plays an important role in many physiologic processes and is ubiquitous in human cells. Fyn kinase is primarily found on the cytoplasmic face of the plasma membrane where it phosphorylates tyrosine residues of a number of different enzymes involved in the signaling pathways associated with various cell-surface receptors. Fyn kinase is involved in cellular development, apoptosis, and homeostatic regulation, as well as in the development of many different kinds of pathologies. Fyn kinase represents an attractive target for drug therapies designed to control cellular metabolism for management of diabetes, pre-diabetes and general weight loss applications, as an anti-cancer therapeutic and as potential target for the control or prevention of Multiple Sclerosis, Alzheimer's and Parkinson's disease.

Fyn knockout mice exhibit increased lipid utilization and increased energy expenditure. Wild-type mice treated with the highly selective Src family kinase inhibitor SU6656, exhibit similar increases in lipid utilization and energy utilization, whereas the Fyn knockout strains show no increase in either parameter upon treatment with SU6656 (WO 2011/119199). Both the Fyn knockout and SU6656 treated mice have significantly reduced fat mass relative to untreated or genetically matched Fyn-competent control mice. Treatment with SU6656 appears to reduce adiposity and promote weight loss, likely through a Fyn-kinase-dependent mechanism.

Fyn kinases ability to regulate fatty acid oxidation and increase energy expenditure is thought to result from its affect on sequestration of LKB1 to the nucleus of skeletal muscle cells. Fyn kinase phosphorylates LKB1 present in the cytoplasm of such cells and the phosphorylated LKB1 is preferentially localized to the nucleus where it has little or no access to AMPK, which is found almost exclusively in the cytoplasm. Thus, LKB1 phosphorylated by Fyn kinase cannot activate AMPK (AMP-dependent protein kinase). Activated AMPK serves as a cellular energy sensor directly regulated by alterations in the intracellular AMP/ATP ratio that occurs during prolonged fasting and re-feeding. At high AMP/ATP ratios activation of AMPK results in phosphorylation and inhibition of Acetyl CoA Carboxylase, thereby increasing fatty acid oxidation and decreasing fatty acid biosynthesis. Specific inhibition of Fyn kinase allows LKB1 to constitutively activate AMPK. In this model inhibition of Fyn kinase results in increased cytoplasmic localization of LKB1, resulting in increased levels of activated AMPK.

AMPK also regulates glucose metabolism in liver. Hepatic glucose production that is not regulated by insulin is known to play an important role in development of Type 2 diabetes. The asymptomatic insulin resistance phase of Type 2 diabetes is generally followed by defects in insulin secretion that result in severe hyperglycemia if left untreated. Chronic high glucose levels have been shown to result in the death of pancreatic β-cells and loss of insulin production altogether. Activated AMPK reduces insulin secretion and is thought to have a pro-apoptotic effect on pancreatic β-cells.

Like many Src family kinases, Fyn plays a role in regulating several physiological processes including cellular growth, proliferation, morphogenesis and motility. Fyn has also been recognized as a potential oncogene and has been shown to be capable of inducing the fully tumorigenic phenotype. Fyn interacts with a number of cancer related pathways. Fyn is a mediator of growth-factor induced anti-apoptotic activity of Akt/PKB, and regulates Rac and Rho GTPases and activates the ERK/MAPK pathways. Fyn also plays a key role in the regulation of matrix formation and degradation, which is important for matrix remodeling and cellular adherence.

In addition to metabolic and oncogenic regulation, Fyn is recognized as playing a key role in T-cell development as well as dendritic maturation of cells within the central nervous system. Further, inhibition of Fyn kinase is viewed as an attractive therapeutic target for treatment of Multiple Sclerosis, Alzheimer's and Parkinson's disease. It is the object of this disclosure to describe pharmaceutically effective inhibitors of Fyn kinase with enhanced specificity for therapeutic treatment of one or more of the pathologies in which Fyn kinase plays a role.

Structurally, Fyn kinase is relatively well characterized despite the lack of a complete high-resolution structure. The enzyme comprises 537 amino acids in a single polypeptide chain organized into 4 domains, with a molecular weight of 59 kilodaltons. The N-terminal membrane anchoring domain (SH4) possesses myristylated or palmitylated residues essential for proper enzyme trafficking and localization to the cytoplasmic membrane, immediately adjacent to this are the SH3 and SH2 domains, which play critical roles in the interaction of Fyn kinase with its protein targets, followed by a flexible linker connecting the C-terminal tyrosine kinase domain (SH1). Although a complete high-resolution structure of the entire Fyn kinase protein is not available, such structures are available for each of the SH2, 3 and 4 domains, individually.

The SH2 domain of Fyn kinase binds phosphotyrosine-containing sequences and functions as a target recognition domain. The SH3 domain promiscuously complexes with polyproline peptides and plays a role in mediating protein-protein interactions between Fyn kinase and other polypeptides. Interaction between the SH3 and SH2 domains enhances the specificity of ligand binding and regulates the activity of the kinase (SH4) domain.

The well conserved SH4 domain contains two potential inhibitor binding sites, the first, sensitive to non-specific competitive inhibitors of ATP such as staurosporine, represents the actual ATP binding site of the kinase domain, whereas the second site, immediately adjacent to the ATP binding pocket, is oriented towards the SH2 domain. This second site may be occupied in such a way that ATP binding at the first site is not directly blocked. However, free access to the second site is blocked by the presence of ATP at the first site, and hence, inhibitors targeted to the second site display pseudo-competitive kinetics with respect to the availability of ATP. Although the ATP binding site is highly conserved among Src kinases, the amino acids comprising the hydrophobic pocket typical of the second site are less conserved and may represent the best target for Fyn-specific inhibitors. Regardless, the SH1 domain is essential for the activity of Fyn kinase on any of its protein targets, and has been targeted for the development of potent Fyn kinase inhibitors.

Existing Fyn kinase inhibitors all suffer from a lack of specificity and although many Fyn kinase inhibitors have been isolated, most significantly cross-react with other Src family enzymes. Some of the best known Fyn kinase inhibitors include: phenolic compounds such as rosmarinic acid, (−)-epigallocatechin gallate and myricetin; the pyrazolol[3,4-d]pyrimidines PP1, PP2, and various derivatives thereof; as well as other fused pyrimidine compounds such as benzyl 21-methoxy-5,7,19-trioxa-2,13,24,26-tetraazapentacyclo [18.6.2.0³,¹¹.0⁴,⁸.0²³,²⁷]octacosa-1(26),3(11),4(8),9,20,22,24,27-octaene-13-carboxylate (Janssen Pharmaceuticals, U.S. Pat. No. 8,492,377) and CT5263 and CT5102 (CellTech). The structure of a few of these compounds and their associated IC50 (when known) and log P values are presented in Table 1.

TABLE 1 Known Fyn kinase inhibitors. IC50 logP FYN (con- Common Structure IUPAC name (μM) sensus) name

(2R)-3-(3,4-dihydroxy- phenyl)-2-{[(2E)-3-(3,4- dihydroxyphenyl)prop- 2-enoyl]oxy} propanoic acid 1.3   3.00 rosmarinic acid

(2R,3R)-5,7-dihydroxy- 2-(3,4,5-trihydroxy- phenyl)-3,4-dihydro-2H- 1-benzopyran-3-yl 3,4,5-trihydroxy- benzoate unknown 3.08 (−)-epigallo- catechin gallate

5,7-dihydroxy-2-(3,4,5- trihydroxyphenyl)-4H- chromen-4-one unknown 0.65 myricetin

1-tert-butyl-3-(4- methylphenyl)-1H- pyrazolo[3,4-d] pyrimidin-4-amine 0.006  3.23 PP1 (Pfizer)

1-tert-butyl-3-(4- chlorophenyl)-1H- pyrazolo[3,4-d] pyrimidin-4-amine 0.006  3.32 PP2 (Pfizer)

N-(4-{4-amino-1- [(1r,4r)-4-(4-methyl- piperazin-1-yl)cyclo- hexyl]-1H-pyrazolo [3,4-d]pyrimidin-3- yl}-2-methoxy- phenyl)-1-methyl-1H- indole-2-carboxamide 0.330  3.81 A-420983 (Abbott)

benzyl- 21-methoxy-5,7,19- trioxa-2,13,24,26- tetraazapenta- cyclo[18.6.2.0³, ¹¹.0⁴,⁸.0²³,² ⁷ ]octacosa- 1(26),3(11),4(8),9, 20,22,24,27-octaene- 13-carboxylate 0.00669 5.13 Compound B50 (U.S. Pat. No. 8,492,377) (Janssen Pharma- ceuticals)

9-methoxy-N-{3- methoxy-4-[3- (pyrrolidin-1-yl)propyl] phenyl}-6,6-dimethyl- 5H,6H-benzo[h] quinazolin-2-amine 0.008  6.12 CT5263 (CellTech)

N-{4-[2-(dimethyl- amino)ethoxy]- 3,5-dimethyl phenyl}-9-methoxy- 5H,6H-benzo[h] quinazolin-2-amine 0.008  5.49 CT5102 (CellTech)

SUMMARY OF THE INVENTION

Among its many embodiments, the present invention comprises methods for inhibiting Fyn kinase using 5-[R2]-3-[R1] pyridin-2-amine compounds or pharmaceutical compositions comprising such compounds and methods of treatment, prevention, inhibition or amelioration of one or more of the diseases or conditions associated with Fyn kinase.

In one aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being 5-[R2]-3-[R1] pyridin-2-amine, wherein R1 and R2 are each individually selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate.

In another aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being one of the 5-[R2]-3-[R1] pyridin-2-amine derivatives of Tables 3 and 4.

In another aspect, the present invention provides a method of treating, or slowing progression of a disease associated with Fyn kinase, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being at least one of the 5-[R2]-3-[R1] pyridin-2-amines described above, or a pharmaceutically acceptable salt or solvate thereof.

In another embodiment, the present invention comprises methods for inhibiting Fyn kinase using 6-[R2]-3-[R1] imidazo[1,2-a] pyrazine compounds or pharmaceutical compositions comprising such compounds and methods of treatment, prevention, inhibition or amelioration of one or more of the diseases or conditions associated with Fyn kinase.

In one aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being 6-[R2]-3-[R1] imidazo[1,2-a] pyrazine, wherein R1 and R2 are each individually selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate.

In another aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being one of the 6-[R2]-3-[R1] imidazo[1,2-a]pyrazine derivatives of Tables 3 and 4.

In another aspect, the present invention provides a method of treating, or slowing progression of a disease associated with Fyn kinase, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being at least one of the 6-[R2]-3-[R1] imidazo[1,2-a] pyridines described above, or a pharmaceutically acceptable salt or solvate thereof.

In another embodiment, the present invention comprises methods for inhibiting Fyn kinase using 6-[R2]-3-[R1] imidazo[1,2-b] pyridazine compounds or pharmaceutical compositions comprising such compounds and methods of treatment, prevention, inhibition or amelioration of one or more of the diseases or conditions associated with Fyn kinase.

In one aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being 6-[R2]-3-[R1] imidazo [1,2-b] pyridazine, wherein R1 and R2 are each individually selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate.

In another aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being one of the 6-[R2]-3-[R1] imidazo [1,2-b]pyridazine derivatives of Tables 3 and 4.

In another aspect, the present invention provides a method of treating, or slowing progression of a disease associated with Fyn kinase, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being at least one of the 6-[R2]-3-[R1] imidazo [1,2-b] pyridoxines described above, or a pharmaceutically acceptable salt or solvate thereof.

In another embodiments, the present invention comprises methods for inhibiting Fyn kinase using N-(5-[R2] imidazo [2,1-b][1,3,4] thiadiazol-2-yl)[R1]-amine compounds or pharmaceutical compositions comprising such compounds and methods of treatment, prevention, inhibition or amelioration of one or more of the diseases or conditions associated with Fyn kinase.

In one aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being N-(5-[R2]imidazo[2,1-b][1,3,4] thiadiazol-2-yl)[R1]-amine, wherein R1 and R2 are each individually selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate.

In another aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being one of the N-(5-[R2]imidazo[2,1-b][1,3,4]thiadiazol-2-yl)[R1]-amine derivatives of Tables 3 and 4.

In another aspect, the present invention provides a method of treating, or slowing progression of a disease associated with Fyn kinase, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being at least one of the N-(5-[R2] imidazo [2,1-b][1,3,4] thiadiazol-2-yl) [R1]-amines described above, or a pharmaceutically acceptable salt or solvate thereof.

In another embodiment, the present invention comprises methods for inhibiting Fyn kinase using 4-[R2]-3-[R1]-1H-pyrazolo[3,4-b] pyridine compounds or pharmaceutical compositions comprising such compounds and methods of treatment, prevention, inhibition or amelioration of one or more of the diseases or conditions associated with Fyn kinase.

In one aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being 4-[R2]-3-[R1]-1H-pyrazolo[3,4-b] pyridine, wherein R1 and R2 are each individually selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate.

In another aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being one of the 4-[R2]-3-[R1]-1H-pyrazolo[3,4-b]pyridine derivatives of Tables 3 and 4.

In another aspect, the present invention provides a method of treating, or slowing progression of a disease associated with Fyn kinase, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being at least one of the 4-[R2]-3-[R1]-1H-pyrazolo[3,4-b] pyridines described above, or a pharmaceutically acceptable salt or solvate thereof.

In another embodiment, the present invention comprises methods for inhibiting Fyn kinase using N-(3-[R2] imidazo [1,2-b] pyridazin-6-yl) [R1] amine compounds or pharmaceutical compositions comprising such compounds and methods of treatment, prevention, inhibition or amelioration of one or more of the diseases or conditions associated with Fyn kinase.

In one aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being N-(3-[R2] imidazo [1,2-b] pyridazin-6-yl) [R1] amine, wherein R1 and R2 are each individually selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate.

In another aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being one of the N-(3-[R2] imidazo [1,2-b] pyridazin-6-yl) [R1] amine derivatives of Tables 3 and 4.

In another aspect, the present invention provides a method of treating, or slowing progression of a disease associated with Fyn kinase, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being at least one of the N-(3-[R2] imidazo [1,2-b] pyridazin-6-yl) [R1] amine described above, or a pharmaceutically acceptable salt or solvate thereof.

In another aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound selected from the group consisting of N-[3-[6-(2-furylmethylamino)pyrazin-2-yl]phenyl]acetamide, 4-[6-[1-(hydroxymethyl)propylamino]pyrazin-2-yl]phenol, 2-[[6-(5-isopropyl-2-methoxy-phenyl)pyrazin-2-yl]amino]butan-1-ol, 6-(3-aminophenyl)-N-benzyl-pyrazin-2-amine, 2-[[6-(4-aminophenyl)pyrazin-2-yl]amino]butan-1-ol, N-[3-(dimethylamino)propyl]-3-[6-(4-methoxyphenyl)pyrazin-2-yl]benzamide, 2-methoxy-4-[6-(4-methoxyphenyl)pyrazin-2-yl]phenol, N-[3-[6-(4-methoxyphenyl)pyrazin-2-yl]phenyl]acetamide, N-[3-[6-(3-hydroxyphenyl)pyrazin-2-yl]phenyl]acetamide, 3-[5-(3-furylmethylamino)-3-pyridyl]phenol, N-[3-[5-(3,4,5-trimethoxyanilino)-3-pyridyl]phenyl]acetamide, 3-[(3-methoxyphenyl)methyl]-5-(3,4,5-trimethoxyphenyl)-1H-imidazo[4,5-b]pyrazin-2-one, N,N-dimethyl-3-[2-oxo-3-[(1 S)-1-phenylethyl]-1H-imidazo[4,5-b]pyrazin-5-yl]benzamide, 5-[3-(dimethylamino)phenyl]-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine, 3-[5-[(6-methoxy-3-pyridyl)amino]pyrazolo [1,5-a]pyrimidin-3-yl]phenol, 3-(3-methoxyphenyl)-N-(6-methoxy-3-pyridyl)pyrazolo[1,5-a]pyrimidin-5-amine, 1-[3-[5-[(6-methoxy-3-pyridyl)amino]pyrazolo[1,5-a]pyrimidin-3-yl]phenyl]ethanone, N-[5-[[3-(3-hydroxyphenyl)pyrazolo [1,5-a]pyrimidin-5-yl]amino]-2-methyl-phenyl]methanesulfonamide, 3-(3,4-dimethoxyphenyl)-N-(3-pyridylmethyl)pyrazolo[1,5-a]pyrimidin-5-amine, N-(3-pyridylmethyl)-3-(3,4,5-trimethoxyphenyl)pyrazolo [1,5-a]pyrimidin-5-amine, N-(4-isopropylphenyl)-3-(4-methoxyphenyl)pyrazolo [1,5-a]pyrimidin-5-amine, 3-(5-methoxy-3-pyridyl)-N-(4-morpholinophenyl)pyrazolo[1,5-a]pyrimidin-5-amine, 3-(3-aminophenyl)-N-(3-pyridylmethyl)pyrazolo[1,5-a]pyrimidin-5-amine, 3-(2-methoxyphenyl)-N-(3-pyridylmethyl)pyrazolo [1,5-a]pyrimidin-5-amine, (E)-3-[3-[5-(3-pyridylmethylamnino)pyrazolo [1,5-a]pyrimidin-3-yl]phenyl]prop-2-enoic acid, N-[3-(dimethylamino)propyl]-4-[6-(2-fluoro-3-methoxy-phenyl)-1H-pyrazolo [3,4-b]pyridin-3-yl]benzamide, 6-(1H-indol-5-yl)-N-methyl-pyrazin-2-amine, N-ethyl-2-(3,4,5-trimethoxyanilino)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxamide, 6-propyl-N-(3,4,5-trimethoxyphenyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-2-amine, [2-[3-(dimethylamino)anilino]-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl]-(2-methoxyphenyl)methanone, N-[3-(4-fluorophenyl)-6-[4-(morpholine-4-carbonyl)phenyl]imidazo[1,2-a]pyridin-8-yl]formamide, N-[3-(3-acetylphenyl)-6-[4-(morpholine-4-carbonyl)phenyl]imidazo[1,2-a]pyridin-8-yl]formamide, N-[3-(3-chloro-4-fluoro-phenyl)-6-[3-(methanesulfonamido)phenyl]imidazo[1,2-a]pyridin-8-yl] formamide, N-[3-(4-fluorophenyl)-6-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyridin-8-yl] formamide, 1-methyl-N-[4-(4-methylpiperazin-1-yl)phenyl]-2-[3-(trifluoromethyl)phenyl]pyrrolo[3,2-c]pyridin-6-amine, 1-methyl-N-pyrimidin-4-yl-2-[3-(trifluoromethyl)phenyl]pyrrolo[3,2-c]pyridin-6-amine, 2-(3-fluorophenyl)-1-methyl-N-[4-(4-methylpiperazin-1-yl)phenyl]pyrrolo[3,2-c]pyridin-6-amine, 2-(3-fluorophenyl)-1-methyl-N-pyrimidin-4-yl-pyrrolo[3,2-c]pyridin-6-amine, 1-benzyl-N-[4-(4-methylpiperazin-1-yl)phenyl]-2-(3-pyridyl)pyrrolo[3,2-c]pyridin-6-amine, 2-(1H-pyrazol-4-yl)-N-(2-pyridyl)-1H-pyrrolo[3,2-c]pyridin-6-amine, N-(4-methylsulfonylphenyl)-2-(1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridin-6-amine, 1-benzyl-2-(3-pyridyl)-N-pyrimidin-4-yl-pyrrolo[3,2-c]pyridin-6-amine, N-(3-methoxyphenyl)-2-(1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridin-6-amine, N-(3,4-dimethoxyphenyl)-2-(1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridin-6-amine, 1-benzyl-N-[4-(4-methylpiperazin-1-yl)phenyl]-2-phenyl-pyrrolo[3,2-c]pyridin-6-amine, N-[3-[8-acetamido-3-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]acetamide, N-[3-(3-acetylphenyl)-6-(3-methoxyphenyl)imidazo[1,2-a]pyridin-8-yl]acetamide, N-[3-(3-acetylphenyl)-6-(2,4-dimethoxyphenyl)imidazo[1,2-a]pyridin-8-yl]acetamide, N-[3-(3-acetylphenyl)-6-(2-methoxyphenyl)imidazo[1,2-a]pyridin-8-yl]acetamide, N-[6-(4-aminophenyl)-3-(4-fluorophenyl)imidazo[1,2-a]pyridin-8-yl]acetamide, N-[3-(3-acetylphenyl)-6-[4-(morpholine-4-carbonyl)phenyl]imidazo[1,2-a]pyridin-8-yl]acetamide, N,N-dimethyl-4-[4-[4-(4-methylpiperazin-1-yl)anilino]-1H-pyrrolo[3,2-c]pyridin-2-yl]benzamide, 4-[2-(3,5-dimethoxyphenyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]morpholine, N-[4-[[2-(2-methoxyphenyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]amino]phenyl]acetamide, 2-(2-methoxyphenyl)-1-methyl-N-[3-(trifluoromethyl)phenyl]pyrrolo[3,2-c]pyridin-4-amine, 6-(3-chlorophenyl)-3-(3,4-dimethoxyphenyl)pyrazolo[1,5-a]pyrimidin-7-amine, 5-amino-4-(1H-benzimidazol-2-yl)-1-(1,3-benzodioxol-5-yl)-2H-pyrrol-3-one, 8-(2,5-dimethoxyphenyl)-7-(4-fluorophenyl)-1-methyl-3H-imidazo[1,2-g]purine-2,4-dione, methyl 2-amino-1-(3-hydroxyphenyl)pyrrolo[3,2-b]quinoxaline-3-carboxylate, 2-(3,4-dimethoxyphenyl)-6-hydroxy-chromen-4-one, 2-amino-1-(3-methoxyphenyl)pyrrolo[3,2-b]quinoxaline-3-carboxamide.

In another aspect, the present invention provides a method of treating, or slowing progression of a disease associated with Fyn kinase, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, wherein the compound is selected from the group consisting of N-[3-[6-(2-furylmethylamino)pyrazin-2-yl]phenyl]acetamide, 4-[6-[1-(hydroxymethyl)propylamino]pyrazin-2-yl]phenol, 2-[[6-(5-isopropyl-2-methoxy-phenyl)pyrazin-2-yl]amino]butan-1-ol, 6-(3-aminophenyl)-N-benzyl-pyrazin-2-amine, 2-[[6-(4-aminophenyl)pyrazin-2-yl]amino]butan-1-ol, N-[3-(dimethylamino)propyl]-3-[6-(4-imethoxyphenyl)pyrazin-2-yl]benzamide, 2-methoxy-4-[6-(4-methoxyphenyl)pyrazin-2-yl]phenol, N-[3-[6-(4-methoxyphenyl)pyrazin-2-yl]phenyl]acetamide, N-[3-[6-(3-hydroxyphenyl)pyrazin-2-yl]phenyl]acetamide, 3-[5-(3-furylmethylamino)-3-pyridyl]phenol, N-[3-[5-(3,4,5-trimethoxyanilino)-3-pyridyl]phenyl]acetamide, 3-[(3-methoxyphenyl)methyl]-5-(3,4,5-trimethoxyphenyl)-1H-imidazo[4,5-b]pyrazin-2-one, N,N-dimethyl-3-[2-oxo-3-[(1 S)-1-phenylethyl]-1H-imidazo[4,5-b]pyrazin-5-yl]benzamide, 5-[3-(dimethylamino)phenyl]-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine, 3-[5-[(6-methoxy-3-pyridyl)amino]pyrazolo [1,5-a]pyrimidin-3-yl]phenol, 3-(3-methoxyphenyl)-N-(6-methoxy-3-pyridyl)pyrazolo[1,5-a]pyrimidin-5-amine, 1-[3-[5-[(6-methoxy-3-pyridyl)amino]pyrazolo[1,5-a]pyrimidin-3-yl]phenyl]ethanone, N-[5-[[3-(3-hydroxyphenyl)pyrazolo[1,5-a]pyrimidin-5-yl]amino]-2-methyl-phenyl]methanesulfonamide, 3-(3,4-dimethoxyphenyl)-N-(3-pyridylmethyl)pyrazolo[1,5-a]pyrimidin-5-amine, N-(3-pyridylmethyl)-3-(3,4,5-trimethoxyphenyl)pyrazolo [1,5-a]pyrimidin-5-amine, N-(4-isopropylphenyl)-3-(4-methoxyphenyl)pyrazolo [1,5-a]pyrimidin-5-amine, 3-(5-methoxy-3-pyridyl)-N-(4-morpholinophenyl)pyrazolo[1,5-a]pyrimidin-5-amine, 3-(3-aminophenyl)-N-(3-pyridylmethyl)pyrazolo[1,5-a]pyrimidin-5-amine, 3-(2-methoxyphenyl)-N-(3-pyridylmethyl)pyrazolo[1,5-a]pyrimidin-5-amine, (E)-3-[3-[5-(3-pyridylmethylamino)pyrazolo [1,5-a]pyrimidin-3-yl]phenyl]prop-2-enoic acid, N-[3-(dimethylamino)propyl]-4-[6-(2-fluoro-3-methoxy-phenyl)-1H-pyrazolo [3,4-b]pyridin-3-yl]benzamide, 6-(1H-indol-5-yl)-N-methyl-pyrazin-2-amine, N-ethyl-2-(3,4,5-trimethoxyanilino)-7,8-dihydro-5H-pyrido [4,3-d]pyrimidine-6-carboxamide, 6-propyl-N-(3,4,5-trimethoxyphenyl)-7,8-dihydro-5H-pyrido [4,3-d]pyrimidin-2-amine, [2-[3-(dimethylamino)anilino]-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl]-(2-methoxyphenyl)methanone, N-[3-(4-fluorophenyl)-6-[4-(morpholine-4-carbonyl)phenyl]imidazo[1,2-a]pyridin-8-yl]formamide, N-[3-(3-acetylphenyl)-6-[4-(morpholine-4-carbonyl)phenyl]imidazo[1,2-a]pyridin-8-yl]formamide, N-[3-(3-chloro-4-fluoro-phenyl)-6-[3-(methanesulfonamido)phenyl]imidazo[1,2-a]pyridin-8-yl]formamide, N-[3-(4-fluorophenyl)-6-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyridin-8-yl] formamide, 1-methyl-N-[4-(4-methylpiperazin-1-yl)phenyl]-2-[3-(trifluoromethyl)phenyl]pyrrolo[3,2-c]pyridin-6-amine, 1-methyl-N-pyrimidin-4-yl-2-[3-(trifluoromethyl)phenyl]pyrrolo[3,2-c]pyridin-6-amine, 2-(3-fluorophenyl)-1-methyl-N-[4-(4-methylpiperazin-1-yl)phenyl]pyrrolo[3,2-c]pyridin-6-amine, 2-(3-fluorophenyl)-1-methyl-N-pyrimidin-4-yl-pyrrolo[3,2-c]pyridin-6-amine, 1-benzyl-N-[4-(4-methylpiperazin-1-yl)phenyl]-2-(3-pyridyl)pyrrolo[3,2-c]pyridin-6-amine, 2-(1H-pyrazol-4-yl)-N-(2-pyridyl)-1H-pyrrolo[3,2-c]pyridin-6-amine, N-(4-methylsulfonylphenyl)-2-(1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridin-6-amine, 1-benzyl-2-(3-pyridyl)-N-pyrimidin-4-yl-pyrrolo[3,2-c]pyridin-6-amine, N-(3-methoxyphenyl)-2-(1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridin-6-amine, N-(3,4-dimethoxyphenyl)-2-(1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridin-6-amine, 1-benzyl-N-[4-(4-methylpiperazin-1-yl)phenyl]-2-phenyl-pyrrolo[3,2-c]pyridin-6-amine, N-[3-[8-acetamido-3-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]acetamide, N-[3-(3-acetylphenyl)-6-(3-methoxyphenyl)imidazo[1,2-a]pyridin-8-yl]acetamide, N-[3-(3-acetylphenyl)-6-(2,4-dimethoxyphenyl)imidazo[1,2-a]pyridin-8-yl] acetamide, N-[3-(3-acetylphenyl)-6-(2-methoxyphenyl)imidazo[1,2-a]pyridin-8-yl]acetamide, N-[6-(4-aminophenyl)-3-(4-fluorophenyl)imidazo[1,2-a]pyridin-8-yl]acetamide, N-[3-(3-acetylphenyl)-6-[4-(morpholine-4-carbonyl)phenyl]imidazo[1,2-a]pyridin-8-yl]acetamide, N,N-dimethyl-4-[4-[4-(4-methylpiperazin-1-yl)anilino]-1H-pyrrolo[3,2-c]pyridin-2-yl]benzamide, 4-[2-(3,5-dimethoxyphenyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]morpholine, N-[4-[[2-(2-methoxyphenyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]amino]phenyl]acetamide, 2-(2-methoxyphenyl)-1-methyl-N-[3-(trifluoromethyl)phenyl]pyrrolo[3,2-c]pyridin-4-amine, 6-(3-chlorophenyl)-3-(3,4-dimethoxyphenyl)pyrazolo [1,5-a]pyrimidin-7-amine, 5-amino-4-(1H-benzimidazol-2-yl)-1-(1,3-benzodioxol-5-yl)-2H-pyrrol-3-one, 8-(2,5-dimethoxyphenyl)-7-(4-fluorophenyl)-1-methyl-3H-imidazo[1,2-g]purine-2,4-dione, methyl 2-amino-1-(3-hydroxyphenyl)pyrrolo[3,2-b]quinoxaline-3-carboxylate, 2-(3,4-dimethoxyphenyl)-6-hydroxy-chromen-4-one, 2-amino-1-(3-methoxyphenyl)pyrrolo[3,2-b]quinoxaline-3-carboxamide.

In another aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being any one of those listed in Tables 3 and 4.

In another aspect, the present invention provides a method of treating, or slowing progression of a disease associated with Fyn kinase, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, of at least one compound described above, or a pharmaceutically acceptable salt or solvate thereof. Without limitation, the Fyn kinase inhibitors described here may be utilized to treat Types I and II diabetes, pre-diabetes and may prove effective in facilitating overall weight control, extend longevity and improve physical and mental well-being. In addition, such Fyn kinase inhibitors may improve exercise tolerance and increase the human body's ability to endure physical stress, as well as improve recovery from exercise and physical stress.

Fyn kinase inhibitors may be effective cancer therapeutics and may, when administered prophylactically, reduce the occurrence of various cancers in an individual. Due to its central role in intracellular regulatory phosphorylation cascades, Fyn kinase can play diverse roles in many common cancers. In breast cancers Fyn kinase regulates phosphorylation of ERB receptors and has been directly implicated in the genesis of tamoxifen and trastuzumab resistant breast cancers. Fyn kinase is also implicated in many forms of prostate cancer and Fyn expression is unusually high in prostate cancer cells. In liver cancers, and hepatocellular cancers generally, Fyn expression also appears to be significantly elevated. Mutant pancreatic cancer cells transfected with highly expressed kinase-dead Fyn genes have been shown to have decreased liver metastases activity in mouse models, suggesting a model by which Fyn kinase activity regulates cell proliferation and apoptosis. Esophageal and gastric cancers also exhibit high levels of Fyn kinase and such cancers are thought to be particularly sensitive to the epidermal growth factor receptor signaling pathway in which Fyn plays a key role. Fyn also plays a role in cervical and ovarian cancers. Elevated levels of Fyn kinase observed in many such cancers appears to be the result of overexpression of NRDG1, which when suppressed by shRNA treatment results in concomitant decrease in Fyn expression and a subsequent decrease in cell adhesion, migration and invasion activity.

Existing Fyn kinase inhibitors are also known to mitigate and lessen the severity of neurodegenerative diseases such as Multiple Sclerosis, Alzheimer's and Parkinson's and the Fyn kinase inhibitors described here may exhibit improved therapeutic efficacy in such treatments. The Fyn kinase inhibitors described here may also be effective in improving recovery from head or spinal trauma as well as promoting overall neurological health.

The invention described here relate to pharmacophores identified by analysis of specific chemical, physical and biological properties of a large set of chemical combinations based on a limited set of pharmacores. Such pharmacophores define the relevant parameters necessary to specifically modulate Fyn kinase activity and to provide therapeutic treatment for physiologic and pathologic conditions amenable to treatment by regulation of Fyn kinase activity in patients in need of such treatment.

Definitions

As used herein and throughout this disclosure, the following terms are to be understood to have the following meaning.

“Acyl” means an H—C(O)—, alkyl-C(O)— or cycloalkyl-C(O)—, group in which the various groups are as previously described. The bond to the parent moiety is through the carbonyl. Preferred acyls contain a lower alkyl. Non-limiting examples of suitable acyl groups include formyl, acetyl and propanoyl.

“Alcohol” means a functional group of the general formula R—OH, wherein R represents and alkane, alkene or any other carbon-containing group.

“Alkyl” means an aliphatic hydrocarbon group which may be straight or branched and comprising about 1 to about 20 carbon atoms in the chain. Preferred alkyl groups contain about 1 to about 12 carbon atoms in the chain. More preferred alkyl groups contain about 1 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkyl chain. “Lower alkyl” means a group having about 1 to about 6 carbon atoms in the chain which may be straight or branched. “Alkyl” may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, aryl, cycloalkyl, cyano, hydroxy, alkoxy, alkylthio, amino, —NH(alkyl), —NH(cycloalkyl), —N(alkyl)2, carboxy and —C(O)O-alkyl. Non-limiting examples of suitable alkyl groups include methyl, ethyl, n-propyl, isopropyl and t-butyl.

“Alkenyl” means an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred alkenyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 6 carbon atoms in the chain. Branched means that one or more 20 lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkenyl chain. “Lower alkenyl” means about 2 to about 6 carbon atoms in the chain which may be straight or branched. “Alkenyl” may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl. aryl, cycloalkyl, cyano, alkoxy and -5(alkyl). Non-limiting examples of suitable alkenyl groups include ethenyl, propenyl, n-butenyl, 3-methylbut-2-enyl, n-pentenyl, octenyl and decenyl.

“Alkoxy” means an alkyl-O-group. Non-limiting examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy. The bond to the parent moiety is through the ether oxygen.

“Alkylene” means a difunctional group obtained by removal of a hydrogen atom from an alkyl group that is defined above. Non-limiting examples of alkylene include methylene, ethylene and propylene.

“Alkynyl” means an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred alkynyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkynyl chain. “Lower alkynyl” means about 2 to about 6 carbon atoms in the chain which may be straight or branched. Non-limiting examples of suitable alkynyl groups include ethynyl, propynyl, 2-butynyl and 3-methylbutynyl. “Alkynyl” may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of alkyl, aryl and cycloalkyl.

“Alkynylalkyl” means an alkynyl-alkyl-group in which the alkynyl and alkyl are as previously described. Preferred alkynylalkyls contain a lower alkynyl and a lower alkyl group. The bond to the parent moiety is through the alkyl. Non-limiting examples of suitable alkynylalkyl groups include propargylmethyl.

“Alkylphosphate” means a compound of the general formula ROP(O)3-, wherein the R represents any alkyl group.

“Alkylsulfate” means a compound of the general formula ROS(O)3-, wherein the R represents any alkyl group.

“Aryl” means an aromatic monocyclic or multicyclic ring system comprising about 6 to about 14 carbon atoms, preferably about 6 to about 10 carbon atoms. The aryl group can be optionally substituted with one or more “ring system substituents” which may be the same or different, and are as defined herein. Non-limiting examples of suitable aryl groups include phenyl and naphthyl.

“Aroyl” means an aryl-C(O)-group. The bond to the parent moiety is through the carbonyl. Non-limiting examples of suitable groups include benzoyl and 1-naphthoyl.

“Arylalkyl” means an aryl-alkyl-group in which the aryl and alkyl are as previously described. Preferred aralkyls comprise a lower alkyl group. Non-limiting examples of suitable aralkyl groups include benzyl, 2-phenethyl and naphthalenylmethyl. The bond to the parent moiety is through the alkyl.

“Alkylaryl” means an alkyl-aryl-group in which the alkyl and aryl are as previously described. Preferred alkylaryls comprise a lower alkyl group. A non-limiting example of a suitable alkylaryl group is tolyl. The bond to the parent moiety is through the aryl.

“Alkylthio” means an alkyl-S-group. Non-limiting examples of suitable alkylthio groups include methylthio and ethylthio. The bond to the parent moiety is through the sulfur.

“Arylphosphate” means a compound of the general formula ROP(O)3-, wherein the R represents any aryl group.

“Arylsulfate” means a compound of the general formula ROS(O)3-, wherein the R represents any aryl group.

“Arylthio” means an aryl-S-group. Non-limiting examples of suitable arylthio groups include phenylthio and naphthylthio. The bond to the parent moiety is through the sulfur.

“Alkoxycarbonyl” means an alkyl-O—CO-group. Non-limiting examples of suitable alkoxycarbonyl groups include methoxycarbonyl and ethoxycarbonyl. The bond to the parent moiety is through the carbonyl.

“Aryloxycarbonyl” means an aryl-O—C(O)-group. Non-limiting examples of suitable aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl. The bond to the parent moiety is through the carbonyl.

“Aralkoxycarbonyl” means an aralkyl-O—C(O)— group. Non-limiting example of a suitable aralkoxycarbonyl group is benzyloxycarbonyl. The bond to the parent moiety is through the carbonyl.

“Alkylsulfonyl” means an alkyl-S(02)-group. Preferred groups are those in which the alkyl group is lower alkyl. The bond to the parent moiety is through the sulfonyl.

“Amide” means a functional group comprising (R1)C(O)N(R2)(R3) wherein the R groups refer to H or organic groups and the carbon and nitrogen atoms are covalently linked. Other amides include “sulfonamides” of the general formula (R1)S(O2)N(R2)(R3), wherein the sulfur and nitrogen atoms are covalently linked; and “phosphoramides” of the general formula (R1)(R2)O(O)N(R3)(R4), wherein the phosphate and the nitrogen are covalently linked. A non-limiting example of an amide is acetamide.

“Amine” means a functional group comprising: NH2(R1), a “primary amine”; NH(R1)(R2), a “secondary amine”; N(R1)(R2)(R3), a “tertiary amine”, wherein the bond to the parent moiety runs through the nitrogen.

“Arylsulfonyl” means an aryl-S(02)-group. The bond to the parent moiety is through the sulfonyl.

“Aralkylthio” means an aralkyl-S-group in which the aralkyl group is as previously described. Non-limiting example of a suitable aralkylthio group is benzylthio. The bond to the parent moiety is through the sulfur.

“Arylalkenyl” means an alkenyl-aryl-group. Preferred arylalkenyls comprise a lower alkenyl group. A non-limiting example of a suitable arylalkenyl group is phenylacetylene.

“Aryloxy” means an aryl-O-group. Non-limiting examples of suitable aryloxy groups include phenoxy and naphthoxy. The bond to the parent moiety is through the ether oxygen.

“Aralkyloxy” means an aralkyl-O-group in which the aralkyl group is as previously described. Non-limiting examples of suitable aralkyloxy groups include benzyloxy and 1- or 2-naphthalenemethoxy. The bond to the parent moiety is through the ether oxygen.

“Composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.

“Cyano” means a —CN group in which the bond to the parent moiety is through the carbon.

“Cycloalkyl” means a non-aromatic mono- or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms. Preferred cycloalkyl rings contain about 5 to about 7 ring atoms. The cycloalkyl can be optionally substituted with one or more “ring system substituents” which may be the same or different. and are as defined above. Non-limiting examples of suitable monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. Non-limiting examples of suitable multicyclic cycloalkyls include 1-decalinyl, norbomyl, adamantyl and the like.

“Cycloalkylalkyl” means a cycloalkyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable cycloalkylalkyls include cyclohexylmethyl, adamantylmethyl and the like.

“Cycloalkenyl” means a non-aromatic mono or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms which contain at least one carbon-carbon double bond. Preferred cycloalkenyl rings contain about 5 to about 7 ring atoms. The cycloalkenyl can be optionally substituted with one or more “ring system substituents” which may be the same or different, and are as defined above. Non-limiting examples of suitable monocyclic cycloalkenyls include cyclopentenyl, cyclohexenyl, cyclohepta-1,3-dienyl, and the like. Non-limiting example of a suitable multicyclic cycloalkenyl is norbomylenyl.

“Cycloalkenylalkyl” means a cycloalkenyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable cycloalkenylalkyls include cyclopentenylmethyl, cyclohexenylmethyl and the like.

“Effective amount” or “therapeutically effective amount” is meant to describe an amount of compound or a composition of the present invention effective in inhibiting the above-noted diseases and thus producing the desired therapeutic, ameliorative, inhibitory or preventative effect.

“Furan” is a heterocyclic aromatic compound of the formula C4H4O. Compounds comprising such structures may be referred to as “furans.”

“Halogen” or “halo” means fluorine, chlorine, bromine, or iodine. Preferred are fluorine, chlorine and bromine.

“Heteroaryl” means an aromatic monocyclic or multicyclic ring system comprising about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the ring atoms is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. Preferred heteroaryls contain about 5 to about 6 ring atoms. The “heteroaryl” can be optionally substituted by one or more “ring system substituents” which may be the same or different, and are as defined herein. The prefix aza, oxa or thia before the heteroaryl root name means that at least one of a nitrogen, oxygen or sulfur atom respectively, is present as a ring atom. A nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide. Non-limiting examples of suitable heteroaryls include pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, pyridone (including N-substituted pyridones), isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, pyrazolyl, triazolyl, 1,2,4-thiadiazolyl, pyrazinyl, pyridazinyl, quinoxalinyl, phthalazinyl, oxindolyl, imidazo[1,2-a]pyridinyl, imidazo[2, 1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolinyl, imidazolyl, thienopyridyl, quinazolinyl, thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, isoquinolinyl, benzoazaindolyl, 1,2,4-triazinyl, benzothiazolyl and the like. The term “heteroaryl” also refers to partially saturated heteroaryl moieties such as, for example, tetrahydroisoquinolyl, tetrahydroquinolyl and the like.

“Heteroarylalkyl” means a heteroaryl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable heteroarylalkyls include 2-pyridinylmethyl, quinolinylmethyl and the like.

“Heterocyclyl” means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to 30 about 1 0 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. There are no adjacent oxygen and/or sulfur atoms present in the ring system. Preferred heterocyclyls contain about 5 to about 6 ring atoms. The prefix aza, oxa or thia before the heterocyclyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom. Any —NH in a heterocyclyl ring may exist protected such as, for example, as an —N(Boc), —N(CBz), —N(Tos) group and the like; such protections are also considered part of this invention. The heterocyclyl can be optionally substituted by one or more “ring system substituents” which may be the same or different, and are as defined herein. The nitrogen or sulfur atom of the heterocyclyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Non-limiting examples of suitable monocyclic heterocyclyl rings include piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, lactam, lactone, and the like.

“Heterocyclylalkyl” means a heterocyclyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable heterocyclylalkyls include piperidinylmethyl, piperazinylmethyl and the like.

“Heterocyclenyl” means a non-aromatic monocyclic or multicyclic ring system comprising about 3 to about 1 0 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur atom, alone or in combination, and which contains at least one carbon-carbon double bond or carbon-nitrogen double bond. There are no adjacent oxygen and/or sulfur atoms present in the ring system. Preferred heterocyclenyl rings contain about 5 to about 6 ring atoms. The prefix aza, oxa or thia before the heterocyclenyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom. The heterocyclenyl can be optionally substituted by one or more ring system substituents, wherein “ring system substituent” is as defined above. The nitrogen or sulfur atom of the heterocyclenyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Non-limiting examples of suitable heterocyclenyl groups include 1,2,3,4-tetrahydropyridine, 1,2-dihydropyridyl, 1,4-dihydropyridyl, 1,2,3,6-tetrahydropyridine, 1,4,5,6-tetrahydropyrimidine, 2-pyrrolinyl, 3-pyrrolinyl, 2-imidazolinyl, 2-pyrazolinyl, dihydroimidazole, dihydrooxazole, dihydrooxadiazole, dihydrothiazole, 3,4-dihydro-2H-pyran, dihydrofuranyl, fluorodihydrofuranyl, 7oxabicyclo[2.2. 1]heptenyl, dihydrothiophenyl, dihydrothiopyranyl, and the like.

“Hydroxyalkyl” means a HO-alkyl-group in which alkyl is as previously defined. Preferred hydroxyalkyls contain lower alkyl. Non-limiting examples of suitable hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl.

“Patient” or “Subject” includes both human and animals.

“Pharmacore” means a specific chemical structure to which combinations of additional chemical constituents may be added. The combination of pharmacore and additional chemical groups represents the “pharmacophore.”

“Pharmacophore” is the ensemble of steric and electronic features of a pharmacore and any additional chemical constituents necessary to ensure supramolecular interactions with a specific biological target structure to trigger or block its biological response. A pharmacophore does not necessarily represent a real molecule or association of functional groups, although it may, but embodies the concept that accounts for the common molecular interaction capacities of a group of compounds towards their target structure. The pharmacophore can be considered the largest common denominator shared by a set of active molecules.

“Physiologic function” is the physiological activity of an organ, body part, or pathway within an animal.

“Purified”, “in purified form”, “isolated”, or “in isolated and purified form” for a compound refers to the physical state of said compound after being isolated from a synthetic process or natural source or combination thereof. Thus, the term “purified”, “in purified form”, “isolated”, or “in isolated and purified form” for a compound refers to the physical state of said compound after being obtained from a purification process or processes described herein or well known to the skilled artisan, in sufficient purity to be characterizable by standard analytical techniques described herein or well known to the skilled artisan.

“Pyrrole” is a heterocyclic aromatic compound of the formula C4H4N. Compounds comprising such structures may be referred to as “pyrroles.”

“Ring system substituent” means a substituent attached to an aromatic or non-aromatic ring system which, for example, replaces an available hydrogen on the ring system. Ring system substituents may be the same or different, each being independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, alkylaryl, heteroaralkyl, heteroarylalkenyl, heteroarylalkynyl, alkylheteroaryl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio, cycloalkyl, heterocyclyl, —C(═N—CN)—NH2, —C(═NH)—NH2, —C(═NH)—NH(alkyl), Y1Y2N—, Y1Y2N-alkyl-, Y1Y2NC(O)—, Y1Y2NSOr and —S02NY1Y2, wherein Y1 and Y2 can be the same or different and are independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, and aralkyl. “Ring system substituent” may also mean a single moiety which simultaneously replaces two available hydrogens on two adjacent carbon atoms (one H on each carbon) on a ring system. Examples of such moieties are methylene dioxy, ethylenedioxy, —C(CH3) 2- and the like.

“Substituted” means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. By “stable compound’ or “stable structure” is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent. The term “optionally substituted” means optional substitution with the specified groups, radicals or moieties.

“Thiol” means a functional group of the general formula R—SH, wherein R represents and alkane, alkene or any other carbon-containing group, may also be referred to as a “mercaptan” or “sulfhydryl” group.

“Thiophene” is a heterocyclic aromatic compound of the formula C4H4S, may also be referred to as thiofuran.

Any carbon as well as heteroatom with unsatisfied valences in the text, examples and Tables herein is assumed to have the sufficient number of hydrogen atom(s) to satisfy the valences.

The compounds described herein may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of these compounds as well as mixtures thereof, including racemic mixtures, form part of the present invention. In addition, the present invention embraces all geometric and positional isomers. For example, if a compound incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention.

Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Enantiomers can also be separated by use of chiral HPLC column.

The compounds herein may in some cases form salts which are also within the scope of this invention. Reference to a compound herein is understood to include reference to salts thereof, unless otherwise indicated. The term “salt(s)”, as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases.

“Solvate” means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. “Solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. “Hydrate” is a solvate wherein the solvent molecule is water. One or more compounds of the invention may also exist as, or optionally be converted to, a solvate. Preparation of solvates is generally known.

The compounds of this invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms.

It is also possible that the compounds herein may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention.

DETAILED DESCRIPTION OF THE INVENTION

Identifying FYN Kinase Inhibitors.

Individual compounds within a chemical library consisting of 600 potential kinase inhibitors were assayed with the ADP-Glo™ Kinase Assay kit (V9102, Promega UK Ltd., Southhampton, Hampshire, UK) to identify the most potent FYN kinase inhibitors within the collection. The chemical library was comprised of the SoftFocus ATP-competitive hinge binding compounds described by Harris, C. J., Hill, R. D., Sheppard, D. W., et al., The Design and Application of Target-Focused Compound Libraries. Combinatorial Chemistry and High Throughput Screening 14:521-31 (2011). The specific pharmacore chemistries included SFK52 comprising 6-[R2]-3-[R1]imidazo[1,2-b] pyridazine compounds, SFK33 comprising N-(3-[R2] imidazo [1,2-b] pyridazin-6-yl) [R1] amine compounds, SFK49 comprising N-(5-[R2] imidazo [2,1-b][1,3,4] thiadiazol-2-yl)[R1]-amine compounds, SFK 40 comprising 5-[R2]-3-[R1] pyridin-2-amine compounds, SFK43 comprising 6-[R2]-3-[R1]imidazo[1,2-a]pyrazine compounds, and SFK63. The scaffold structure of each pharmacore is shown in Table 2. The chemical structures of the initial 600 potential kinase inhibitors are presented in Table 3, with those chosen for additional analysis presented in Table 4. Comparison of the compounds presented in Table 1 and those of Tables 2, 3 and 4, illustrate the novelty of the chemical structures claimed herein.

FYN kinase (10 micrograms) was from the FYN A Kinase Enzyme System (V3571, Promega UK Ltd.), a full-length recombinant human FYN A containing an N-terminal GST tag of about 85 kDa, expressed by bacullovirus in S19 insect cells, supplied at a concentration of 0.1 microgram/microliter in 5× reaction buffer. The FYN substrate, a 12 amino acid peptide of the sequence EFGTYGTLSKKK, containing a single tyrosine phosphorylation site, was custom synthesized (Peptide Synthetics, Peptide Protein Research, Fareham, UK) and supplied as a 4 mg/ml aqueous solution. All other reagents were obtained from Sigma (Sigma-Aldrich, Gillingham, Dorset, UK), with the exception of UltraPure ATP (V9102, Promega UK Ltd.) and the ATP-competitive broad spectrum protein kinase inhibitor staurosporine (569397, Merck Millipore, Watford, Hertfordshire, UK), or as otherwise indicated.

The assay procedure determines the IC50 of each potential FYN kinase inhibitor by measuring the enzyme catalyzed ATP-dependent phosphorylation of the FYN substrate peptide. The ADP-Glo™ Kinase Assay is specifically designed to quantify kinase activity by measuring the ADP produced in the reaction The reaction buffer comprises 40 mM Tris.HCl (pH 7.5), 20 mM MgCl₂, 0.1 mg/ml BSA and 5 microM DTT. Individual compounds within the chemical library were dissolved in DMSO at known concentrations. Briefly, 2.5 microliters of reaction buffer containing 3 picograms of FYN kinase and serial dilutions of each potential FYN kinase inhibitor (9 3-fold dilutions of a 10 micromolar top sample) are placed into each well of a 384 well microtiter plate and incubated at room temperature for 30 minutes. An additional 2.5 microliters of reaction buffer containing 100 picograms of the FYN substrate and 12.5 picomoles of ATP are then added to each well and the reaction carried out for 90 minutes at room temperature. The reactions are terminated by addition of 5 microliters of the ADP-Glo™ Reagent component of the ADP-Glo™ Kinase Assay kit to each well. The ADP-Glo™ Reagent comprises an ATP-dependent adenylate cyclase, an inorganic pyrophosphatase and an excess of staurosporine. The adenylate cyclase converts the remaining ATP to cAMP and pyrophospahte, the pyrophosphatase converts the pyrophosphate to phosphate and the staurosporine inhibits the activity of the FYN kinase, the net effect is to remove all residual ATP while preserving the ADP produced by FYN kinase. The terminated reactions are incubated for 40 minutes at room temperature, prior to addition of the Kinase Detection Reagent component of the ADP-Glo™ Kinase Assay kit to each well. The Kinase Detection Reagent comprises pyruvate kinase, phosphoenol pyruvate (PEP), luciferin and luciferase. The pyruvate kinase converts PEP to pyruvate and in the process generates ATP from the residual ADP present in the terminated reaction. The ATP is then consumed by the luciferase catalyzed, light emitting conversion of luciferin to oxyluciferin producing AMP, pyrophosphate and C02. The emitted light was measured on an Envion Luminometer to determine the relative activity of the FYN kinase in each well. A 10 point dose-response curve for each potential FYN kinase inhibitor dilution series was used to determine the IC50, of each compound. Details of the analysis, including assay procedures and representative dilution schema for measuring kinase inhibitors are presented in the Technical Manual accompanying the ADP-Glo™ Kinase Assay kit (Doc. TM313, Promega Corp.) as well as U.S. Pat. Nos. 8,183,007 and 8,802,411, the contents of which are incorporated herein, in their entirety.

The results of screening candidate libraries are presented in Table 3, which lists the structure of each compound, the standard IUPAC name of the compound, the observed IC50 and the calculated lipophilicity of the compound. The most potent FYN kinase inhibitors, generally those with the most favorable combination of IC50 and drugability were resynthesized and subjected to further testing and expansion. In general, the best candidate compounds exhibit an IC50 of less than 200 nM and drugability as measured by LLE (Ligand-lipophilicity efficiency) of greater than 2.5. LLE=(pIC50-c Log P) where pIC50 is the negative log of the observed IC50 and c Log P is a calculated consensus measure of the lipophilicity of the compound. In practice, this means a c Log P of less than 3.5, based on an average IC50 of less than or equal to 1 μM, represents a favorable level of drugability (LLE>2.5). Candidate compounds selected for additional testing and expansion are listed in Table 4.

Cell Based Assay(s) of FYN Kinase Inhibitors

Test compounds exhibiting superior IC50 and LLE profiles are further tested for their ability to stimulate T cell proliferation and to inhibit production of Interleukin 2 by stimulated T-cells.

T-cell proliferation is analyzed by staining with carboxy-fluorescein diacetate succinimidyl ester (CFSE) at a final concentration 5 μM (Molecular Probes, Invitrogen) according to the manufacturer's instructions. Briefly, cells are resuspended in warm PBS containing 5 μM CFSE and incubated at 37° C. for 10 minutes. Subsequently, cells are washed twice and resuspended in culture media containing 10% FBS before the experimental treatments are initiated. Cells may be analyzed by flow cytometry after 5 days in culture. Alternatively, a 96-well plate is coated with a monoclonal antibody to CD3 (G19-4), the antibody is allowed to bind, and then the plate is washed. Normal human peripheral blood T cells are added to the wells, along with test compound and anti-CD28 antibody to provide co-stimulation. After 3 days, [³H]thymidine is added to the cells and incubated for 6 hours. The cells are harvested and counted in a liquid scintillation counter to measure proliferation.

To measure the ability of test compounds to block IL-2 production by Fyn mediated tyrosine phosphorylation induced by anti-CD3 and IL-2 stimulated T-cell proliferation, human T-cells, such as Jurkat cells are preincubated with various concentrations of test compound in serum-free medium at 37° C. for 10 min and then stimulated with plastic-immobilized anti-CD3 mAbs. Cells are cultured in complete media supplemented with 5% fetal bovine serum for 24 h in the presence of 10 μg/ml of anti-human CD25 mAbs to prevent IL-2 autocrine consumption. The supernatants are then harvested and centrifuged, and the IL-2 in the supernatant measured in a bioassay using a murine IL-2-dependent cell line, such as CTLL-4, as described by Trevillyan, et al., J. Immunol. 145:3223-30 (1990). To avoid the influence of residual test compound in the supernatants on proliferation of CTLL-4 cells, the test compound is removed by extensive dialysis against phosphate-buffered saline (0.1 M, pH 7.4). A control supernatant harvested from anti-CD3-stimulated Jurkat cells lacking Lck is spiked with 200 μM test compound is included along with the test compound dilution series to ascertain that all test compound is removed by the dialysis procedure. This “dialysis control” supernatant stimulates CTLL-4 proliferation as well as the positive control supernatant without added test compound, indicating the dialysis procedure has removed the test compound. Alternatively, IL-2 can be directly measured with an in vitro cytokine assays using labeled anti-IL2 mAbs, such as CisBio's Human IL2 Assay Kit (CisBio US, Bedford, Mass.) without requiring prior removal of test compound.

One of skill in the art will recognize that other assays may be devised to measure the efficacy of Fyn kinase inhibition by test compounds and that such assays are conventional in the art and known to those of ordinary skill.

TABLE 2 Representative scaffold structures of SoftFocus library pharmacores

5-[R2]-3-[R1]pyridin-2-amine Formula I (SFK40 pharmacore)

6-[R2]-3-[R1]imidazo[1,2-a] pyrazine Formula II (SFK43 pharmacore)

6-[R2]-3-[R1]imidazo[1,2-b] pyridazine Formula III (SFK52 pharmacore)

N-(5-[R2]imidazo[2,1- b][1,3,4]thiadiazol-2- yl)[R1]amine Formula IV (SFK49 pharmacore)

4-[R2]-3-[R1]-1H- pyrazolo[3,4-b]pyridine Formula V (SFK63 pharmacore)

N-(3-[R2]imidazo[1,2- b]pyridazin-6-yl)[R1]amine Formula VI (SFK33 pharmacore)

TABLE 3 Primary screen- initial compounds. IC50 logP FYN (con- Structure IUPAC name (μM) sensus) Compound ID.

1 N-[3-[6-(2-furyl- methylamino) pyrazin-2- yl]phenyl] acetamide 11.18502 1.66 035_0144_0081

2 4-[6-[1- (hydroxymethyl) propylamino] pyrazin-2- yl]phenol 15.34591 1.58 035_0153_0080

3 2-[[6-(5-isopropyl- 2-methoxy- phenyl)pyrazin-2- yl]amino]butan- 1-ol 11.79042 2.97 035_0153_0286

4 6-(3- aminophenyl)-N- benzyl-pyrazin-2- amine 6.67663 2.53 035_0232_0005

5 2-[[6-(4- aminophenyl) pyrazin-2- yl]amino]butan- 1-ol 21.05663 1.06 035_0153_0333

6 3-[5-(3-furyl- methylamino)- 3-pyridyl]phenol 10.89609 2.44 081_0284_2069

7 N-[3-[5-(3,4,5- trimethoxyanilino)- 3-pyridyl]phenyl] acetamide 0.3913 2.61 081_0087_0081

8 3-[(3- methoxyphenyl) methyl]-5-(3,4,5- trimethoxy- phenyl)-1H- imidazo[4,5- b]pyrazin-2-one 23.44 3.07 170_4313_0087

9 N,N-dimethyl-3- [2-oxo-3-[(1S)-1- phenylethyl]-1H- imidazo[4,5- b]pyrazin-5- yl]benzamide 1.77669 3.42 170_0148_0349

10 5-[3-(dimethyl- amino)phenyl]- N-(4-morpholino- phenyl) imidazo[1,2- a]pyrazin-8- amine 2.70242 3.14 184_0088_0135

11 N-(2-methoxy- ethyl)-3-(3- thienyl)imidazo [1,2-b]pyridazin- 6-amine 5.2312 2.02 229_0033_0074

12 3-(3,4- dimethoxy- phenyl)-N-(2- methoxyethyl) imidazo[1,2- b]pyridazin-6- amine 1.54534 1.93 229_0033_0079

13 3-(4-fluoro- phenyl)-N-(2- methoxyethyl) imidazo[1,2- b]pyridazin-6- amine 4.00393 2.38 229_0033_0339

14 4-[6-(2- furylmethyl- amino) imidazo[1,2- b]pyridazin-3- yl]benzoic acid 3.879 2.73 229_0144_0140

15 N-(2-furyl- methyl)-3-(4- methoxyphenyl) imidazo[1,2- b]pyridazin-6- amine 3.67644 2.91 229_0144_0280

16 [4-[6-(2-furyl- methylamino) imidazo[1,2- b]pyridazin-3- yl]phenyl] methanol 2.20497 2.30 229_0144_0285

17 [3-[6-(2-furyl- methylamino) imidazo[1,2- b]pyridazin-3- yl]phenyl] methanol 3.85557 2.30 229_0144_0291

18 1-[3-[6-(2-furyl- methylamino) imidazo[1,2- b]pyridazin-3- yl]phenyl] ethanone 0.99711 2.63 229_0144_4145

19 [4-[6-(2- thienylmethyl- amino) imidazo[1,2- b]pyridazin-3- yl]phenyl] methanol 1.09479 3.16 229_0146_0285

20 3-(4-amino- phenyl)-N-(2- thienylmethyl) imidazo[1,2- b]pyridazin-6- amine 5.42153 3.10 229_0146_0333

21 3-(4-fluoro- phenyl)-N-(2- thienylmethyl) imidazo[1,2- b]pyridazin-6- amine 3.28447 4.07 229_0146_0339

22 3-(3- methoxyphenyl)- N-(2- thienylmethyl) imidazo[1,2- b]pyridazin-6- amine 2.94644 3.77 229_0146_4140

23 1-[3-[6-(2- thienylmethyl- amino) imidazo[1,2- b]pyridazin-3- yl]phenyl] ethanone 0.44073 3.48 229_0146_4145

24 2-[[3-(3,4,5- trimethoxy- phenyl) imidazo[1,2- b]pyridazin-6- yl]amino] butan-1-ol 1.2806 2.06 229_0153_0087

25 2-[[3-(4- methoxyphenyl) imidazo[1,2- b]pyridazin-6- yl]amino] butan-1-ol 1.27502 2.38 229_0153_0280

26 2-[[3-[4- (hydroxy- methyl)phenyl] imidazo[1,2- b]pyridazin-6- yl]amino]butan- 1-ol 2.46631 1.77 229_0153_0285

27 2-[[3-(6- methoxy-3- pyridyl)imidazo [1,2-b]pyridazin- 6-yl]amino] butan-1-ol 2.36648 1.76 229_0153_0311

28 2-[[3-(3- methoxyphenyl) imidazo[1,2- b]pyridazin-6- yl]amino]butan- 1-ol 1.55019 1.76 229_0153_4140

29 [3-[6-[(3- chlorophenyl) methylamino] imidazo[1,2- b]pyridazin-3- yl]phenyl] methanol 5.10524 3.85 229_0223_0291

30 3-(4- aminophenyl)- N-[(3- chlorophenyl) methyl]imidazo [1,2-b]pyridazin- 6-amine 3.41043 3.79 229_0223_0333

31 [4-[6-[(4- fluorophenyl) methylamino] imidazo[1,2- b]pyridazin-3- yl]phenyl] methanol 2.4449 3.39 229_0224_0285

32 N-(1,3- benzodioxol-5- ylmethyl)-3-(4- pyridyl)imidazo [1,2-b]pyridazin- 6-amine 0.37966 2.42 229_0236_0069

33 4-[6-(1,3- benzodioxol- 5-ylmethyl- amino) imidazo[1,2- b]pyridazin-3- yl]phenol 5.67256 3.33 229_0236_0080

34 3-(benzofuran- 2-yl)-N-(4- pyridylmethyl) imidazo[1,2- b]pyridazin-6- amine 6.44995 2.87 229_0237_0073

35 3-(3- aminophenyl)- N-tetrahydro- pyran-4-yl- imidazo[1,2- b]pyridazin-6- amine 0.74599 1.42 229_0242_0005

36 3-(3,4- dimethoxy- phenyl)-N-tetra- hydropyran-4- yl-imidazo[1,2- b]pyridazin-6- amine 0.54713 1.93 229_0242_0079

37 N-[3-[6- (tetrahydro- pyran-4- ylamino) imidazo[1,2- b]pyridazin- 3-yl]phenyl] acetamide 0.58811 1.49 229_0242_0081

38 N- tetrahydropyran- 4-yl-3-(3,4,5- trimethoxy- phenyl) imidazo[1,2- b]pyridazin-6- amine 0.61737 1.78 229_0242_0087

39 3-(1H-indol- 5-yl)-N- tetrahydropyran- 4-yl-imidazo[1,2- b]pyridazin-6- amine 1.16563 2.35 229_0242_0204

40 3-(3-methoxy- phenyl)-N- tetrahydro- pyran-4- yl-imidazo[l,2- b]pyridazin-6- amine 0.87042 2.09 229_0242_4140

41 2-methoxy- 4-[6-[(4- methoxyphenyl) methylamino] imidazo[1,2- b]pyridazin-3- yl]phenol 4.01326 3.39 229_0244_0314

42 3-[[3-(1,3- benzodioxol-5- yl)imidazo[1,2- b]pyridazin-6- yl]amino] propan-1-ol 0.9286 1.28 229_0248_0068

43 3-[[3-(1H- indol-5- yl)imidazo[1,2- b]pyridazin-6- yl]amino] propan-1-ol 2.71742 1.76 229_0248_0204

44 3-[[3-[3- (trifluoro- methyl)phenyl] imidazo[1,2- b]pyridazin-6- yl]amino] propan-1-ol 3.41334 2.54 229_0248_0312

45 4-[6-(3- hydroxy- propylamino) imidazo[1,2- b]pyridazin- 3-yl]- 2-methoxy- phenol 0.32856 1.20 229_0248_0314

46 3-[[3-(4- phenoxyphenyl) imidazo[1,2- b]pyridazin-6- yl]amino] propan-1-ol 5.54336 3.16 229_0248_1029

47 (2S)-2-[[3-(3- aminophenyl) imidazo[1,2- b]pyridazin-6- yl]amino]-3- methyl-butan- 1-ol 1.80698 2.07 229_0254_0005

48 (2S)-2-[[3-(1,3- benzodioxol-5- yl)imidazo[1,2- b]pyridazin-6- yl]amino]-3- methyl-butan- 1-ol 1.82017 2.52 229_0254_0068

49 (2S)-2-[[3-(3,4- dimethoxyphenyl) imidazo[1,2- b]pyridazin-6- yl]amino]-3- methyl-butan- 1-ol 0.7782 2.59 229_0254_0079

50 N-[3-[6-[[(1S)-1- (hydroxymethyl)- 2-methyl- propyl]amino] imidazo[1,2- b]pyridazin-3- yl]phenyl] acetamide 0.80076 2.14 229_0254_0081

51 4-[6-[[(1S)-1- (hydroxymethyl)- 2-methyl- propyl]amino] imidazo[1,2- b]pyridazin-3- yl]benzonitrile 3.17911 2.76 229_0254_0086

52 (2S)-2-[[3-(4- aminophenyl) imidazo[1,2- b]pyridazin-6- yl]amino]-3- methyl-butan- 1-ol 3.05172 2.07 229_0254_0333

53 3-(1,3- benzodioxol-5- yl)-N-(2- pyridylmethyl) imidazo[1,2- b]pyridazin-6- amine 0.79705 2.50 229_4007_0068

54 N-(cyclopropyl- methyl)-3-(3- methoxyphenyl) imidazo[1,2- b]pyridazin-6- amine 3.29534 2.91 229_4051_4140

55 3-[5-[(6- methoxy-3- pyridyl)amino] pyrazolo[1,5- a]pyrimidin-3- yl]phenol 3.39371 3.25 294_0042_0284

56 3-(3- methoxyphenyl)- N-(6-methoxy-3- pyridyl)pyrazolo [1,5- a]pyrimidin- 5-amine 5.3146 3.40 294_0042_4140

57 1-[3-[5-[(6- methoxy-3- pyridyl)amino] pyrazolo[1,5- a]pyrimidin-3- yl]phenyl] ethanone 1.63557 3.11 294_0042_4145

58 N-[5-[[3-(3- hydroxyphenyl) pyrazolo[1,5- a]pyrimidin-5- yl]amino]-2- methyl- phenyl]methane- sulfonamide 3.17096 2.92 294_0123_0284

59 3-(3,4- dimethoxy- phenyl)-N-(3- pyridylmethyl) pyrazolo[1,5- a]pyrimidin-5- amine 1.63605 2.56 294_4003_0079

60 N-(3- pyridylmethyl)- 3-(3,4,5- trimethoxy- phenyl) pyrazolo[1,5- a]pyrimidin-5- amine 2.35332 2.40 294_4003_0087

61 N-(4- isopropylphenyl)- 3-(4- methoxyphenyl) pyrazolo[1,5- a]pyrimidin-5- amine 4.17999 5.42 294_6937_0280

62 N-(2- furylmethyl)-3- phenyl- imidazo[1,2- b]pyridazin-6- amine 6.37501 3.07 229_0144_0061

63 N-(2- furylmethyl)-3- (3,4,5- trimethoxyphenyl) imidazo[1,2- b]pyridazin-6- amine 4.89592 2.60 229_0144_0086

64 3-(3- aminophenyl)- N-(2- thienyimethyl) imidazo[1,2- b]pyridazin-6- amine 1.79421 3.10 229_0146_0005

65 N-(2- thienylmethyl)- 3-(3,4,5- trimethoxyphenyl) imidazo[1,2- b]pyridazin-6- amine 3.10009 3.45 229_0146_0087

66 3-(4- methoxyphenyl)- N-(2- thienylmethyl) imidazo[1,2- b]pyridazin-6- amine 5.3884 3.77 229_0146_0280

67 3-[6-(2- thienylmethyl- amino) imidazo[1,2- b]pyridazin-3- yl]phenol 1.70365 3.62 229_0146_0284

68 2-[[3-(2- thienyl)imidazo [1,2-b]pyridazin- 6-yl]amino] butan-1-ol 3.96823 2.31 229_0153_4147

69 N-[(3- chlorophenyl) methyl]-3-(4- methoxyphenyl) imidazo[1,2- b]pyridazin-6- amine 10.74649 4.46 229_0223_0280

70 N-[(3- chlorophenyl) methyl]-3-(6- methoxy-3- pyridyl)imidazo [1,2-b]pyridazin- 6-amine 8.33916 3.84 229_0223_0311

71 4-[6-[(3- chlorophenyl) methylamino] imidazo[1,2- b]pyridazin-3- yl]-2-methoxy- phenol 3.51753 4.15 229_0223_0314

72 3-(3- aminophenyl)- N-propyl- imidazo[1,2- b]pyridazin-6- amine 0.93247 2.34 229_0226_0005

73 3-(1,3- benzodioxol-5- yl)-N-propyl- imidazo[1,2- b]pyridazin-6- amine 2.05098 2.79 229_0226_0068

74 N-propyl-3-(3- thienyl)imidazo [1,2-b]pyridazin- 6-amine 4.03981 2.95 229_0226_0074

75 3-(3,4- dimethoxy- phenyl)-N- propyl- imidazo[1,2- b]pyridazin-6- amine 0.51897 2.85 229_0226_0079

76 N-[3-[6- (propylamino) imidazo[1,2- b]pyridazin-3- yl]phenyl] acetamide 0.62919 2.40 229_0226_0081

77 4-[6- (propylamino) imidazo[1,2- b]pyridazin-3- yl]benzoic acid 9.76838 2.82 229_0226_0140

78 3-(4- methoxyphenyl)- N-propyl- imidazo[1,2- b]pyridazin-6- amine 5.42987 3.01 229_0226_0280

79 3-[6- (propylamino) imidazo[1,2- b]pyridazin-3- yl]phenol 0.93003 2.86 229_0226_0284

80 3-(3- methoxyphenyl)- N-propyl- imidazo[1,2- b]pyridazin-6- amine 2.21992 3.01 229_0226_4140

81 1-[3-[6- (propylamino) imidazo[1,2- b]pyridazin-3- yl]phenyl] ethanone 0.36718 2.72 229_0226_4145

82 4-[6-[(3,4- dichlorophenyl) methylamino] imidazo[1,2- b]pyridazin-3- yl]benzoic acid 1.00617 4.88 229_0227_0140

83 3-phenyl-N-(4- pyridylmethyl) imidazo[1,2- b]pyridazin-6- amine 4.05638 2.79 229_0237_0061

84 3-(4- aminophenyl)-N- tetrahydropyran- 4-yl-imidazo[1,2- b]pyridazin-6- amine 3.12587 1.42 229_0242_0333

85 4-[6-[(2,4- dimethylphenyl) methylamino] imidazo[1,2- b]pyridazin-3- yl]-2-methoxy- phenol 5.30595 4.58 229_4319_0314

86 3-(5-methoxy-3- pyridyl)-N-(4- morpholino- phenyl)pyrazolo [1,5-a]pyrimidin- 5-amine 2.24998 2.85 294_0088_0196

87 3-(3-amino- phenyl)-N-(3- pyridylmethyl) pyrazolo[1,5- a]pyrimidin-5- amine 2.5122 2.05 294_4003_0005

88 3-(2- methoxyphenyl)- N-(3- pyridylmethyl) pyrazolo[1,5- a]pyrimidin-5- amine 1.22114 2.72 294_4003_0083

89 N-[3- (dimethylamino) propyl]-3-[6-(4- methoxyphenyl) pyrazin-2- yl]benzamide 9.05883 2.60 035_0280_0302

90 2-methoxy-4- [6-(4- methoxyphenyl) pyrazin-2- yl]phenol 5.17907 2.99 035_0280_0314

91 N-[3-[6-(4- methoxyphenyl) pyrazin-2- yl]phenyl] acetamide 3.50136 2.68 035_0081_0280

92 N-[3-[6-(3- hydroxyphenyl) pyrazin-2- yl]phenyl] acetamide 3.87844 2.54 035_0081_0284

93 N-[3- (dimethylamino) propyl]-4-[6-(2- fluoro-3- methoxy- phenyl)-1H- pyrazolo[3,4- b]pyridin-3- yl]benzamide 7.3354 3.65 267_0180_7936

94 3-[2-amino-5- (3,4-dimethoxy- phenyl)-3- pyridyl]phenol 2.00489 3.20 382_0284_0079

95 3-[6-amino-5-[3- (dimethylamino) phenyl]-3- pyridyl]-N-(2- hydroxyethyl) benzamide 3.57159 2.31 382_0135_0192

96 5-(3- methoxyphenyl)- 3-(3,4,5- trimethoxyphenyl) pyridin-2-amine 9.5028 3.18 382_0087_4140

97 4-[2-amino-5-(4- methylsulfonyl- phenyl)-3-pyridyl]- 2-methoxy- phenol 0.34919 2.19 382_0314_0174

98 4-[2-amino-5-(p- tolyl)-3-pyridyl]- 2-methoxy- phenol 4.3442 3.87 382_0314_4139

99 4-[2-amino-5-(3- chlorophenyl)-3- pyridyl]-2- methoxy-phenol 3.5107 3.96 382_0314_0279

100 4-[2-amino-5-(3- fluorophenyl)-3- pyridyl]-2- methoxy-phenol 2.02739 3.50 382_0314_0313

101 4-(2-amino-5- phenyl-3- pyridyl)-2- methoxy-phenol 1.47705 3.35 382_0314_0061

102 4-[6-amino-5-(4- hydroxy-3- methoxy- phenyl)-3- pyridyl]-2,6- dimethyl-phenol 0.52648 4.08 382_0314_0315

103 4-[2-amino-5-(4- fluorophenyl)-3- pyridyl]-2- methoxy-phenol 3.24026 3.50 382_0314_0339

104 4-[2-amino-5- (3,4,5-trimethoxy- phenyl)-3- pyridyl]-2- methoxy-phenol 0.08059 2.88 382_0314_0087

105 4-[6-amino-5-[4- (methoxy- methoxy)phenyl]- 3-pyridyl] benzamide 3.42268 2.57 382_0341_0346

106 [3-[6-amino-5-[4- (methoxymethoxy) phenyl]-3- pyridyl]phenyl] methanol 4.62016 2.95 382_0341_0291

107 3-[6-amino-5-[4- (methoxymethoxy) phenyl]-3- pyridyl]benzamide 3.02265 2.57 382_0341_0347

108 N-[3-[6-amino-5- 4-(methoxy- methoxy) phenyl]-3- pyridyl]phenyl] acetamide 1.5493 2.96 382_0341_0081

109 4-[6-amino-5-[4- (hydroxymethyl) phenyl]-3- pyridyl]- 2,6-dimethyl- phenol 4.64395 3.77 382_0285_0315

110 3-[4- (methoxymethoxy) phenyl]-5- (3,4,5- trimethoxy- phenyl)pyridin- 2-amine 1.90467 3.25 382_0341_0087

111 3-[2-amino-5-(4- morpholino- phenyl)-3- pyridyl]phenol 4.64154 3.40 382_0284_0001

112 N-[3-[6-amino- 5-(4- hydroxyphenyl)- 3-pyridyl]phenyl] acetamide 0.83784 2.75 382_7249_0081

113 4-[2-amino-5- (3,4,5- trimethoxy- phenyl)-3- pyridyl]phenol 0.20886 3.04 382_7249_0087

114 4-[2-amino-5-[3- (dimethylamino) phenyl]-3- pyridyl]phenol 2.19069 3.62 382_7249_0135

115 3-[2-amino-5- (3,4,5- trimethoxy- phenyl)-3- pyridyl]phenol 1.01519 3.04 382_0284_0087

116 4-[2-amino-5-(4- methylsulfonyl- phenyl)-3- pyridyl]phenol 1.25339 2.35 382_7249_0174

117 3-(3- aminophenyl)-5- (3,4,5- trimethoxy- phenyl)pyridin- 2-amine 2.96823 2.51 382_0005_0087

118 4-[2-amino-5-(3- methoxyphenyl)- 3-pyridyl]phenol 3.49074 3.35 382_7249_4140

119 4-[6-amino-5-(4- pyridyl)-3- pyridyl]-2,6- dimethyl-phenol 1.70457 3.32 382_0069_0315

120 5-[6-[3- (dimethylamino) propoxy]-3- pyridyl]-3-(3,4,5- trimethoxy- phenyl)pyridin- 2-amine 0.5304 2.64 382_0087_0002

121 5-(3- fluorophenyl)-3- (3,4,5- trimethoxy- phenyl)pyridin- 2-amine 1.5198 3.49 382_0087_0313

122 4-[6-amino-5- (3,4,5- trimethoxyphenyl)- 3-pyridyl]-2,6- dimethyl-phenol 0.71164 4.07 382_0087_0315

123 N-[3-[6-amino-5- (3,4,5-trimethoxy- phenyl)-3- pyridyl]phenyl] methane- sulfonamide 0.5248 1.72 382_0087_6488

124 5-phenyl-3- (3,4,5-trimethoxy- phenyl)pyridin- 2-amine 0.8934 3.34 382_0087_0061

125 3-[6-amino-5- (3,4,5-trimethoxy- phenyl)-3- pyridyl]-N-(2- hydroxyethyl) benzamide 0.48532 1.73 382_0087_0192

126 5-(4- aminophenyl)- 3-(3,4,5- trimethoxy- phenyl)pyridin- 2-amine 0.97087 2.51 382_0087_0333

127 4-[6-amino-5- (3,4,5-trimethoxy- phenyl)-3- pyridyl]phenol 1.72584 3.04 382_0087_7249

128 5-(4-fluoro- phenyl)-3- (3,4,5-trimethoxy- phenyl)pyridin- 2-amine 2.85921 3.49 382_0087_0339

129 4-[6-amino-5- (3,4,5-trimethoxy- phenyl)-3- pyridyl]-N- cyclopropyl- benzamide 0.5072 2.88 382_0087_7489

130 5- (benzothiophen- 2-yl)-3-(3,4,5- trimethoxyphenyl) pyridin-2-amine 2.69043 4.22 382_0087_0076

131 3-[6-amino-5- (3,4,5-trimethoxy- phenyl)-3- pyridyl]phenol 0.72322 3.04 382_0087_0284

132 5-(6-methoxy-3- pyridyl)-3-(3,4,5- trimethoxyphenyl) pyridin-2-amine 1.06095 2.56 382_0087_0311

133 5-[3-(dimethyl- amino)phenyl]- 3-(3,4,5- trimethoxyphenyl) pyridin-2-amine 0.59506 3.45 382_0087_0135

134 [3-[6-amino-5-[3- (dimethylamino) phenyl]-3- pyridyl]phenyl]- (4-methyl- piperazin-1- yl)methanone 4.43871 3.07 382_0135_0200

135 4-[6-amino-5-[3- (dimethylamino) phenyl]-3- pyridyl]-2- methoxy-phenol 2.10895 3.46 382_0135_0314

136 3-[3-(dimethyl- amino)phenyl]- 5-(3,4,5- trimethoxy- phenyl)pyridin- 2-amine 3.13462 3.45 382_0135_0087

137 4-[6-amino-5-[3- (dimethylamino) phenyl]-3- pyridyl]-2,6- dimethyl-phenol 4.20127 4.65 382_0135_0315

138 3-[3-(dimethyl- amino)phenyl]- 5-(3- pyridyl)pyridin- 2-amine 7.11159 2.71 382_0135_0071

139 [3-[6-amino-5-[3- (dimethylamino) phenyl]-3- pyridyl]phenyl] methanol 2.6979 3.16 382_0135_0291

140 3-[3- (dimethylamino) phenyl]-5-[6- [3-(dimethyl- amino) propoxy]-3- pyridyl]pyridin- 2-amine 4.66462 3.22 382_0135_0002

141 3-[6-amino-5-[3- (dimethylamino) phenyl]-3- pyridyl] benzamide 3.52109 2.77 382_0135_0347

142 5-(3,4- dimethoxy- phenyl)-3-[3- (dimethylamino) phenyl]pyridin- 2-amine 5.04712 3.61 382_0135_0079

143 4-[2-amino-5-(3- chloro-4-fluoro- phenyl)-3- pyridyl]-2- methoxy-phenol 11.34048 4.10 382_0314_0164

144 5-(4- methoxyphenyl)- 3-(3,4,5- trimethoxy- phenyl)pyridin- 2-amine 2.97729 3.18 382_0087_0280

145 4-[2-amino-5-(4- methoxyphenyl)- 3-pyridyl]-2- methoxy-phenol 4.15847 3.20 382_0314_0280

146 5-(3-furyl)-3- (3,4,5-trimethoxy- phenyl)pyridin- 2-amine 12.0965 2.48 382_0087_0343

147 5-(2- phenoxyphenyl)- 3-(3,4,5- trimethoxy- phenyl)pyridin- 2-amine 9.00592 4.84 382_0087_0063

148 4-[6-amino-5- (3,4,5-trimethoxy- phenyl)-3- pyridyl]benzamide 0.40043 2.19 382_0087_0346

149 4-[2-amino-5-(3- methoxyphenyl)- 3-pyridyl]-2- methoxy-phenol 1.19944 3.20 382_0314_4140

150 [4-[2-amino-5- (3,4-dimethoxy- phenyl)-3- pyridyl]phenyl] methanol 5.13242 2.73 382_0285_0079

151 5-[4-(4- methylpiperazin- 1-yl)phenyl]-3- (3,4,5-trimethoxy phenyl)pyridin- 2-amine 0.32234 3.30 382_0087_0218

152 3-(4-fluoro- phenyl)-N-methyl- imidazo[1,2- b]pyridazin-6- amine 3.25909 2.43 437_0339

153 3-(4- methoxyphenyl)- N-methyl- imidazo[1,2- b]pyridazin-6- amine 4.15763 2.13 437_0280

154 2-[6- (methylamino) imidazo[1,2- b]pyridazin-3- yl]phenol 1.13395 1.98 437_0340

155 N-methyl-3-(3- thienyl)imidazo [1,2-b]pyridazin- 6-amine 4.23169 2.07 437_0074

156 3-[6-(methyl- amino) imidazo[1,2- b]pyridazin-3- yl]phenol 2.17588 1.98 437_0284

157 3-(3,4-dimethoxy phenyl)-N- methyl- imidazo[1,2- b]pyridazin-6- amine 1.24313 1.97 437_0079

158 N,N-dimethyl- 3-[6- (methylamino) imidazo[1,2- b]pyridazin-3- yl]benzamide 2.94156 1.59 437_0349

159 N-methyl-3-(1- methylpyrazol-4- yl)imidazo[1,2- b]pyridazin-6- amine 5.63446 0.72 437_7468

160 N-[3-[6- (methylamino) imidazo[1,2- b]pyridazin-3- yl]phenyl] acetamide 1.75426 1.53 437_0081

161 3-(6-methoxy-3- pyridyl)-N- methyl- imidazo[1,2- b]pyridazin-6- amine 4.46164 1.51 437_0311

162 6-(1H-indol-5-yl)- N-methyl- pyrazin-2-amine 14.94246 1.74 445_0204

163 N-ethyl-2-(3,4,5- trimethoxy- anilino)-7,8- dihydro-5H- pyrido[4,3- d]pyrimidine-6- carboxamide 4.24682 1.18 582_9377_5725

164 6-propyl-N- (3,4,5-trimethoxy- phenyl)-7,8- dihydro-5H- pyrido[4,3- d]pyrimidin-2- amine 14.67829 2.59 582_9377_5632

165 [2-[3- (dimethylamino) anilino]-5,7- dihydropyrrolo [3,4-d]pyrimidin- 6-yl]-(2- methoxyphenyl) methanone 10.08397 2.97 585_9372_5053

166 N-(2- hydroxyethyl)-4- [3-(4- hydroxyphenyl) imidazo[1,2- a]pyrazin-6- yl]benzamide 0.64093 1.22 388_0080_0328

167 3-[3-(4- hydroxyphenyl) imidazo[1,2- a]pyrazin-6-yl]- N,N-dimethyl- benzamide 0.97398 2.14 388_0080_0349

168 4-[6-[4-(4- isopropyl- piperazin-1- yl)phenyl]imidazo [1,2-a]pyrazin- 3-yl]phenol 0.63733 3.57 388_0080_0182

169 4-[6-(1- benzylpyrazol-4- yl)imidazo[1,2- a]pyrazin-3- yl]phenol 6.6194 2.99 388_0080_7469

170 4-[3-(2- thienyl)imidazo [1,2-a]pyrazin-6- yl]phenol 6.25235 2.62 388_4147_0080

171 3,6-bis(2- thienyl)imidazo [1,2-a]pyrazine 5.02752 2.70 388_4147_4147

172 N-(2-hydroxy- ethyl)-3-[3-(4- hydroxyphenyl) imidazo[1,2- a]pyrazin-6- yl]benzamide 1.03081 1.22 388_0080_0192

173 N-cyclopropyl-4- [3-(4- hydroxyphenyl) imidazo[1,2- a]pyrazin-6- yl]benzamide 1.95812 2.38 388_0080_7489

174 4-[6-[4-(4- methyl- piperazin-1- yl)phenyl]imidazo [1,2-a]pyrazin- 3-yl]phenol 0.67809 2.79 388_0080_0218

175 4-[6-(6-amino-3- pyridyl)imidazo [1,2-a]pyrazin- 3-yl]phenol 1.9327 1.39 388_0080_7905

176 5-[3-(2- thienyl)imidazo [1,2-a]pyrazin-6- yl]pyridin-2- amine 8.16191 1.47 388_4147_7905

177 4-[3-(3- acetylphenyl) imidazo[1,2- a]pyrazin-6-yl]- N-(2-dimethyl- aminoethyl) benzamide 4.07021 1.79 388_4145_0327

178 N-(2- dimethylamino- ethyl)-4-[3-(2- thienyl)imidazo [1,2-a]pyrazin- 6-yl]benzamide 8.52139 2.01 388_4147_0327

179 4-[3-(3,5- dimethoxyphenyl) imidazo[1,2- a]pyrazin-6-yl]- N-[3-(dimethyl- amino)propyl] benzamide 6.69112 1.98 388_7492_0180

180 N-(2- dimethylamino- ethyl)-4-[3-(4- pyridyl)imidazo [1,2-a]pyrazin-6- yl]benzamide 6.90909 1.02 388_0069_0327

181 4-[6-[2- (dimethylamino) phenyl]imidazo [1,2-a]pyrazin-3- yl]-2-methoxy- phenol 1.75434 2.79 388_0314_0006

182 N-(2- hydroxyethyl)-3- [3-(4-hydroxy-3- methoxy- phenyl)imidazo [1,2-a]pyrazin-6- yl]benzamide 0.8957 1.07 388_0314_0192

183 2-methoxy-4-[6- (3-pyridyl) imidazo[1,2- a]pyrazin-3- yl]phenol 3.06577 1.46 388_0314_0071

184 4-[6-(2- chlorophenyl) imidazo[1,2- a]pyrazin-3-yl]-2- methoxy-phenol 2.53905 3.28 388_0314_4027

185 4-[6-(3- ethoxyphenyl) imidazo[1,2- a]pyrazin-3-yl]- 2-methoxy- phenol 1.36347 2.88 388_0314_0205

186 N-(2- dimethylamino- ethyl)-4-[3-(4- hydroxy-3- methoxy- phenyl)imidazo [1,2-a]pyrazin-6- yl]benzamide 0.44033 1.77 388_0314_0327

187 4-[6-(6-amino-3- pyridyl)imidazo [1,2-a]pyrazin-3- yl]-2-methoxy- phenol 1.41172 1.23 388_0314_7905

188 2-methoxy-4-[6- [6-(4- methylpiperazin- 1-yl)-3- pyridyl]imidazo [1,2-a]pyrazin- 3-yl]phenol 1.13372 2.01 388_0314_0016

189 2-methoxy-4-[6- (1-methylpyrazol- 4-yl)imidazo[1,2- a]pyrazin-3- yl]phenol 0.74595 1.11 388_0314_8400

190 N-[3-[3-(3,4,5- trimethoxyphenyl) imidazo[1,2- a]pyrazin-6- yl]phenyl] methane- sulfonamide 2.79564 1.04 388_0087_6488

191 N-[3- (dimethylamino) propyl]-4-[3-(4- hydroxy-3- methoxy- phenyl)imidazo [1,2-a]pyrazin-6- yl]benzamide 0.60574 1.83 388_0314_0180

192 2-methoxy-4-[6- [6-(2- morpholinoethyl- amino)-3- pyridyl]imidazo [1,2-a]pyrazin- 3-yl]phenol 1.35363 1.33 388_0314_0003

193 6-(1- methylpyrazol-4- yl)-3-(3- thienyl)imidazo [1,2-a]pyrazine 6.37648 1.35 388_0074_8400

194 6-phenyl-3-(3- thienyl)imidazo [1,2-a]pyrazine 3.94995 2.92 388_0074_0061

195 [4-[3-(3- thienyl)imidazo [1,2-a]pyrazin- 6-yl]phenyl] methanol 2.3518 2.16 388_0074_0285

196 4-[3-(4- methoxyphenyl) imidazo[1,2- a]pyrazin-6- yl]phenol 10.45826 2.68 388_0280_0080

197 6-(3-pyridyl)-3- (3- thienyl)imidazo [1,2-a]pyrazine 4.33598 1.70 388_0074_0071

198 3-(4-pyridyl)-6- (2- thienyl)imidazo [1,2-a]pyrazine 5.68757 1.70 388_0069_4147

199 4-[3-(3- thienyl)imidazo [1,2-a]pyrazin-6- yl]phenol 2.70168 2.62 388_0074_0080

200 6-(2-thienyl)-3- (3- thienyl)imidazo [1,2-a]pyrazine 2.24904 2.70 388_0074_4147

201 N-[3-[3-(3- thienyl)imidazo [1,2-a]pyrazin-6- yl]phenyl] acetamide 2.32941 2.16 388_0074_0081

202 N-[3-[3-(3- thienyl)imidazo [1,2-a]pyrazin-6- yl]phenyl] methane- sulfonamide 3.32047 1.30 388_0074_6488

203 6-(2-furyl)-3-(3- thienyl)imidazo [1,2-a]pyrazine 6.25008 1.98 388_0074_0142

204 3-(6- phenylimidazo [1,2-a]pyrazin- 3-yl)phenol 6.54588 2.84 388_0284_0061

205 3-[3-(3- hydroxyphenyl) imidazo[1,2- a]pyrazin-6- yl]benzamide 1.58014 1.69 388_0284_0347

206 4-[6-(3- pyridyl)imidazo [1,2-a]pyrazin- 3-yl]phenol 2.72591 1.62 388_0080_0071

207 4-[3-(4- phenoxyphenyl) imidazo[1,2- a]pyrazin-6- yl]phenyl] methanol 4.72246 3.88 388_1029_0285

208 4-[6-(4- chlorophenyl) imidazo[1,2- a]pyrazin-3- yl]phenol 6.37838 3.44 388_0080_0160

209 3-[6-(2- thienyl)imidazo [1,2-a]pyrazin- 3-yl]phenol 2.78435 2.62 388_0284_4147

210 6-(1- methylpyrazol- 4-yl)-3-(4- phenoxyphenyl) imidazo[1,2- a]pyrazine 1.92958 3.07 388_1029_8400

211 3-[6-(2- furyl)imidazo [1,2-a]pyrazin- 3-yl]phenol 6.11196 1.90 388_0284_0142

212 4-[6-(6-methoxy- 3- pyridyl)imidazo [1,2-a]pyrazin- 3-yl]phenol 1.97871 2.06 388_0080_0311

213 3-[6-[4- (hydroxymethyl) phenyl]imidazo [1,2-a]pyrazin- 3-yl]phenol 3.35687 2.07 388_0284_0285

214 3-[6-(1- methylpyrazol-4- yl)imidazo[1,2- a]pyrazin-3- yl]phenol 2.78229 1.27 388_0284_8400

215 4-[6-(1- methylpyrazol-4- yl)imidazo[1,2- a]pyrazin-3- yl]phenol 1.58926 1.27 388_0080_8400

216 6-[6-(4- methylpiperazin- 1-yl)-3-pyridyl]- 3-(4- phenoxyphenyl) imidazo[1,2- a]pyrazine 2.13162 3.97 388_1029_0016

217 N-(2- hydroxyethyl)- 3-[3-(4- phenoxyphenyl) imidazo[1,2- a]pyrazin-6- yl]benzamide 1.48118 3.03 388_1029_0192

218 N-(2- dimethylamino- ethyl)-4-[3-(4- phenoxyphenyl) imidazo[1,2- a]pyrazin-6- yl]benzamide 0.1649 3.74 388_1029_0327

219 N-(2- hydroxyethyl)-4- [3-(4- phenoxyphenyl) imidazo[1,2- a]pyrazin-6- yl]benzamide 0.62307 3.03 388_1029_0328

220 4-[3-(3- chlorophenyl) imidazo[1,2- a]pyrazin-6-yl]- N-[3- (dimethylamino) propyl]benzamide 8.43215 2.90 388_0279_0180

221 5-[3-(4- phenoxyphenyl) imidazo[1,2- a]pyrazin-6- yl]pyridin-2- amine 1.71808 3.19 388_1029_7905

222 N-[3- (dimethylamino) propyl]-4-[3-(3- thienyl)imidazo [1,2-a]pyrazin-6- yl]benzamide 3.87213 2.08 388_0074_0180

223 3-(4- methoxyphenyl)- 6-[4-(4-methyl- piperazin-1- yl)phenyl] imidazo[1,2- a]pyrazine 5.25112 2.94 388_0280_0218

224 N-(2- hydroxyethyl)-3- [3-(3- thienyl)imidazo [1,2-a]pyrazin- 6-yl]benzamide 3.67126 1.31 388_0074_0192

225 6-[6-(4- methylpiperazin- 1-yl)-3-pyridyl]-3- (3- thienyl)imidazo [1,2-a]pyrazine 7.04574 2.25 388_0074_0016

226 5-[3-(3- thienyl)imidazo [1,2-a]pyrazin- 6-yl]pyridin-2- amine 2.45583 1.47 388_0074_7905

227 3,6-bis(3- thienyl)imidazo [1,2-a]pyrazine 8.47406 2.70 388_0074_0074

228 N-(2- dimethylamino- ethyl)-4-[3-(3- thienyl)imidazo [1,2-a]pyrazin- 6-yl]benzamide 1.89752 2.02 388_0074_0327

229 3-(1- methylpyrazol-4- yl)-6-(2- phenoxyphenyl) imidazo[1,2- a]pyrazine 1.81873 3.07 388_8400_0063

230 3-[6-[6-(4- methylpiperazin- 1-yl)-3- pyridyl]imidazo [1,2-a]pyrazin- 3-yl]phenol 3.14141 2.17 388_0284_0016

231 3-[[5-[3-(1,3- benzodioxol-5- yl)imidazo[1,2- a]pyrazin-6-yl]-2- pyridyl]oxy]- N,N-dimethyl- propan-1-amine 9.85132 2.06 388_0068_0002

232 3-[6-(3- ethoxyphenyl) imidazo[1,2- a]pyrazin-3- yl]phenol 6.6859 3.04 388_0284_0205

233 3-(1,3- benzodioxol-5- yl)-6-[4-(4- methylpiperazin- 1-yl)phenyl] imidazo[1,2- a]pyrazine 7.93105 2.72 388_0068_0218

234 3-[6-(3- thienyl)imidazo [1,2-a]pyrazin- 3-yl]phenol 2.51787 2.62 388_0284_0074

235 3-[6-[4-(4- methyl- piperazin-1- yl)phenyl]imidazo [1,2-a]pyrazin- 3-yl]phenol 1.58793 2.79 388_0284_0218

236 4-[3-(4- chlorophenyl) imidazo[1,2- a]pyrazin-6-yl]- N-[3- (dimethylamino) propyl]benzamide 4.90272 2.90 388_0160_0180

237 4-[3-(1,3- benzodioxol-5- yl)imidazo[1,2- a]pyrazin-6-yl]- N-(2-dimethyl- aminoethyl) benzamide 3.79881 1.86 388_0068_0327

238 3-[6-(6-amino-3- pyridyl)imidazo [1,2-a]pyrazin-3- yl]phenol 2.88877 1.39 388_0284_7905

239 N-(2- dimethylamino- ethyl)-4-[3-(3- hydroxyphenyl) imidazo[1,2- a]pyrazin-6- yl]benzamide 0.81226 1.93 388_0284_0327

240 4-[3-(4- chlorophenyl) imidazo[1,2- a]pyrazin-6-yl]- N-(2- dimethylamino- ethyl)benzamide 4.15862 2.84 388_0160_0327

241 3-[6-[6-(2- morpholino- ethylamino)-3- pyridyl]imidazo [1,2-a]pyrazin-3- yl]phenol 2.93938 1.49 388_0284_0003

242 N-[3- (dimethylamino) propyl]-4-[3-(3- hydroxyphenyl) imidazo[1,2- a]pyrazin-6- yl]benzamide 1.61113 1.99 388_0284_0180

243 N-(2- hydroxyethyl)-4- [3-(3- hydroxyphenyl) imidazo[1,2- a]pyrazin-6- yl]benzamide 1.72336 1.22 388_0284_0328

244 4-[3-(1,3- benzodioxol-5- yl)imidazo[1,2- a]pyrazin-6-yl]- N-[3- (dimethylamino) propyl]benzamide 6.03233 1.92 388_0068_0180

245 6-[6-(4- methylpiperazin- 1-yl)-3-pyridyl]- 3-phenyl- imidazo[1,2- a]pyrazine 10.85328 2.47 388_0061_0016

246 3-[6-[4-(4- isopropyl- piperazin-1- yl)phenyl]imidazo [1,2-a]pyrazin- 3-yl]phenol 2.61352 3.57 388_0284_0182

247 5-[3-(1,3- benzodioxol-5- yl)imidazo[1,2- a]pyrazin-6- yl]pyridin-2- amine 10.23913 1.31 388_0068_7905

248 4-[6-[6-[3- (dimethylamino) propoxy]-3- pyridyl]imidazo [1,2-a]pyrazin- 3-yl]phenol 1.32178 2.14 388_0080_0002

249 4-[6-[6-(2- morpholino- ethylamino)-3- pyridyl]imidazo [1,2-a]pyrazin- 3-yl]phenol 1.31444 1.49 388_0080_0003

250 4-[6-[6-(4- methylpiperazin- 1-yl)-3- pyridyl]imidazo [1,2-a]pyrazin- 3-yl]phenol 2.21078 2.17 388_0080_0016

251 3-[2-(cyclo- hexylamino) imidazo[2,1-a] [1,3,4]thiadiazol- 5-yl]-N,N- dimethyl- benzamide 0.71795 3.60 699_0052_0349

252 N,N-dimethyl-3- [2-[2-(4- sulfamoylphenyl) ethylamino] imidazo[2,1-a] [1,3,4]thiadiazol- 5-yl]benzamide 0.9091 2.42 699_6182_0349

253 3-[2-[(4- hydroxycyclo- hexyl)amino] imidazo[2,1-b] [1,3,4]thiadiazol- 5-yl]-N,N- dimethyl- benzamide 0.53282 2.22 699_0240_0349

254 1-[3-[2-[(4- hydroxycyclo- hexyl)amino] imidazo[2,1-a] [1,3,4]thiadiazol- 5-yl]phenyl] ethanone 0.48712 2.48 699_0240_4145

255 6-(3- chlorophenyl)- 3-(3,4- dimethoxyphenyl) pyrazolo[1,5- a]pyrimidin-7- amine 0.80424 3.50 DT2008- 0028664

256 N-[3-[2-(2- furylmethylamino) imidazo[2,1-a] [1,3,4]thiadiazol- 5-yl]phenyl] acetamide 4.56802 2.53 699_0144_0081

257 3-[2- (cyclopropyl- methylamino) imidazo[2,1-d] [1,3,4]thiadiazol- 5-yl]-N,N- dimethyl- benzamide 0.97667 2.59 699_4051_0349

258 3-[2- (isobutylamino) imidazo[2,1-d] [1,3,4]thiadiazol- 5-yl]-N,N- dimethyl- benzamide 0.28265 3.05 699_0149_0349

259 3-[2-[(4- fluorophenyl) methylamino] imidazo[2,1-b] [1,3,4]thiadiazol- 5-yl]-N,N- dimethyl- benzamide 2.76099 3.67 699_0224_0349

260 N-[3-[2-(2- thienylmethyl- amino)imidazo [2,1-b] [1,3,4]thiadiazol- 5-yl]phenyl] acetamide 3.92554 3.38 699_0146_0081

261 4-[2-[[5-(1- methylpyrazol- 4-yl)imidazo[2,1- d][1,3,4] thiadiazol-2- yl]amino]ethyl] benzene- sulfonamide 2.26191 1.55 699_6182_7468

262 4-[[5-[3- (dimethylamino) phenyl]imidazo [2,1-a] [1,3,4]thiadiazol- 2-yl]amino] cyclohexanol 5.79421 3.03 699_0240_0135

263 N-[3-[2- (isobutylamino) imidazo[2,1-b] [1,3,4]thiadiazol- 5-yl]phenyl] methane- sulfonamide 7.06833 2.12 699_0149_6488

264 3-[2-(3- hydroxypropyl- amino)imidazo [2,1-b][1,3,4] thiadiazol-5- yl]benzamide 2.87875 0.73 699_0248_0347

265 4-[2-[(4- hydroxycyclo- hexyl)amino] imidazo[2,1-b] [1,3,4]thiadiazol- 5-yl]phenol 3.804 2.62 699_0240_0080

266 3-[2-(2- furylmethyl- amino) imidazo[2,1-b] [1,3,4]thiadiazol- 5-yl]benzamide 1.22619 2.14 699_0144_0347

267 4-[2-[[5-(6- methoxy-3- pyridyl)imidazo [2,1-b] [1,3,4]thiadiazol- 2-yl]amino] ethyl]benzene- sulfonamide 2.61127 2.35 699_6182_0311

268 N,N-dimethyl-3- [2-(tetrahydro- pyran-4- ylmethylamino) imidazo[2,1-b] [1,3,4]thiadiazol- 5-yl]benzamide 2.72692 2.23 699_0243_0349

269 N,N-dimethyl-3- [2-(o-tolyl- methylamino) imidazo[2,1-b] [1,3,4]thiadiazol- 5-yl]benzamide 3.73043 4.04 699_8074_0349

270 N-isobutyl-5-(5- methoxy-3- pyridyl)imidazo [2,1-b] [1,3,4]thiadiazol- 2-amine 5.16693 2.38 699_0149_0196

271 N-(1,3- benzodioxol-5- ylmethyl)-5-(5- methoxy-3- pyridyl)imidazo [2,1-b] [1,3,4]thiadiazol- 2-amine 0.44781 2.48 699_0236_0196

272 N-[4-[3-(4- hydroxy-3- methoxy- phenyl)imidazo [1,2-b]pyridazin- 6-yl]phenyl] acetamide 0.16907 3.03 828_0314_0722

273 N-[3-[6-(1,3- benzodioxol-5- yl)imidazo[1,2- b]pyridazin-3- yl]phenyl] acetamide 1.16817 3.11 828_0081_0068

274 N-[3-[3-(1,3- benzodioxol-5- yl)imidazo[1,2- b]pyridazin-6- yl]phenyl] acetamide 1.10979 3.11 828_0068_0081

275 N-[3-(3- acetylphenyl)-6- 4-(morpholine-4- carbonyl)phenyl] imidazo[1,2- a]pyridin-8- yl]acetamide 2.02757 1.85 802_4145_0337

276 N-[3-[6-[3- (trifluoromethoxy) phenyl]imidazo [1,2-b]pyridazin- 3-yl]phenyl] acetamide 1.5009 4.92 828_0081_0168

277 1-[3-[6-(3,4- dimethoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] ethanone 0.65302 3.50 828_4145_0079

278 N-[3-[6-(4- methylsulfonyl- phenyl)imidazo [1,2-b]pyridazin- 3-yl]phenyl] acetamide 1.08226 2.33 828_0081_0174

279 N-[3-[3-(3- acetamidophenyl) imidazo[1,2-b] pyridazin-6- yl]phenyl] acetamide 0.55312 2.73 828_0081_0081

280 3-[2-[(4- methoxyphenyl) methylamino] imidazo[2,1-b] [1,3,4]thiadiazol- 5-yl]-N,N- dimethyl- benzamide 2.33054 3.37 699_0244_0349

281 N-[3-[3-(3- acetylphenyl) imidazo[1,2- b]pyridazin-6- yl]phenyl] acetamide 0.6205 3.05 828_4145_0081

282 4-[3-(3- acetamidophenyl) imidazo[1,2- b]pyridazin-6- yl]benzamide 0.22155 2.34 828_0081_0346

283 N-[4-[3-(3- hydroxyphenyl) imidazo[1,2- b]pyridazin-6- yl]phenyl] acetamide 0.51873 3.19 828_0284_0722

284 N-[2-(4- pyridyl)ethyl]-5- (3,4,5- trimethoxy- phenyl)imidazo [2,1-b][1,3,4] thiadiazol-2- amine 1.77014 2.83 699_0039_0087

285 N-[3-(4- fluorophenyl)-6- [4-(morpholine-4- carbonyl)phenyl] imidazo[1,2- a]pyridin-8- yl]formamide 3.59432 2.39 788_0339_0337

286 3-[2- (benzylamino) imidazo[2,1-d] [1,3,4]thiadiazol- 5-yl]-N,N- dimethyl- benzamide 1.50507 3.53 699_0232_0349

287 5-(6-methoxy-3- pyridyl)-N-(4- pyridylmethyl) imidazo[2,1-b] [1,3,4]thiadiazol- 2-amine 2.58601 2.23 699_0237_0311

288 N-[3-[3-[3- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6-yl]phenyl] acetamide 1.63929 2.72 828_0291_0081

289 3-[2-(2- furylmethylamino) imidazo[2,1-p] [1,3,4]thiadiazol- 5-yl]-N,N- dimethyl- benzamide 2.46273 2.59 699_0144_0349

290 N-[3-[6-(4- dimethylamino- phenyl)imidazo [1,2-a]pyridazin- 3-yl]phenyl] acetamide 1.09863 3.60 828_0081_0004

291 N-[3-(3- acetylphenyl)-6- [4-(morpholine-4- carbonyl)phenyl] imidazo[1,2- a]pyridin-8- yl]formamide 2.99487 1.80 788_4145_0337

292 N-[3-[3-(4- hydroxy-3- methoxy- phenyl)imidazo [1,2-b]pyridazin- 6-yl]phenyl] acetamide 0.10208 3.03 828_0314_0081

293 N-[3-[3-[4- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6-yl]phenyl] methane- sulfonamide 0.83024 1.86 828_0285_6488

294 1-[3-[6-(3- hydroxyphenyl) imidazo[1,2- a]pyridazin-3- yl]phenyl] ethanone 0.99396 3.51 828_4145_0284

295 [4-[3-[3- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6-yl]phenyl] methanol 2.22994 2.72 828_0291_0285

296 4-[3-[3- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6-yl]benzamide 1.89185 2.34 828_0291_0346

297 N-(2- dimethylamino- ethyl)-3-[6-[4- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 3-yl]benzamide 1.47637 2.58 828_0176_0285

298 3-[3-(3- hydroxyphenyl) imidazo[1,2- b]pyridazin-6- yl]benzamide 0.31104 2.80 828_0284_0347

299 4-[3-[4- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6-yl]-2-methoxy- phenol 0.22297 3.02 828_0285_0314

300 2-(3,4- dimethoxy- phenyl)-6- hydroxy- chromen-4-one 8.95228 2.35 DT2012- 0347380

301 [3-[6-(3- pyridyl)imidazo [1,2-b]pyridazin- 3-yl]phenyl] methanol 2.03689 2.27 828_0291_0071

302 [3-[6-[(4- fluorophenyl) methyl]imidazo [1,2-b]pyridazin- 3-yl]phenyl] methanol 3.9747 3.56 828_0291_6370

303 [3-[6-(3- methoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] methanol 2.74495 3.33 828_0291_4140

304 N-[3-[3-(4- pyridyl)imidazo [1,2-b]pyridazin- 6-yl]phenyl] methane- sulfonamide 0.29796 1.41 828_0069_6488

305 1-benzyl-N-[4- (4-methyl- piperazin-1-yl) phenyl]-2-(3- pyridyl)pyrrolo [3,2-c]pyridin-6- amine 13.73604 5.14 809_2675_6001_0091

306 2-(1H-pyrazol-4- yl)-N-(2-pyridyl)- 1H-pyrrolo[3,2- c]pyridin-6-amine 7.566 2.14 809_2678_0263_0259

307 N-(4-methyl- sulfonylphenyl)- 2-(1H-pyrazol- 4-yl)-1H- pyrrolo[3,2- c]pyridin-6-amine 4.77594 1.60 809_2678_0263_9248

308 1-benzyl-2-(3- pyridyl)-N- pyrimidin-4-yl- pyrrolo[3,2- c]pyridin-6-amine 6.84653 3.86 809_2675_6001_6410

309 N-(3- methoxyphenyl)- 2-(1H-pyrazol-4- yl)-1H- pyrrolo[3,2- c]pyridin-6-amine 16.58236 2.60 809_2678_0263_0026

310 N-(3,4- dimethoxy- phenyl)-2-(1H- pyrazol-4-yl)- 1H-pyrrolo[3,2- 2]pyridin-6- amine 12.71137 2.44 809_2678_0263_0036

311 1-benzyl-N-[4-(4- methylpiperazin- 1-yl)phenyl]-2- phenyl- pyrrolo[3,2- c]pyridin-6-amine 15.018 6.36 809_9960_6001_0091

312 6-(2- methoxyphenyl)- 3-(4- pyridyl)imidazo [1,2-b]pyridazine 0.58491 2.88 828_0069_0083

313 3-[3-(4- pyridyl)imidazo [1,2-b]pyridazin- 6-yl]benzamide 1.2024 1.89 828_0069_0347

314 N-[3-(6- phenylimidazo [1,2-b]pyridazin- 3-yl)phenyl] acetamide 0.77278 3.49 828_0081_0061

315 N-[3-[6-(3- hydroxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] acetamide 1.0711 3.19 828_0081_0284

316 3-(3,4- dimethoxy- phenyl)-6-(3- fluorophenyl) imidazo[1,2- b]pyridazine 1.0392 4.08 828_0079_0313

317 N-[3-[6-[4- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 3-yl]phenyl] acetamide 0.49363 2.72 828_0081_0285

318 [3-(6- phenylimidazo [1,2-b]pyridazin- 3-yl)phenyl] methanol 1.74526 3.49 828_0291_0061

319 6-(3- chlorophenyl)-3- (4-pyridyl)imidazo [1,2-b]pyridazine 0.25819 3.64 828_0069_0279

320 4-[3-(3,4- dimethoxy- phenyl)imidazo [1,2-b]pyridazin- 6-yl]-2-methoxy- phenol 0.22231 3.48 828_0079_0314

321 N-[3-[6-(2- methoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] acetamide 2.85447 3.33 828_0081_0083

322 N-[3-[6-[3- (trifluoromethyl) phenyl]imidazo [1,2-b]pyridazin- 3-yl]phenyl] acetamide 1.6027 4.37 828_0081_0312

323 [3-[6-(2- methoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] methanol 1.06972 3.33 828_0291_0083

324 4-[3-[3- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6-yl]-2-methoxy- phenol 0.15309 3.02 828_0291_0314

325 3-phenyl-6-(4- pyridyl)imidazo [1,2-b]pyridazine 6.92543 3.04 828_0061_0069

326 3-[3-(4- pyridyl)imidazo [1,2-b]pyridazin- 6-yl]phenol 0.22268 2.73 828_0069_0284

327 3-(3,4- dimethoxy- phenyl)-6- phenyl- imidazo[1,2- b]pyridazine 0.42017 3.94 828_0079_0061

328 3-(3,4- dimethoxy- phenyl)-6-(4- fluorophenyl) imidazo[1,2- b]pyridazine 1.33171 4.08 828_0079_0339

329 N-[3-[6-(3,4,5- trimethoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] acetamide 3.13438 3.02 828_0081_0087

330 N-[3-[6-(4- hydroxy-3- methoxy- phenyl)imidazo [1,2-b]pyridazin- 3-yl]phenyl] acetamide 0.09296 3.03 828_0081_0314

331 3-phenyl-6-(3- pyridyl)imidazo [1,2-b]pyridazine 3.84274 3.04 828_0061_0071

332 4-[3-(4- pyridyl)imidazo [1,2-b]pyridazin- 6-yl]phenyl] methanol 0.2553 2.27 828_0069_0285

333 3-(3,4- dimethoxy- phenyl)-6-(2- methoxyphenyl) imidazo[1,2- b]pyridazine 3.12222 3.78 828_0079_0083

334 3-(3,4- dimethoxy- phenyl)-6-(3- furyl)imidazo [1,2- b]pyridazine 0.98263 3.08 828_0079_0343

335 N-[3-[6-(3- furyl)imidazo [1,2-b]pyridazin- 3-yl]phenyl] acetamide 1.2569 2.63 828_0081_0343

336 [3-[6-(3- furyl)imidazo [1,2-b]pyridazin- 3-yl]phenyl] methanol 3.99398 2.63 828_0291_0343

337 N,N-dimethyl-4- [3-(4-pyridyl) imidazo[1,2-b] pyridazin-6- yl]aniline 0.39834 3.14 828_0069_0004

338 [3-[6-(4- methylsulfonyl- phenyl)imidazo [1,2-b]pyridazin- 3-yl]phenyl] methanol 3.03776 2.33 828_0291_0174

339 N-[3-(3- phenylimidazo [1,2-b]pyridazin- 6-yl)phenyl] acetamide 3.66176 3.49 828_0061_0081

340 6-phenyl-3-(4- pyridyl)imidazo [1,2-b]pyridazine 0.22894 3.04 828_0069_0061

341 6-(3- fluorophenyl)-3- (4-pyridyl) imidazo[1,2- b]pyridazine 0.35611 3.18 828_0069_0313

342 3-(3,4- dimethoxy- phenyl)-6-(3- methoxyphenyl) imidazo[1,2- b]pyridazine 0.95169 3.78 828_0079_4140

343 N-[3-[6-(5- methoxy-3- pyridyl)imidazo [1,2-b]pyridazin- 3-yl]phenyl] acetamide 0.614 2.12 828_0081_0196

344 3-[6-(5-methoxy- 3-pyridyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] methanol 2.14052 2.11 828_0291_0196

345 6-(1,3- benzodioxol-5- yl)-3-(4- pyridyl)imidazo [1,2-b]pyridazine 0.21745 2.66 828_0069_0068

346 6-(3-furyl)-3-(4- pyridyl)imidazo [1,2-b]pyridazine 1.02049 2.18 828_0069_0343

347 N-[3-[6-(3- chlorophenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] acetamide 0.3705 4.10 828_0081_0279

348 N-[3-[6-(3- methoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] acetamide 0.40863 3.33 828_0081_4140

349 3-[3-[3- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6-yl]phenol 0.95381 3.18 828_0291_0284

350 4-(3- phenylimidazo [1,2-b]pyridazin- 6-yl)benzamide 2.14265 3.10 828_0061_0346

351 3-[3-(1,3- benzodioxol-5- yl)imidazo[1,2- b]pyridazin-6- yl]phenol 0.91497 3.57 828_0068_0284

352 6-phenyl-3-(3- pyridyl)imidazo [1,2-b]pyridazine 1.94131 3.04 828_0071_0061

353 3-(3-pyridyl)-6- (2-thienyl) imidazo[1,2-b] pyridazine 0.34617 2.81 828_0071_4147

354 N-[3-[6-(3- acetylphenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] acetamide 0.46574 3.05 828_0081_4145

355 3-[6-(3- methoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenol 1.2357 3.79 828_0284_4140

356 4-[6-(3,4- dimethoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]-2-methoxy- phenol 0.04451 3.48 828_0314_0079

357 1-[3-[6-(2- methoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] ethanone 2.3343 3.65 828_4145_0083

358 1-[3-[6-(1- methylpyrazol-4- yl)imidazo[1,2- 3]pyridazin-3- yl]phenyl] ethanone 0.37322 2.24 828_4145_7468

359 N-[3-[3-(2- thienyl)imidazo [1,2-b]pyridazin- 6-yl]phenyl] methane- sulfonamide 1.20815 2.40 828_4147_6488

360 3-(1,3- benzodioxol-5- yl)-6-(3- pyridyl)imidazo [1,2-b]pyridazine 0.68757 2.66 828_0068_0071

361 [4-[3-(3- pyridyl)imidazo [1,2-b]pyridazin- 6-yl]phenyl] methanol 2.9094 2.27 828_0071_0285

362 6-benzyl-3-(3,4- dimethoxyphenyl) imidazo[1,2- b]pyridazine 0.97448 3.87 828_0079_6001

363 3-[6-[4- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 3-yl]phenol 0.28545 3.18 828_0284_0285

364 4-[6-(2- methoxyphenyl) imidazo[1,2- 3]pyridazin-3- yl]phenyl] methanol 3.90029 3.33 828_0285_0083

365 [4-[6-(3- methoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] methanol 1.55838 3.33 828_0285_4140

366 2-methoxy-4-[6- (3-methoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenol 0.22071 3.63 828_0314_4140

367 1-[3-[6- (3-furyl)imidazo [1,2-b]pyridazin- 3-yl]phenyl] ethanone 3.4398 2.95 828_4145_0343

368 4-[3-(2- thienyl)imidazo [1,2-b]pyridazin- 6-yl]benzamide 0.95101 2.88 828_4147_0346

369 3-[3-(1,3- benzodioxol-5- yl)imidazo[1,2- b]pyridazin-6- yl]-N-(2- hydroxyethyl) benzamide 0.36748 2.26 828_0068_0192

370 [3-[3-(1,3- benzodioxol-5- yl)imidazo[1,2- b]pyridazin-6- yl]phenyl] methanol 0.33166 3.11 828_0068_0291

371 N-[3-[6-(2- thienyl)imidazo [1,2-b]pyridazin- 3-yl]phenyl] acetamide 0.20995 3.27 828_0081_4147

372 3-(6- phenylimidazo [1,2-b]pyridazin- 3-yl)phenol 0.89352 3.95 828_0284_0061

373 1-[3-[3-(3- hydroxyphenyl) imidazo[1,2- b]pyridazin-6- yl]phenyl] ethanone 1.60026 3.51 828_0284_4145

374 [4-[6-(3- fluorophenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] methanol 2.95859 3.63 828_0285_0313

375 1-[3-[3-[3- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6-yl]phenyl] ethanone 2.16824 3.04 828_0291_4145

376 1-[3-[6-[3- (dimethylamino) phenyl]imidazo [1,2-b]pyridazin- 3-yl]phenyl] ethanone 0.88623 3.92 828_4145_0135

377 1-[3-[6-(6- amino-3-pyridyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] ethanone 0.28267 2.36 828_4145_7905

378 [4-[3-(2- thienyl)imidazo [1,2-b]pyridazin- 6-yl]phenyl] methanol 2.35649 3.26 828_4147_0285

379 N-[3-[3-(3,4- dimethoxyphenyl) imidazo[1,2- b]pyridazin-6- yl]phenyl] methane- sulfonamide 0.70252 2.31 828_0079_6488

380 3-[3-(3- acetylphenyl) imidazo[1,2- b]pyridazin-6- yl]benzamide 0.51895 2.66 828_4145_0347

381 N-[3-[3-(3- pyridyl)imidazo [1,2-b]pyridazin- 6-yl]phenyl] methane- sulfonamide 1.41022 1.41 828_0071_6488

382 3-[6-(4- pyridyl)imidazo [1,2-b]pyridazin- 3-yl]phenol 0.20283 2.73 828_0284_0069

383 3-[6-(5- quinolyl)imidazo [1,2-b]pyridazin- 3-yl]phenol 14.63638 4.11 828_0284_6831

384 N-[3-[3-[3- hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6-yl]phenyl] methane- sulfonamide 1.15032 1.86 828_0291_6488

385 2-methoxy-4-[6- (2-methoxy- phenyl) imidazo[1,2- b]pyridazin-3- yl]phenol 0.95886 3.63 828_0314_0083

386 3-[3-(3- acetylphenyl) imidazo[1,2- b]pyridazin-6- yl]-N-methyl- benzamide 1.71793 2.89 828_4145_7965

387 [3-[3-(2- thienyl)imidazo [1,2-b]pyridazin- 6-yl]phenyl] methanol 1.68324 3.26 828_4147_0291

388 6-(1- methylpyrazol-4- yl)-3-(2- thienyl)imidazo [1,2-b]pyridazine 1.3135 2.46 828_4147_7468

389 3-[3-(3,4- dimethoxyphenyl) imidazo[1,2- a]pyridazin-6-yl]- N-(2- hydroxyethyl) benzamide 0.3666 2.32 828_0079_0192

390 3-(1,3- benzodioxol-5- yl)-6-(1- methylpyrazol-4- yl)imidazo[1,2- b]pyridazine 0.95557 2.30 828_0068_7468

391 3-(3,4- dimethoxy- phenyl)-6-(1- methylpyrazol-4- yl)imidazo[1,2- b]pyridazine 0.36693 2.37 828_0079_7468

392 3-[6-(3- fluorophenyl) imidazo[1,2- b]pyridazin-3- yl]phenol 2.26441 4.09 828_0284_0313

393 1-[3-[6-(3- aminophenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] ethanone 1.12246 2.98 828_4145_0005

394 6-(2-methoxy- phenyl)-3-(3- pyridyl)imidazo [1,2-b]pyridazine 2.3503 2.88 828_0071_0083

395 3-(3,4- dimethoxy- phenyl)-6-(4- pyridyl)imidazo [1,2-b]pyridazine 0.40386 2.72 828_0079_0069

396 3-[6-(3- pyridyl)imidazo [1,2-b]pyridazin- 3-yl]phenol 0.58643 2.73 828_0284_0071

397 3-[6-(1- methylpyrazol-4- yl)imidazo[1,2- b]pyridazin-3- yl]phenol 0.38762 2.38 828_0284_7468

398 [4-[6-(4- fluorophenyl) imidazo[1,2- 3]pyridazin-3- yl]phenyl] methanol 2.94383 3.63 828_0285_0339

399 4-[6-(3- hydroxyphenyl) imidazo[1,2- b]pyridazin-3- yl]-2-methoxy- phenol 0.29478 3.49 828_0314_0284

400 6-(3,4- dimethoxy- phenyl)-3-(4- pyridyl)imidazo [1,2-b]pyridazine 0.28231 2.72 828_0069_0079

401 6-(4- fluorophenyl)-3- (3- pyridyl)imidazo [1,2-b]pyridazine 2.77876 3.18 828_0071_0339

402 [3-[3-(3- chlorophenyl) imidazo[1,2- b]pyridazin-6- yl]phenyl] methanol 9.81893 4.09 828_0279_0291

403 3-[6-(4- fluorophenyl) imidazo[1,2- b]pyridazin-3- yl]phenol 11.87843 4.09 828_0284_0339

404 3-phenyl-6-(2- thienyl)imidazo [1,2-b]pyridazine 1.9697 4.03 828_0061_4147

405 3-(3,4- dimethoxy- phenyl)-6-(3- pyridyl)imidazo [1,2-b]pyridazine 0.54944 2.72 828_0079_0071

406 N-[3-[3-(3- hydroxyphenyl) imidazo[1,2- b]pyridazin-6- yl]phenyl] acetamide 1.64512 3.19 828_0284_0081

407 4-[6-[4- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 3-yl]-2-methoxy- phenol 0.12455 3.02 828_0314_0285

408 3-[3-(3,4- dimethoxyphenyl) imidazo[1,2- b]pyridazin-6- yl]-N-methyl- benzamide 3.49397 3.01 828_0079_7965

409 N-[3-[3-(4- pyridyl)imidazo [1,2-b]pyridazin- 6-yl]phenyl] acetamide 0.59778 2.27 828_0069_0081

410 6-(3-furyl)-3-(3- pyridyl)imidazo [1,2-b]pyridazine 2.34906 2.18 828_0071_0343

411 N-[3-[6-(3,4- dimethoxyphenyl) imidazo[1,2- p]pyridazin-3- yl]phenyl] acetamide 0.25932 3.18 828_0081_0079

412 3-[6-(3- furyl)imidazo[1,2- b]pyridazin-3- yl]phenol 1.05684 3.09 828_0284_0343

413 1-[3-[6-(4- pyridyl)imidazo [1,2-b]pyridazin- 3-yl]phenyl] ethanone 0.37149 2.59 828_4145_0069

414 6-(m- tolylmethyl)-3-(4- pyridyl)imidazo [1,2-b]pyridazine 0.97706 3.48 828_0069_6291

415 3-(1,3- benzodioxol-5- yl)-6-(4- fluorophenyl) imidazo[1,2- b]pyridazine 7.60066 4.02 828_0068_0339

416 3,6-bis(3,4- dimethoxyphenyl) imidazo[1,2- b]pyridazine 0.53841 3.62 828_0079_0079

417 3-[6-(2- methoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenol 2.73595 3.79 828_0284_0083

418 [4-(6- phenylimidazo [1,2-b]pyridazin- 3-yl)phenyl] methanol 1.45898 3.49 828_0285_0061

419 N-[4-[3-[4- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6-yl]phenyl] acetamide 21.45348 2.72 828_0285_0722

420 4-[6-[3- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 3-yl]-2-methoxy- phenol 0.10235 3.02 828_0314_0291

421 1-[3-[6-[3- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 3-yl]phenyl] ethanone 0.17883 3.04 828_4145_0291

422 3-(4-pyridyl)-3- (2- thienyl)imidazo [1,2-b]pyridazine 0.49696 2.81 828_4147_0069

423 2-methoxy-4-[3- (2-thienyl) imidazo[1,2-b] pyridazin-6- yl]phenol 0.69396 3.57 828_4147_0314

424 N-(2- hydroxyethyl)-3- (3-phenyl- imidazo[1,2-b] pyridazin-6- yl)benzamide 13.86362 2.64 828_0061_0192

425 6-benzyl-3-(4- pyridyl)imidazo [1,2-b]pyridazine 0.6243 2.97 828_0069_6001

426 4-[3-(3- pyridyl)imidazo [1,2-b]pyridazin- 6-yl]benzamide 11.24348 1.89 828_0071_0346

427 1-[3-[6-(3- pyridyl)imidazo [1,2-b]pyridazin- 3-yl]phenyl] ethanone 1.23395 2.59 828_4145_0071

428 1-[3-[6-(3- methoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] ethanone 1.78495 3.65 828_4145_4140

429 6-[(4- fluorophenyl) methyl]-3-(4- pyridyl)imidazo [1,2-b]pyridazine 1.44642 3.11 828_0069_6370

430 3-[3-(1,3- benzodioxol-5- yl)imidazo[1,2- b]pyridazin-6- yl]aniline 0.84313 3.05 828_0068_0005

431 3-(1,3- benzodioxol-5- yl)-6-(3-furyl) imidazo[1,2- b]pyridazine 1.60154 3.02 828_0068_0343

432 [4-[6-(3,4- dimethoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] methanol 3.9402 3.17 828_0285_0079

433 3-[3-(1,3- benzodioxol-5- yl)imidazo[1,2- b]pyridazin-6- yl]-N-(2- dimethylamino- ethyl)benzamide 0.39289 2.97 828_0068_0176

434 N-[3-[6-(3-chloro- 4-fluoro- phenyl)imidazo [1,2-b]pyridazin- 3-yl]phenyl] acetamide 0.52521 4.24 828_0081_0164

435 3-[3-[4- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6-yl]phenol 1.13696 3.18 828_0285_0284

436 [3-[6-(3,4- dimethoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] methanol 0.74933 6.29 828_0291_0079

437 1-[3-[3-(3- acetylphenyl) imidazo[1,2- b]pyridazin-6- yl]phenyl] ethanone 0.58173 3.37 828_4145_4145

438 N-(2-dimethyl- aminoethyl)-3- [3-(2-thienyl) imidazo[1,2- b]pyridazin-6- yl]benzamide 1.1611 3.12 828_4147_0176

439 3-(1,3- benzodioxol-5- yl)-6-phenyl- imidazo[1,2- b]pyridazine 3.08798 3.88 828_0068_0061

440 3-[3-(3- pyridyl)imidazo [1,2-b]pyridazin- 6-yl]phenol 1.81461 2.73 828_0071_0284

441 3-(3,4- dimethoxy- phenyl)-6-(2- thienyl)imidazo [1,2-b]pyridazine 0.21139 3.72 828_0079_4147

442 3-[3-(3- hydroxyphenyl) imidazo[1,2- b]pyridazin-6- yl]phenol 0.98714 3.65 828_0284_0284

443 N-[3-[3-[4- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6-yl]phenyl] acetamide 2.2389 2.72 828_0285_0081

444 1-[3-[6-(4- fluorophenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] ethanone 4.81048 3.95 828_4145_0339

445 3-[3-(3- acetamido- phenyl)imidazo [1,2-b]pyridazin- 6-yl]-N-methyl- benzamide 1.3298 2.57 828_0081_7965

446 [3-(3- phenylimidazo [1,2-b]pyridazin- 6-yl)phenyl] methanol 1.92857 3.49 828_0061_0291

447 6-(1- methylpyrazol- 4-yl)-3-(4- pyridyl)imidazo [1,2-b]pyridazine 30 1.46 828_0069_7468

448 N-(2- dimethylamino- ethyl)-3-[3-[3- (trifluoromethoxy) phenyl]imidazo [1,2-b]pyridazin- 6-yl]benzamide 3.93108 4.78 828_0168_0176

449 [4-[3-[4- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6-yl]phenyl] methanol 1.03522 2.72 828_0285_0285

450 4-[6-(1,3- benzodioxol-5- yl)imidazo[1,2- b]pyridazin-3- yl]-2-methoxy- phenol 0.1999 3.42 828_0314_0068

451 1-[3-[6-(2- thienyl)imidazo [1,2-b]pyridazin- 3-yl]phenyl] ethanone 0.41575 3.59 828_4145_4147

452 6-(5-methoxy-3- pyridyl)-3-(2- thienyl)imidazo [1,2-b]pyridazine 2.86231 2.66 828_4147_0196

453 3,6-bis(2- thienyl)imidazo [1,2-b]pyridazine 4.89416 3.81 828_4147_4147

454 N-(2-dimethyl- aminoethyl)-3- [6-(1-methyl- pyrazol-4- yl)imidazo[1,2- b]pyridazin-3- yl]benzamide 1.76458 1.77 828_0176_7468

455 3-[6-(1,3- benzodioxol-5- yl)imidazo[1,2- b]pyridazin-3- yl]-N-(2- dimethylamino- ethyl)benzamide 2.01862 2.97 828_0176_0068

456 3-[3-[3-(2- dimethylamino- ethylcarbamoyl) phenyl]imidazo [1,2-b]pyridazin- 6-yl]benzamide 4.14881 2.20 828_0176_0347

457 N-(2- hydroxyethyl)-3- [3-(3- hydroxyphenyl) imidazo[1,2- b]pyridazin-6- yl]benzamide 0.35163 2.33 828_0284_0192

458 2-methoxy-4-[6- (3,4,5- trimethoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenol 1.81139 3.32 828_0314_0087

459 [3-[3-(3-furyl) imidazo[1,2- b]pyridazin-6- yl]phenyl] methanol 7.32807 2.63 828_0343_0291

460 4-(6- benzylimidazo [1,2-b]pyridazin- 3-yl)benzamide 0.71127 3.04 828_0346_6001

461 3-[6-(4- acetamidophenyl) imidazo[1,2- b]pyridazin-3- yl]-N-(2- dimethylamino- ethyl)benzamide 0.98309 2.58 828_0176_0722

462 2-methoxy-4-[6- [3-(trifluoro- methoxy)phenyl] imidazo[1,2- b]pyridazin- 3-yl]phenol 0.83451 5.22 828_0314_0168

463 N-(2- dimethylamino- ethyl)-3-[6-[3- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 3-yl]benzamide 0.81608 2.58 828_0176_0291

464 4-[6-[(3,4- difluorophenyl) methyl]imidazo [1,2-b]pyridazin- 3-yl]benzamide 3.07271 3.52 828_0346_6007

465 3-[6-(3- acetamidophenyl) imidazo[1,2- b]pyridazin-3-yl]- N-(2- dimethylamino- ethyl)benzamide 3.16865 2.58 828_0176_0081

466 2-methoxy-4-[6- [3-(trifluoro- methyl)phenyl] imidazo[1,2- b]pyridazin-3- yl]phenol 1.08271 4.67 828_0314_0312

467 6-benzyl-3-(5- methoxy-3- pyridyl)imidazo [1,2-b]pyridazine 2.67306 2.81 828_0196_6001

468 4-[6-(m- tolylmethyl) imidazo[1,2- b]pyridazin-3- yl]benzamide 3.10262 3.55 828_0346_6291

469 N-(2- dimethylamino- ethyl)-3-[6-(2- methoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]benzamide 2.13745 3.19 828_0176_0083

470 N-(2- dimethylamino- ethyl)-3-[6-(3- phenoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]benzamide 19.18297 4.85 828_0176_4032

471 3-(6-cyclo- propylimidazo[1,2- b]pyridazin-3- yl)phenol 1.88565 2.83 828_0284_7494

472 4-[6-(3-fluoro- phenyl)imidazo [1,2-b]pyridazin- 3-yl]-2-methoxy- phenol 0.28065 3.93 828_0314_0313

473 6-[(4-fluoro- phenyl)methyl]- 3-(5-methoxy- 3-pyridyl)imidazo [1,2-b]pyridazine 4.41614 2.95 828_0196_6370

474 4-[6-[(4-fluoro- phenyl)methyl] imidazo[1,2- b]pyridazin-3- yl]benzamide 1.30064 3.18 828_0346_6340

475 N-(2- hydroxyethyl)- 3-[3-[4- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6-yl]benzamide 2.14389 1.87 828_0285_0192

476 3-[3-(4-hydroxy- 3-methoxy- phenyl)imidazo [1,2-b]pyridazin- 6-yl]benzamide 0.22316 2.64 828_0314_0347

477 3-(1- methylpyrazol- 4-yl)-6-(m- tolylmethyl) imidazo[1,2- b]pyridazine 1.79534 3.13 828_7468_6291

478 3-[3-(3- acetylphenyl) imidazo[1,2- b]pyridazin-6- yl]-N-(2- hydroxyethyl) benzamide 0.6293 2.20 828_4145_0192

479 [4-(6- benzylimidazo [1,2-b]pyridazin- 3-yl)phenyl] methanol 3.22675 3.42 828_0285_6001

480 4-[6-[(4- fluorophenyl) methyl]imidazo [1,2-b]pyridazin- 3-yl]-2-methoxy- phenol 2.08974 3.87 828_0314_6370

481 6-[(4- fluorophenyl) methyl]-3-(1- methylpyrazol- 4-yl)imidazo [1,2- b]pyridazine 1.29697 2.76 828_7468_6370

482 N-(2- dimethylamino- ethyl)-3-[6-(4- fluorophenyl) imidazo[1,2- b]pyridazin-3- yl]benzamide 2.23882 3.49 828_0176_0339

483 3-[3-(3- chlorophenyl) imidazo[1,2- b]pyridazin-6- yl]-N-(2- hydroxyethyl) benzamide 30 3.24 828_0279_0192

484 3-[6-(m- tolylmethyl) imidazo[1,2- b]pyridazin-3- yl]benzamide 2.16636 3.55 828_0347_6291

485 1-[3-(6- benzylimidazo [1,2-b]pyridazin- 3-yl)phenyl] ethanone 3.9717 3.74 828_4145_6001

486 5-(6- benzylimidazo [1,2-b]pyridazin- 3-yl)pyridin-2- amine 3.63637 2.73 828_7905_6001

487 N-(2- dimethylamino- ethyl)-3-[6-(3- furyl)imidazo [1,2-b]pyridazin- 3-yl]benzamide 3.88391 2.49 828_0176_0343

488 3-[3-[4- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6-yl]-N-methyl- benzamide 14.94149 2.56 828_0285_7965

489 4-[4-[3-(2- methoxyphenyl)- 1H-pyrazolo[3,4- b]pyridin-4- yl]phenyl] morpholine 1.38698 3.86 932_2105_0001

490 4-(3-chloro-4- fluoro-phenyl)- 3-(2-methoxy- phenyl)-1H- pyrazolo[3,4- b]pyridine 1.28108 4.72 932_2105_0164

491 3-(2- methoxyphenyl)- 4-(6-methoxy-3- pyridyl)-1H- pyrazolo[3,4- b]pyridine 2.93037 3.19 932_2105_0311

492 3-(2- methoxyphenyl)- 4-(2-methoxy- pyrimidin-5- yl)-1H- pyrazolo[3,4- b]pyridine 6.43118 2.57 932_2105_7628

493 4-[3-(3- fluorophenyl)- 1H-pyrazolo[3,4- b]pyridin-4-yl]- N,N-dimethyl- benzamide 3.86464 3.57 932_5640_7464

494 N,N-dimethyl-4- [3-(3-thienyl)-1H- pyrazolo[3,4- b]pyridin-4- yl]benzamide 11.19371 3.20 932_2055_7464

495 N-[4-(3- cyclopropyl-1H- pyrazolo[3,4- b]pyridin-4- yl)phenyl] acetamide 8.88989 2.24 932_2070_0722

496 3-[3-(4-pyridyl)- 1H-pyrazolo[3,4- b]pyridin-4- yl]aniline 18.00668 2.08 932_5650_0005

497 4-[3-(3- fluorophenyl)- 1H-pyrazolo[3,4- b]pyridin-4- yl]phenyl] methanol 3.87681 3.50 932_5640_0285

498 3-(2- methoxyphenyl)- 4-(3-thienyl)-1H- pyrazolo[3,4- b]pyridine 2.66842 3.75 932_2105_0074

499 N-[4-[3-(3,4,5- trimethoxy- phenyl)-1H- pyrazolo[3,4- b]pyridin-4- yl]phenyl] acetamide 2.02053 2.89 932_4516_0722

500 3-(2- methoxyphenyl)- 4-[(E)-styryl]-1H- pyrazolo[3,4- b]pyridine 1.12832 4.66 932_2105_0170

501 4-(3- fluorophenyl)-3- [2-methoxy- phenyl)-1H- pyrazolo[3,4- b]pyridine 1.35112 4.11 932_2105_0313

502 4-[3-(2- methoxyphenyl)- 1H-pyrazolo[3,4- b]pyridin-4- yl]benzamide 1.47616 2.82 932_2105_0346

503 [4-(3-phenyl-1H- pyrazolo[3,4- b]pyridin-4- yl)phenyl] methanol 7.10693 3.36 932_2047_0285

504 3-phenyl-4-(1H- pyrazol-4-yl)-1H- pyrazolo[3,4- b]pyridine 0.8524 2.43 932_2047_7467

505 4-(4- isopropylphenyl)- 3-(3,4,5- trimethoxy- phenyl)-1H- pyrazolo[3,4- b]pyridine 20.88874 4.90 932_4516_0283

506 4-(3- chlorophenyl)-3- cyclopropyl-1H- pyrazolo[3,4- b]pyridine 30 3.61 932_2070_0279

507 N-(2- dimethylamino- ethyl)-3-[3-(2- methoxyphenyl)- 1H-pyrazolo[3,4- b]pyridin-4- yl]benzamide 4.85182 3.06 932_2105_0176

508 [3-[3-(2- methoxyphenyl)- 1H-pyrazolo[3,4- b]pyridin-4- yl]phenyl] methanol 1.66776 3.20 932_2105_0291

509 4-[3-(3- fluorophenyl)- 1H-pyrazolo[3,4- b]pyridin-4- yl]benzamide 2.04666 3.12 932_5640_0346

510 4-[3-(4- chlorophenyl)- 1H-pyrazolo[3,4- b]pyridin-4- yl]benzamide 5.71214 3.58 932_5666_0346

511 3-[3-(3,4,5- trimethoxy- phenyl)-1H- pyrazolo[3,4- b]pyridin-4- yl]phenol 5.02812 3.35 932_4516_0284

512 1-[3-[3-(4- piperidyl)-1H- pyrazolo[3,4- b]pyridin-4- yl]phenyl] ethanone 19.65771 1.89 932_2802_4145

513 N-[4-[3-(3- thienyl)-1H- pyrazolo[3,4- b]pyridin-4- yl]phenyl] acetamide 4.86579 3.14 932_2055_0722

514 2-methoxy-4-[3- (4-piperidyl)-1H- pyrazolo[3,4- b]pyridin-4- yl]phenol 11.88451 1.87 932_2802_0314

515 N-[3-[3-(3,4,5- trimethoxy- phenyl)-1H- pyrazolo[3,4- b]pyridin-4- yl]phenyl] methane- sulfonamide 12.76436 2.03 932_4516_6488

516 4-(3-furyl)-3-(2- methoxyphenyl)- 1H-pyrazolo[3,4- b]pyridine 4.89672 3.11 932_2105_0343

517 3-[3-(1,3- benzodioxol-5- yl)-1H- pyrazolo[3,4- b]pyridin-4- yl]phenol 6.24902 3.45 932_5654_0284

518 4-(3-furyl)-3-(3- pyridyl)-1H- pyrazolo[3,4- b]pyridine 14.29835 2.05 932_2094_0343

519 [4-[3-(3,4,5- trimethoxy- phenyl)-1H- pyrazolo[3,4- b]pyridin-4- yl]phenyl] methanol 5.38048 2.89 932_4516_0285

520 4-(3- methoxyphenyl)- 3-(4-piperidyl)- 1H-pyrazolo[3,4- b]pyridine 17.59629 2.17 932_2802_4140

521 4-[3-(2- methoxyphenyl)- 1H-pyrazolo[3,4- b]pyridin-4- yl]benzonitrile 1.58329 3.82 932_2105_0086

522 N,N-dimethyl-4- [3-(3,4,5- trimethoxy- phenyl)-1H- pyrazolo[3,4- b]pyridin-4- yl]benzamide 11.14532 2.95 932_4516_7464

523 [4-[3-(1,3- benzodioxol-5- yl)-1H- pyrazolo[3,4- b]pyridin-4- yl]phenyl] methanol 4.64328 2.98 932_5654_0285

524 4-(5-fluoro-2- methoxy- phenyl)-3-(4- piperidyl)-1H- pyrazolo[3,4- b]pyridine 11.69312 2.31 932_2802_8363

525 4-(4- methylsulfonyl- phenyl)-3-(3,4,5- trimethoxy- phenyl)-1H- pyrazolo[3,4- b]pyridlne 11.16027 2.49 932_4516_0174

526 [4-[3-(3- chlorophenyl)- 1H-pyrazolo[3,4- b]pyridin-4- yl]phenyl] methanol 6.49611 3.96 932_2049_0285

527 [3-[3-(1,3- benzodioxol-5- yl)-1H- pyrazolo[3,4- b]pyridin-4- yl]phenyl] methanol 3.09057 2.98 932_5654_0291

528 4-(3-furyl)-3- phenyl-1H- pyrazolo[3,4- b]pyridine 8.62504 3.27 932_2047_0343

529 4-(6-methoxy-3- pyridyl)-3-(3,4,5- trimethoxy- phenyl)-1H- pyrazolo[3,4- b]pyridine 16.92312 2.87 932_4516_0311

530 3-cyclopropyl-4- (2-furyl)-1H- pyrazolo[3,4- b]pyridine 12.61441 2.06 932_2070_0142

531 4-(2-furyl)-3-(2- methoxyphenyl)- 1H-pyrazolo[3,4- b]pyridine 2.27665 3.03 932_2105_0142

532 [4-[3-(2- methoxyphenyl)- 1H-pyrazolo[3,4- b]pyridin-4- yl]phenyl] methanol 1.10049 3.20 932_2105_0285

533 1-[3-[3-(2- methoxyphenyl)- 1H-pyrazolo[3,4- b]pyridin-4- yl]phenyl] ethanone 6.60309 3.53 932_2105_4145

534 4-(3-furyl)-3-(4- pyridyl)-1H- pyrazolo[3,4- b]pyridine 20.24336 2.05 932_5650_0343

535 3-[3-(3- fluorophenyl)- 1H-pyrazolo[3,4- b]pyridin-4- yl]aniline 15.07442 3.44 932_5640_0005

536 3-(3-phenyl-1H- pyrazolo[3,4- b]pyridin-4- yl)benzamide 11.71738 2.98 932_2047_0347

537 3-[3-(3,4,5- trimethoxy- phenyl)-1H- pyrazolo[3,4- b]pyridin-4- yl]aniline 14.80741 2.82 932_4516_0005

538 4-(3- fluorophenyl)-3- (3,4,5- trimethoxy- phenyl)-1H- pyrazolo[3,4- b]pyridine 5.22838 3.80 932_4516_0313

539 (E)-3-[3-[5-(3- pyridylmethyl- amino)pyrazolo [1,5-a]pyrimidin- 3-yl]phenyl]prop- 2-enoic acid 2.27421 3.04 294_4003_0289

540 3-[6-amino-5- (3,4,5- trimethoxy- phenyl)- 3-pyridyl] benzamide 0.44196 2.19 382_0087_0347

541 1-[5-[6-amino- 5-[3-(dimethyl- amino)phenyl]- 3-pyridyl]-2- thienyl]ethanone 3.41528 3.39 382_0135_0066

542 (Z)-5-[6- (methylamino) imidazo[1,2- b]pyridazin-3- yl]pent-4-en- 1-ol 31.48029 1.22 437_0299

543 2-methoxy-4-[2- (tetrahydropyran- 4-ylmethyl- amino)imidazo [2,1-b][1,3,4] thiadiazo-5- yl]phenol 2.16407 2.47 699_0243_0314

544 N-[3-[8- acetamido-3- (3,4-dimethoxy- phenyl)imidazo [1,2-a]pyridin- 6-yl]phenyl] acetamide 1.59766 2.13 802_0079_0081

545 N-[3-(3- acetylphenyl)- 6-[3-methoxy- phenyl)imidazo [1,2-a]pyridin- 8-yl]acetamide 3.05101 2.61 802_4145_4140

546 5-(5-methoxy-3- pyridyl)-N-(4- pyridylmethyl) imidazo[2,1- b][1,3,4] thiadiazol-2- amine 0.93173 1.64 699_0237_0196

547 4-[[5-(3-chloro- 4-fluoro- phenyl)imidazo [2,1-b][1,3,4] thiadiazol- 2-yl]amino] cyclohexanol 4.05722 3.67 699_0240_0164

548 4-[2-[[5-(3,4- dimethoxyphenyl) imidazo[2,1-b] [1,3,4]thiadiazol- 2-yl]amino] ethyl]benzene- sulfonamide 5.11606 2.81 699_6182_0079

549 N-[3-(3- acetylphenyl)-6- (2,4-dimethoxy- phenyl)imidazo [1,2-a]pyridin-8- yl]acetamide 2.50187 2.45 802_4145_4141

550 5-(3,4- dimethoxy- phenyl)-N- [2-(4-pyridyl) ethyl]imidazo [2,1-b][1,3,4] thiadiazol- 2-amine 3.1387 2.99 699_0039_0079

551 5-(4-pyridyl)-N- (4-pyridylmethyl) imidazo[2,1-b] [1,3,4]thiadiazol- 2-amine 2.64747 1.80 699_0237_0069

552 5-(6-methoxy-3- pyridyl)-N-[2-(4- pyridyl)ethyl] imidazo[2,1-b] [1,3,4]thiadiazol- 2-amine 2.03015 2.52 699_0039_0311

553 4-[2-[[5-(3- pyridyl)imidazo [2,1-d][1,3,4] thiadiazol-2- yl]amino]ethyl] benzene- sulfonamide 1.87926 1.91 699_6182_0071

554 5-(4- morpholino- phenyl)-N-(2- thienylmethyl) imidazo[2,1-b] [1,3,4]thiadiazol- 2-amine 3.82253 4.03 699_0146_0001

555 [4-[2-[(4- methoxyphenyl) methylamino] imidazo[2,1-b] [1,3,4]thiadiazol- 5-yl]phenyl] methanol 2.8094 3.31 699_0244_0285

556 5-(4- chlorophenyl)-N- (3- pyridylmethyl) imidazo[2,1-b] [1,3,4]thiadiazol- 2-amine 3.65935 3.62 699_4003_0160

557 N-[3-[2-[2-(4- pyridyl)ethyl- amino]imidazo [2,1-b][1,3,4] thiadiazol-5- yl]phenyl] acetamide 1.31627 2.54 699_0039_0081

558 N,N-dimethyl-3- [2-[2-(4- pyridyl)ethyl- amino]imidazo [2,1-b][1,3,4] thiadiazol-5- yl]benzamide 0.72142 2.60 699_0039_0349

559 2-methoxy-4-[2- [(4-methoxy- phenyl)methyl- amino]imidazo [2,1-b][1,3,4] thiadiazol-5- yl]phenol 1.77761 3.61 699_0244_0314

560 5-(6-methoxy-3- pyridyl)-N-(3- pyridylmethyl) imidazo[2,1-b] [1,3,4]thiadiazol- 2-amine 2.93804 2.23 699_4003_0311

561 5-(3-chloro-4- fluoro-phenyl)-N- (2-morpholino- ethyl)imidazo [2,1-b][1,3,4] thiadiazol-2- amine 4.81646 3.05 699_0252_0164

562 5-(4-pyridyl)-N- 2-(4- pyridyl)ethyl] imidazo[2,1-b] [1,3,4]thiadiazol- 2-amine 2.42663 2.08 699_0039_0069

563 4-[[5-(6-methoxy- 3-pyridyl) imidazo[2,1-b] [1,3,4]thiadiazol- 2-yl]amino] cyclohexanol 1.61261 2.14 699_0240_0311

564 1-[5-[2-(2- morpholinoethyl- amino)imidazo [2,1-b][1,3,4] thiadiazol-5- yl]-2-thienyl] ethanone 3 1.77 699_0252_0066

565 N-[3-(3- acetylphenyl)-6- [2-methoxy- phenyl)imidazo [1,2-a]pyridin- 8-yl]acetamide 1.58352 2.61 802_4145_0083

566 N-[3-(3-chloro-4- fluoro-phenyl)-6- [3-(methane- sulfonamido) phenyl]imidazo [1,2-a]pyridin- 8-yl]formamide 2.85911 2.28 788_0164_6488

567 5-(4-pyridyl)-N- (2-thienylmethyl) imidazo[2,1-b] [1,3,4]thiadiazol- 2-amine 3.61591 2.93 699_0146_0069

568 N-[3-[2- (cyclohexylamino) imidazo[2,1-b] [1,3,4]thiadiazol- 5-yl]phenyl] methane- sulfonamide 4.33348 2.68 699_0052_6488

569 3-[2- (isobutylamino) imidazo[2,1-b] [1,3,4]thiadiazol- 5-yl]benzamide 1.13221 2.60 699_0149_0347

570 3-[2- (cyclopropyl- methylamino) imidazo[2,1-b] [1,3,4]thiadiazol- 5-yl]benzamide 1.94081 2.14 699_4051_0347

571 4-[[5-(3- fluorophenyl) imidazo[2,1-b] [1,3,4]thiadiazol- 2-yl]amino] cyclohexanol 2.92063 3.06 699_0240_0313

572 4-[[5-(3,4- dimethoxyphenyl) imidazo[2,1-b] [1,3,4]thiadiazol- 2-yl]amino] cyclohexanol 0.48307 2.60 699_0240_0079

573 5-(3-pyridyl)-N- (2-thienylmethyl) imidazo[2,1-b] [1,3,4]thiadiazol- 2-amine 1.94173 2.93 699_0146_0071

574 5-(3,4- dimethoxy- phenyl)-N-(4- pyridylmethyl) imidazo[2,1-b] [1,3,4]thiadiazol- 2-amine 2.1285 2.70 699_0237_0079

575 N-[6-(4- aminophenyl)-3- (4-fluorophenyl) imidazo[1,2-a] pyridin-8- yl]acetamide 5.25032 2.53 802_0339_7917

576 N-[3-(4- fluorophenyl)-6- (1-methylpyrazol- 4-yl)imidazo[1,2- a]pyridin-8- yl]formamide 8.08703 1.73 788_0339_8400

577 2-amino-1-(3- methoxyphenyl) pyrrolo[3,2- b]quinoxaline- 3-carboxamide 1.18486 2.64 DT2012- 0375412

578 N-cyclohexyl-5- (3-fluorophenyl) imidazo[2,1-d] [1,3,4]thiadiazol- 2-amine 4.07753 4.45 699_0052_0313

579 N-(2- furylmethyl)-5- (3-pyridyl)imidazo [2,1-a][1,3,4] thiadiazol-2- amine 3.16405 2.07 699_0144_0071

580 N-(2- furylmethyl)-5- (1-methylpyrazol- 4-yl)imidazo [2,1-b][1,3,4] thiadiazol- 2-amine 5.63578 1.72 699_0144_7468

581 5-(5-methoxy-3- pyridyl)-N-(2- thienylmethyl) imidazo[2,1-b] [1,3,4]thiadiazol- 2-amine 0.72859 2.77 699_0146_0196

582 5-(3,4- dimethoxy- phenyl)-N- isobutyl-imidazo [2,1-b][1,3,4] thiadiazol-2- amine 2.74508 3.44 699_0149_0079

583 1-[3-[2-(isobutyl- amino)imidazo [2,1-a][1,3,4] thiadiazol-5- yl]phenyl] ethanone 15.11833 3.31 699_0149_4145

584 N-benzyl-5-(3- pyridyl)imidazo [2,1-b][1,3,4] thiadiazol-2- amine 0.8393 3.01 699_0232_0071

585 N-benzyl-5-(5- methoxy-3- pyridyl)imidazo [2,1-b][1,3,4] thiadiazol- 2-amine 0.34323 2.86 699_0232_0196

586 5-(3-pyridyl)-N- (tetrahydropyran- 4-ylmethyl) imidazo[2,1-b] [1,3,4]thiadiazol- 2-amine 4.84876 1.71 699_0243_0071

587 5-(5-methoxy-3- pyridyl)-N- (tetrahydro- pyran-4- ylmethyl)imidazo [2,1-d][1,3,4] thiadiazol- 2-amine 0.38423 1.55 699_0243_0196

588 N-[(4- methoxyphenyl) methyl]-5-(5- methoxy-3- pyridyl)imidazo [2,1-3][1,3,4] thiadiazol- 2-amine 9.65333 2.70 699_0244_0196

589 N-(o-tolylmethyl)- 5-(3-pyridyl) imidazo[2,1-b] [1,3,4]thiadiazol- 2-amine 1.07729 3.53 699_8074_0071

590 1-methyl-N-[4-(4- methylpiperazin- 1-yl)phenyl]-2-[3- (trifluoromethyl) phenyl]pyrrolo [3,2-c]pyridin-6- amine 30 5.51 809_2669_5837_0091

591 1-methyl-N- pyrimidin-4-yl- 2-[3-(trifluoro- methyl)phenyl] pyrrolo[3,2- c]pyridin-6- amine 16.77669 4.23 809_2669_5837_6410

592 2-(3- fluorophenyl)-1- methyl-N-[4-(4- methylpiperazin- 1-yl)phenyl] pyrrolo[3,2- c]pyridin-6- amine 12.86554 4.78 809_2670_5837_0091

593 2-(3- fluorophenyl)-1- methyl-N- pyrimidin-4-yl- pyrrolo[3,2- c]pyridin-6- amine 9.08728 3.49 809_2670_5837_6410

594 5-amino-4-(1H- benzimidazol-2- yl)-1-(1,3- benzodioxol-5- yl)-2H-pyrrol-3- one 4.06818 2.64 DT2009- 0160159

595 N,N-dimethyl-4- [4-[4-(4- methylpiperazin- 1-yl)anilino]-1H- pyrrolo[3,2- c]pyridin-2- yl]benzamide 7.04339 3.71 838_2671_0263_0091

596 4-[2-(3,5- dimethoxy- phenyl)-1H- pyrrolo[3,2- c]pyridin-4- yl]morpholine 30 2.59 838_2728_0263_4009

597 N-[4-[[2-(2- methoxyphenyl)- 1H-pyrrolo[3,2- c]pyridin-4-yl] amino]phenyl] acetamide 30 3.54 838_2729_0263_0023

598 2-(2- methoxyphenyl)- 1-methyl-N-[3- (trifluoromethyl) phenyl]pyrrolo [3,2-c]pyridin-4- amine 30 5.40 838_2729_5837_0235

599 8-(2,5-dimethoxy- phenyl)-7-(4- fluorophenyl)-1- methyl-3H-imidazo [1,2-g]purine-2,4- dione [Also listed as: 6-(2,5-dimethoxy- phenyl)-7-(4- fluorophenyl)-4- methyl-purino[7,8- a]imidazole-1,3- dione: 18.44433 2.44 DT2012- 0296118

600 methyl 2-amino- 1-(3-hydroxy- phenyl)pyrrolo [3,2-b]quinoxaline- 3-carboxylate 2.25787 3.64 DT2012- 0351552

TABLE 4 Secondary screen- initial candidate compounds re-synthesized and expanded. logP Compound ID. IUPAC IC50 FYN (con- (prior ID Structure name (μM) sensus) No. if any)

1 5-phenyl-3- (3,4,5- trimethoxy- phenyl)- pyridin- 2-amine 1.3061932482 3.34 BF000312489 (382_0087_0061)

2 5-[4-(4- methyl- piperazin- 1-yl)phenyl]- 3-(3,4,5- trimethoxy- phenyl)- pyridin- 2-amine 0.232041699 3.30 BF000312520 (382_0087_0218)

3 3-[6-amino- 5-(3,4,5- trimethoxy- phenyl)-3- pyridyl]- phenol 0.525870963 3.04 BF000312527 (382_0087_0284)

4 3-[6-amino- 5-(3,4,5- trimethoxy- phenyl)-3- pyridyl]- benzamide 0.4942965 2.19 BF000312539 (382_0087_0347)

5 4-[6-amino- 5-(3,4,5- trimethoxy- phenyl)-3- pyridyl]- benzamide 0.45785952 2.19 BF000312540 (382_0087_0346)

6 3-[6-amino- 5-(3,4,5- trimethoxy- phenyl)-3- pyridyl]-N- (2- hydroxy- ethyl)- benzamide 1.001189887 1.73 BF000312542 (382_0087_0192)

7 5-(4- methyl- sulfonyl- phenyl)- 3-(3,4,5- trimethoxy- phenyl)- pyridin- 2-amine 0.674160478 2.18 BF000312544

8 N-[3-[6- amino-5- (3,4,5- trimethoxy- phenyl)-3- pyridyl]- phenyl]- methane- sulfonamide 0.561599306 1.72 BF000312545 (382_0087_6488)

9 4-[2-amino- 5-(3,4,5- trimethoxy- phenyl)-3- pyridyl]- phenol 0.2885 3.04 BF000313556 (382_7249_0087)

10 4-[6-amino- 5-(4- hydroxy- phenyl)-3- pyridyl]- benzamide 1.085653826 2.36 BF000313559

11 N-[3-[6- amino-5-(4- hydroxy- phenyl)-3- pyridyl]- phenyl]- acetamide 0.898083782 2.75 BF000313562 (382_7249_0081)

12 4-[2-amino- 5-(4-methyl- sulfonyl- phenyl)-3- pyridyl)- phenol 1.551309576 2.35 BF000313563 (382_7249_0174)

13 N-[3- (dimethyl- amino)- propyl]- 4-[3-(4- hydroxy- phenyl)- imidazo[1,2- a]pyrazin- 6-yl]- benzamide 0.705417706 1.99 BF000333874

14 4-[6-[4-(4- methyl- piperazin-1- yl)phenyl]- imidazo[1,2- a]pyrazin-3- yl]phenol 0.464568962 2.79 BF000333878 (388_0080_0218)

15 N-[2- (dimethyl- amino)- ethyl]-4- [3-(4-hydroxy- phenyl)- imidazo[1,2- a]pyrazin- 6-yl]- benzamide 0.486180008 1.93 BF000333881

16 N-(2- hydroxy- ethyl)-4-[3- (4-hydroxy- phenyl)- imidazo[1,2- a]pyrazin-6- yl]benzamide 0.739736615 1.22 BF000333882 (388_0080_0328)

17 N-[3- (dimethyl- amino)- propyl]- 4-[3-(4- hydroxy-3- methoxy- phenyl)- imidazo[1,2- a]pyrazin-6- yl]benzamide 0.647432877 1.83 BF000334019 (388_0314_0180)

18 N-(2- hydroxy- ethyl)-3-[3-(4- hydroxy-3- methoxy- phenyl)- imidazo[1,2- a]pyrazin-6- yl]benzamide 1.275657607 1.07 BF000334020 (388_0314_0192)

19 4-[2-amino- 5-[4-(4- methyl- piperazin-1- yl)phenyl]- 3-pyridyl]- phenol 0.520622627 3.47 BF000710044

20 3-[2-(cyclo- propyl- methyl- amino)- imidazo[2, 1-b][1,3,4]- thiadiazol- 5-yl]-N,N- dimethyl- benzamide 0.884088514 2.59 BF000714798 (699_4051_0349)

21 5-(5- methoxy-3- pyridyl)-N- (2-thienyl- methyl)- imidazo[2, 1-b][1,3,4]- thiadiazol-2- amine 0.437195357 2.77 BF000714968 (699_0146_0196)

22 4-[[5-(3,4- dimethoxy- phenyl)- imidazo[2,1- b][1,3,4]- thiadiazol-2- yl]amino]- cyclohexanol 0.439583985 2.60 BF000717406 (699_0240_0079)

23 3-[2-[(4- hydroxy- cyclohexyl)- amino]- imidazo[2, 1-b][1,3,4]- thiadiazol- 5-yl]-N,N- dimethyl- benzamide 0.288412517 2.22 BF000717418 (699_0240_0349)

24 4-[[5-(5- methoxy-3- pyridyl)- imidazo[2,1- b][1,3,4]- thiadiazol-2- yl]amino]- cyclohexanol 0.300821259 1.54 BF000802724

1 2-methoxy- 4-[6-(propyl- amino)- imidazo[1, 2-b]pyridazin- 3-yl]phenol 0.081593995 2.71 BF000147080

2 3-(4-pyridyl)- N-(2-thienyl- methyl)-[1,2- a]pyridazin- 6-amine 0.104821372 2.71 BF000145941

3 2-methoxy- 4-[6-(tetra- hydropyran-4- ylamino)- imidazo[1,2- b[pyridazin- 3-yl]phenol 0.112523997 1.79 BF000147168

4 4-[2-amino- 5-(3,4,5- trimethoxy- phenyl)-3- pyridyl]-2- methoxy- phenol 0.115507056 2.88 BF000313035 (382_0314_0087)

5 4-[2-amino- 5-[4-(4- methylpiperazin- 1-yl)phenyl]- 3-pyridyl]-2- methoxy- phenol 0.121074357 3.31 BF000313028

6 2-methoxy- 4-[6-(2- thienyl- methyl- amino)- imidazo[1, 2-b]pyridazin- 3-yl]phenol 0.166284575 3.46 BF000145954

7 N-(3-[6-(4- hydroxy-3- methoxy- phenyl)- imidazo[1,2- b]pyridazin- 3-yl]phenyl]- acatamide 0.166802816 3.03 BF000726183 (828_0081_0314)

8 4-[6-(3- hydroxy- propylamino)- imdazo[1,2- b]pyridazin- 3-yl]-2- methoxy- phenol 0.205976791 1.20 BF000146250 (229_0248_0314)

9 4-[6-amino- 5-(4-hydroxy- 3-methoxy- phenyl)-3- pyridyl]- benzamide 0.214088697 2.20 BF000313038

10 N-propyl-3- (4-pyridyl)- imidazo[1,2- b]pyridazin- 6-amine 0.217345163 1.95 BF000147056

11 N-[2- (dimethyl- amino)ethyl]-4- [3-(4- phenoxy- phenyl)- imidazo[1,2- a]pyrazin- 6-yl]- benzamide 0.22160528 3.74 BF000334031

12 2-methoxy- 4-[6-(2- pyridyl- methyl- amino)- imidazo[1,2- b]pyridazin- 3-yl]phenol 0.233047949 2.41 BF000817095

13 N-[3- (dimethyl- amino)- propyl]- 4-[3-(4- phenoxy- phenyl) imidazo[1,2- a]pyrazin-6- yl]benzamide 0.247391087 3.80 BF000816927

14 3-(4- pyridyl)-N- tetrahydro- pyran-4-yl- imidazo[1,2- b]pyridazin- 6-amine 0.270083246 1.03 BF000817099

15 3-(3,4- dimethoxy- phenyl)-N- propyl- imidazo[1,2- b]pyridazin- 6-amine 0.285138703 2.85 BF000147061 (229_0226_0079)

16 N-(1,3- benzodioxol-5- ylmethyl)-3- (4-pyridyl)- imidazo[1,2- b]pyridazin- 6-amine 0.297126173 2.42 BF000146108 (229_0236_0069)

17 N-[3-[6-(3,4- dimethoxy- phenyl)- imidazo[1,2- a]pyridazin- 3-yl]phenyl]- acatamide 0.313364743 3.18 BF000726345 (828_0081_0079)

18 4-[2-amino- 5-(4-methyl- sulfolyl- phenyl)- 3-pyridyl]-2- methoxy- phenol 0.315744691 2.19 BF000313040 (382_0314_0174)

19 N-[2- (dimethyl- amino)ethyl]- 4-[3-(4- hydroxy-3- methoxy- phenyl)- imidazo[1,2- a]pyrazin-6- yl]benzamide 0.336758519 1.77 BF000334023

20 3-(1,3- benzodioxol- 5-yl)-N-(2- pyridyl- methyl)- imidazo[1,2- b]pyridazin- 6-amine 0.354989794 2.50 BF000146330 (229_4007_0068)

21 4-[6-amino- 5-(3,4,5- trimethoxy- phenyl)-3- pyridyl]-N- cyclopropyl- benzamide 0.376810127 2.88 BF000312541 (382_0087_7489)

22 N-[3-[6- (tetra- hydropyran- 4-ylamino)- imidazo[1,2- b]pyridazin- 3-yl)phenyl]- acetamide 0.396885185 1.49 BF000146155 (229_0242_0081)

23 1-[3-[6- (propyl- amino)- imidazo[1,2- b]pyridazin- 3-yl]phenyl]- ethanone 0.405532058 2.72 BF000147088 (229_0226_4145)

24 4-[6-[[(1S)- 1-(hydroxy- methyl)-2- methyl- propyl]- amino]- imidazo[1, 2-b]pyridazin- 3-yl]-2- methoxy- phenol 0.44318569 2.44 BF000146319

25 1-[3-[6-(2- thienyl- methyl- amino)- imidazo[1,2- b]pyridazin- 3-yl]phenyl)- ethanone 0.450916544 3.48 BF000145962 (229_0146_4145)

26 N-(2- hydroxy- ethyl)- 4-[3-(4- phenoxy- phenyl)- imidazo- [1,2-a]- pyrazin-6- yl]benzamide 0.463504693 3.03 BF000334032 (388_1029_0328)

27 3-(3,4- dimethoxy- phenyl)-N- tetrahydro- pyran-4-yl- imidazo[1,2- b]pyridazin- 6-amine 0.479948935 1.93 BF000146153 (229_0242_0079)

28 3-(3,4- dimethoxy- phenyl)-N-(2- pyridyl- methyl)- imidazo[1,2- b]pyridazin- 6-amine 0.494462769 2.56 BF000147233

29 N- tetrahydro- pyran-4-yl-3- (3,4,5- trimethoxy- phenyl)- imidazo[1,2- b]pyridazin- 6-amine 0.503383229 1.78 BF000147394 (229_0242_0087)

30 3-[[3-(4- pyridyl)- imidazo[1,2- b]pyridazin- 6-yl]amino]- propan-1-ol 0.538085737 0.44 BF000722253

31 3-[6- (propylamino)- imidazo[1,2- b]pyridazin- 3-yl]phenol 0.59230731 2.86 BF000147075 (229_0226_0284)

32 2-methoxy- 4-[6-(1- methyl- pyrazol- 4-yl)- imidazo[1,2- a]pyrazin-3- yl]phenol 0.624331939 1.11 BF000333452 (388_0314_8400)

33 (2S)-3- methyl-2- [[3-(4- pyridyl)- imidazo[1,2- b]pyridazin- 6- yl]amino]- butan- 1-ol 0.630941398 1.68 BF000817097

34 1-[3-[6-(3- hydroxy- propyl- amino)- imdazo[1,2- b]pyridazin- 3- yl]phenyl]- ethanone 0.64498853 1.21 BF000817098

35 3-[[3-(1,3- benzodioxol- 5-yl)- imidazo[1,2- b]pyridazin- 6- yl]amino]- propan- 1-ol 0.707789559 1.28 BF000146218 (229_0248_0068)

36 5-[6-(3- (dimethyl- amino)- propoxy]- 3-pyridyl]- 3-(3,4,5- trimethoxy- phenyl)- pyridin- 2-amine 0.709144298 2.64 BF000312521 (382_0087_0002)

37 3-(3,4- dimetboxy- phenyl)-N-(2- thienyl- methyl)- imidazo[1,2- b]pyridazin- 6-amine 0.721406376 3.61 BF000146992

38 3-[[3-(3,4- dimethoxy- phenyl)- imidazo[1,2- b]pyridazin- 6-yl]-amino]- propan-1-ol 0.72516936 1.34 BF000146224

39 N-[3-[6-(4- pyridyl)- imidazo[1,2- b]pyridazin- 3-yl]phenyl]- acetamide 0.740677454 2.27 BF000817142

40 (2S)-2-[[3- (3,4- dimethoxy- phenyl)- imidazo[1,2- b]pyridazin- yl]amino]- 3-methyl- butan-1-ol 0.742215008 2.59 BF000147413 (229_0254_0079)

41 N-[3-[6-[[(1S)-1- (hydroxy- methyl)- 2-methyl- propyl]- amino]- imidazo[1,2- b]pyridazin- 3-yl]- phenyl]acetamide 0.791967537 2.14 BF000146300 (229_0254_0081)

42 3-(3-methoxy- phenyl)-N- tetrahydro- pyran-4-yl- imidazo[1,2- b]pyridazin- 6-amine 0.828721524 2.09 BF000146183 (229_0242_4140)

43 3-[3-(4- hydroxy- phenyl)- imidazo[1,2- a]pyrazin-6- yl]-N,N- dimethyl- benzamide 0.870676961 2.14 BF000333343 (388_0080_0349)

44 4-[6-(1,3- benzodioxol-5- ylmethyl- amino)- imidazo[1,2- b]pyridazin- 3-yl]-2- methoxy- phenol 1.308570599 3.17 BF000146126

45 3-(3- aminophenyl)- N- tetrahydro- pyran- 4-yl- imidazo[1,2- b]pyridazin- 6-amine 1.423322773 1.42 BF000146142 (229_0242_0005)

46 1-[3-[6-(1,3- benzodioxol-5- ylmethyl- amino)- imidazo[1,2- b]pyridazin- 3-yl]phenyl]- ethanone 3.189566346 3.19 BF000147140

47 N-(1,3- benzodioxol- 5-ylmethyl)-3- [3,4- dimethoxy- phenyl)- imidazo[1,2- b]pyridazin- 6-amine 6.216010093 3.32 BF000146114

4-[2-amino- 5-(4-piperazin- 1-ylphenyl)-3- pyridyl]-2- methoxy- phenol 0.060908784 2.93 BF000707279

N-benzyl-5- (3-pyridyl)- imidazo[2,1- b][1,3,4]- thiadiazol-2- amine 0.633579663 3.01 BF000714845 (699_0232_0071)

3-[2-(benzyl- amino)- imidazo[2,1- b][1,3,4]- thiadiazol- 5-yl]-N,N- dimethyl- benzamide 1.233285044 3.53 BF000714847 (699_0232_0349)

N-benzyl-5- (5-methoxy- 3-pyridyl)- imidazo[2,1- b][1,3,4]- thiadiazol-2- amine 0.217465905 2.86 BF000714862 (699_0232_0196)

5-(5- methoxy-3- pyridyl)-N- (tetra- hydropyran-4- ylmethyl)- imidazo[2,1- b][1,3,4]- thiadiazol- 2-amine 0.292588141 1.55 BF000714923 (699_0243_0196)

N-(1,3- benzodioxol-5- ylmethyl)-5- (5-methoxy- 3-pyridyl)- imidazo[2,1- b][1,3,4]- thiadiazol-2- amine 0.289073347 2.48 BF000714981 (699_0236_0196)

N,N- dimethyl-3- [2-(tetra- hydropyran-4- ylmethyl- amino)- imidazo[2,1- b][1,3,4]- thiadiazol-5- yl]benzamide 1.363919415 2.23 BF000715802 (699_0243_0349)

3-[2-(1,3- benzodioxol-5- ylmethyl- amino)- imidazo[2,1- b][1,3,4]- thiadiazol-5-yl]- N,N- dimethyl- benzamide 1.925583132 3.15 BF000717214

2-methoxy- 4-[2- (tetrahydro- pyran- 4-ylmethyl- amino)- imidazo[2,1- b][1,3,4]- thiadiazol-5- yl]phenol 0.710456332 2.47 BF000717555 (699_0243_0314)

3-[3-[3- hydroxy- methyl)- phenyl]- imidazo[1,2- b]pyridazin- 6-yl]phenol 1.166257347 3.18 BF000726195 (828_0291_0284)

N-[3-[3-(3- acetamido- phenyl)- imidazo[1,2- b]pyridazin- 6-yl]phenyl]- acetamide 0.647620035 2.73 BF000726346 (828_0081_0081)

3-[6-(4- pyridyl)- imidazo[1,2- b]pyridazin- 3-yl]phenol 0.342140497 2.73 BF000726352 (828_0284_0069)

[3-[6-(4- pyridyl)- imidpzo[1,2- b]pyridazin- 3-yl]phenyl]- methanol 0.972914631 2.27 BF000726364

[3-[6-(3,4- dimethoxy- phenyl)- imidazo[1,2- b]pyridazin- 3-yl]phenyl]- methanol 0.892824216 3.17 BF000726366 (828_0291_0079)

N-[3-[3-[3- (hydroxy- methyl) phenyl]- imidazo[1, 2-b]pyridazin- 6-yl]phenyl]- acetamide 1.516622765 2.72 BF000726367 (828_0291_0081)

4-[6-(3,4- dimethoxy- phenyl)- imidazo[l,2- b]pyridazin- 3-yl]-2- methoxy- phenol 0.039407867 3.48 BF000726453 (828_0314_0079)

N-[3-[3-(4- hydroxy-3- methoxy- phenyl)- imidazo[1,2- b]pyridazin- 6-yl]phenyl]- acetamide 0.103548636 3.03 BF000726454 (828_0314_0081)

1-[3-[6-[3- (hydroxy- methyl)- phenyl]- imidazo[1,2- b]pyridazin- 3-yl]phenyl]- ethanone 0.290543095 3.04 BF000726471 (828_4145_0291)

4-[6-[4- (hydroxy- methyl)- phenyl]- imidazo[1, 2-b]pyridazin- 3-yl]-2- methoxy- phenol 0.061804045 3.02 BF000726486 828.0314_0285)

4-[6-[3- (hydroxy- methyl)- phenyl]- imidazo[1, 2-b]pyridazin- 3-yl]-2- methoxy- phenol 0.062959987 3.02 BF000726487 (828_0314_0291)

2-methoxy- 4-[6-(4- pyridyl)- imidazo[1,2- b]pyridazin- 3-yl]phenol 0.079413853 2.57 BF000817169

3-(4-pyridyl)- N-(2- pyridyl- methyl)- imidazo[1,2- b]pyridazin- 6-amine 0.170100794 1.66 BF000817170

3,5- bis(3,4,5- trimethoxy- phenyl)- pyridin-2- amine 0.08540726 2.87 BF000817175

4-[2-amino- 5-[4-4- isopropyl- piperazin-1- yl)phenyl]-3- pyridyl]-2- methoxy- phenol 0.078146017 4.08 BF000817185

4-[3-(4- hydroxy-3- methoxy- phenyl)- imidazo[1,2- b]pyridazin- 6-yl]-2- methoxy- phenol 0.02944792 3.33 BF000817186

[3-[3-[3- (hydroxy- methyl)- phenyl]- imidazo[1, 2-b]pyridazin- 6-yl]phenyl]- methanol 0.828494158 2.72 BF000817188

5-(3,4- dimethoxy- phenyl)-N- (tetra- hydropyran-4- ylmethyl)- imidazo[2,1- b][1,3,4]- thiadiazol-2- amine 1.026007749 2.61 BF000817208

N-[3-[6-[3- (hydroxy- methyl)- phenyl]- imidazo[1, 2-b]pyridazin- 3-yl]phenyl]- acetamide 0.435155145 2.72 BF000817329

4-[2-amino- 5-(4- morpholino- phenyl)-3- pyridyl]-2- methoxy- phenol 0.212232208 3.24 BF000817413

5-[6-amino- 5-[4-(4- methyl- piperazin- 1-yl)phenyl]- 3-pyridyl]-2- methoxy- phenol 9.65 3.31 BF000817418 

I claim:
 1. A method for inhibiting activity of Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being represented by the structural formula (I):

wherein: R1 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate, and R2 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate.
 2. A method of treating, or slowing progression of, a disease associated with Fyn kinase, said method comprising administering a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being represented by the structural formula (I):

wherein: R1 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate, and R2 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate.
 3. A compound of formula (I) selected from the group consisting of 3-[2-amino-5-(3,4-dimethoxyphenyl)-3-pyridyl]phenol, 3-[6-amino-5-[3-(dimethylamino)phenyl]-3-pyridyl]-N-(2-hydroxyethyl)benzamide, 5-(3-methoxyphenyl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[2-amino-5-(4-methylsulfonylphenyl)-3-pyridyl]-2-methoxy-phenol, 4-[2-amino-5-(p-tolyl)-3-pyridyl]-2-methoxy-phenol, 4-[2-amino-5-(3-chlorophenyl)-3-pyridyl]-2-methoxy-phenol, 4-[2-amino-5-(3-fluorophenyl)-3-pyridyl]-2-methoxy-phenol, 4-(2-amino-5-phenyl-3-pyridyl)-2-methoxy-phenol, 4-[6-amino-5-(4-hydroxy-3-methoxy-phenyl)-3-pyridyl]-2,6-dimethyl-phenol, 4-[2-amino-5-(4-fluorophenyl)-3-pyridyl]-2-methoxy-phenol, 4-[2-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]-2-methoxy-phenol, 4-[6-amino-5-[4-(methoxymethoxy)phenyl]-3-pyridyl]benzamide, 3-[6-amino-5-[4-(methoxymethoxy)phenyl]-3-pyridyl]phenyl]methanol, 3-[6-amino-5-[4-(methoxymethoxy)phenyl]-3-pyridyl]benzamide, N-[3-[6-amino-5-[4-(methoxymethoxy)phenyl]-3-pyridyl]phenyl]acetamide, 4-[6-amino-5-[4-(hydroxymethyl)phenyl]-3-pyridyl]-2,6-dimethyl-phenol, 3-[4-(methoxymethoxy)phenyl]-5-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 3-[2-amino-5-(4-morpholinophenyl)-3-pyridyl]phenol, N-[3-[6-amino-5-(4-hydroxyphenyl)-3-pyridyl]phenyl]acetamide, 4-[2-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]phenol, 4-[2-amino-5-[3-(dimethylamino)phenyl]-3-pyridyl]phenol, 3-[2-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]phenol, 4-[2-amino-5-(4-methylsulfonylphenyl)-3-pyridyl]phenol, 3-(3-aminophenyl)-5-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[2-amino-5-(3-methoxyphenyl)-3-pyridyl]phenol, 4-[6-amino-5-(4-pyridyl)-3-pyridyl]-2,6-dimethyl-phenol, 5-[6-[3-(dimethylamino)propoxy]-3-pyridyl]-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 5-(3-fluorophenyl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]-2,6-dimethyl-phenol, N-[3-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]phenyl]methanesulfonamide, 5-phenyl-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 3-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]-N-(2-hydroxyethyl)benzamide, 5-(4-aminophenyl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]phenol, 5-(4-fluorophenyl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]-N-cyclopropyl-benzamide, 5-(benzothiophen-2-yl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 3-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]phenol, 5-(6-methoxy-3-pyridyl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 5-[3-(dimethylamino)phenyl]-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, [3-[6-amino-5-[3-(dimethylamino)phenyl]-3-pyridyl]phenyl]-(4-methylpiperazin-1-yl)methanone, 4-[6-amino-5-[3-(dimethylamino)phenyl]-3-pyridyl]-2-methoxy-phenol, 3-[3-(dimethylamino)phenyl]-5-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[6-amino-5-[3-(dimethylamino)phenyl]-3-pyridyl]-2,6-dimethyl-phenol, 3-[3-(dimethylamino)phenyl]-5-(3-pyridyl)pyridin-2-amine, [3-[6-amino-5-[3-(dimethylamino)phenyl]-3-pyridyl]phenyl]methanol, 3-[3-(dimethylamino)phenyl]-5-[6-[3-(dimethylamino)propoxy]-3-pyridyl]pyridin-2-amine, 3-[6-amino-5-[3-(dimethylamino)phenyl]-3-pyridyl]benzamide, 5-(3,4-dimethoxyphenyl)-3-[3-(dimethylamino)phenyl]pyridin-2-amine, 4-[2-amino-5-(3-chloro-4-fluoro-phenyl)-3-pyridyl]-2-methoxy-phenol, 5-(4-methoxyphenyl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[2-amino-5-(4-methoxyphenyl)-3-pyridyl]-2-methoxy-phenol, 5-(3-furyl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 5-(2-phenoxyphenyl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]benzamide, 4-[2-amino-5-(3-methoxyphenyl)-3-pyridyl]-2-methoxy-phenol, [4-[2-amino-5-(3,4-dimethoxyphenyl)-3-pyridyl]phenyl]methanol, 5-[4-(4-methylpiperazin-1-yl)phenyl]-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 3-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]benzamide, 1-[5-[6-amino-5-[3-(dimethylamino)phenyl]-3-pyridyl]-2-thienyl]ethanone, 5-(4-methylsulfonylphenyl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[6-amino-5-(4-hydroxyphenyl)-3-pyridyl]benzamide, 4-[2-amino-5-[4-(4-methylpiperazin-1-yl)phenyl]-3-pyridyl]phenol, 4-[2-amino-5-[4-(4-methylpiperazin-1-yl)phenyl]-3-pyridyl]-2-methoxy-phenol, 4-[6-amino-5-(4-hydroxy-3-methoxy-phenyl)-3-pyridyl]benzamide, 4-[2-amino-5-(4-piperazin-1-ylphenyl)-3-pyridyl]-2-methoxy-phenol, 3,5-bis(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[2-amino-5-[4-(4-isopropylpiperazin-1-yl)phenyl]-3-pyridyl]-2-methoxy-phenol, 4-[2-amino-5-(4-morpholinophenyl)-3-pyridyl]-2-methoxy-phenol, and 5-[6-amino-5-[4-(4-methylpiperazin-1-yl)phenyl]-3-pyridyl]-2-methoxy-phenol.
 4. A method for inhibiting activity of Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being represented by the structural formula (II):

wherein: R1 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate, and R2 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate.
 5. A method of treating, or slowing progression of, a disease associated with Fyn kinase, said method comprising administering a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being represented by the structural formula (II):

wherein: R1 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate, and R2 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate.
 6. A compound of formula (II) selected from the group consisting of N-(2-hydroxyethyl)-4-[3-(4-hydroxyphenyl)imidazo[,2-a]pyrazin-6-yl]benzamide, 3-[3-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-6-yl]-N,N-dimethyl-benzamide, 4-[6-[4-(4-isopropylpiperazin-1-yl)phenyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 4-[6-(1-benzylpyrazol-4-yl)imidazo[1,2-a]pyrazin-3-yl]phenol, 4-[3-(2-thienyl)imidazo[1,2-a]pyrazin-6-yl]phenol, 3,6-bis(2-thienyl)imidazo[1,2-a]pyrazine, N-(2-hydroxyethyl)-3-[3-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, N-cyclopropyl-4-[3-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 4-[6-[4-(4-methylpiperazin-1-yl)phenyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 4-[6-(6-amino-3-pyridyl)imidazo[1,2-a]pyrazin-3-yl]phenol, 5-[3-(2-thienyl)imidazo[1,2-a]pyrazin-6-yl]pyridin-2-amine, 4-[3-(3-acetylphenyl)imidazo[1,2-a]pyrazin-6-yl]-N-(2-dimethylaminoethyl)benzamide, N-(2-dimethylaminoethyl)-4-[3-(2-thienyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 4-[3-(3,5-dimethoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]-N-[3-(dimethylamino)propyl]benzamide, N-(2-dimethylaminoethyl)-4-[3-(4-pyridyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 4-[6-[2-(dimethylamino)phenyl]imidazo[1,2-a]pyrazin-3-yl]-2-methoxy-phenol, N-(2-hydroxyethyl)-3-[3-(4-hydroxy-3-methoxy-phenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 2-methoxy-4-[6-(3-pyridyl)imidazo[1,2-a]pyrazin-3-yl]phenol, 4-[6-(2-chlorophenyl)imidazo[1,2-a]pyrazin-3-yl]-2-methoxy-phenol, 4-[6-(3-ethoxyphenyl)imidazo[1,2-a]pyrazin-3-yl]-2-methoxy-phenol, N-(2-dimethylaminoethyl)-4-[3-(4-hydroxy-3-methoxy-phenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 4-[6-(6-amino-3-pyridyl)imidazo[1,2-a]pyrazin-3-yl]-2-methoxy-phenol, 2-methoxy-4-[6-[6-(4-methylpiperazin-1-yl)-3-pyridyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 2-methoxy-4-[6-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyrazin-3-yl]phenol, N-[3-[3-(3,4,5-trimethoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]phenyl]methanesulfonamide, N-[3-(dimethylamino)propyl]-4-[3-(4-hydroxy-3-methoxy-phenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 2-methoxy-4-[6-[6-(2-morpholinoethylamino)-3-pyridyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 6-(1-methylpyrazol-4-yl)-3-(3-thienyl)imidazo[1,2-a]pyrazine, 6-phenyl-3-(3-thienyl)imidazo[1,2-a]pyrazine, [4-[3-(3-thienyl)imidazo[1,2-a]pyrazin-6-yl]phenyl]methanol, 4-[3-(4-methoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]phenol, 6-(3-pyridyl)-3-(3-thienyl)imidazo[1,2-a]pyrazine, 3-(4-pyridyl)-6-(2-thienyl)imidazo[1,2-a]pyrazine, 4-[3-(3-thienyl)imidazo[1,2-a]pyrazin-6-yl]phenol, 6-(2-thienyl)-3-(3-thienyl)imidazo[1,2-a]pyrazine, N-[3-[3-(3-thienyl)imidazo[1,2-a]pyrazin-6-yl]phenyl]acetamide, N-[3-[3-(3-thienyl)imidazo[1,2-a]pyrazin-6-yl]phenyl]methanesulfonamide, 6-(2-furyl)-3-(3-thienyl)imidazo[1,2-a]pyrazine, 3-(6-phenylimidazo[1,2-a]pyrazin-3-yl)phenol, 3-[3-(3-hydroxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 4-[6-(3-pyridyl)imidazo[1,2-a]pyrazin-3-yl]phenol, [4-[3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]phenyl]methanol, 4-[6-(4-chlorophenyl)imidazo[1,2-a]pyrazin-3-yl]phenol, 3-[6-(2-thienyl)imidazo[1,2-a]pyrazin-3-yl]phenol, 6-(1-methylpyrazol-4-yl)-3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazine, 3-[6-(2-furyl)imidazo[1,2-a]pyrazin-3-yl]phenol, 4-[6-(6-methoxy-3-pyridyl)imidazo[1,2-a]pyrazin-3-yl]phenol, 3-[6-[4-(hydroxymethyl)phenyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 3-[6-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyrazin-3-yl]phenol, 4-[6-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyrazin-3-yl]phenol, 6-[6-(4-methylpiperazin-1-yl)-3-pyridyl]-3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazine, N-(2-hydroxyethyl)-3-[3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, N-(2-dimethylaminoethyl)-4-[3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, N-(2-hydroxyethyl)-4-[3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 4-[3-(3-chlorophenyl)imidazo[1,2-a]pyrazin-6-yl]-N-[3-(dimethylamino)propyl]benzamide, 5-[3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]pyridin-2-amine, N-[3-(dimethylamino)propyl]-4-[3-(3-thienyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 3-(4-methoxyphenyl)-6-[4-(4-methylpiperazin-1-yl)phenyl]imidazo[1,2-a]pyrazine, N-(2-hydroxyethyl)-3-[3-(3-thienyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 6-[6-(4-methylpiperazin-1-yl)-3-pyridyl]-3-(3-thienyl)imidazo[1,2-a]pyrazine, 5-[3-(3-thienyl)imidazo[1,2-a]pyrazin-6-yl]pyridin-2-amine, 3,6-bis(3-thienyl)imidazo[1,2-a]pyrazine, N-(2-dimethylaminoethyl)-4-[3-(3-thienyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 3-(1-methylpyrazol-4-yl)-6-(2-phenoxyphenyl)imidazo[1,2-a]pyrazine, 3-[6-[6-(4-methylpiperazin-1l-yl)-3-pyridyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 3-[[5-[3-(1,3-benzodioxol-5-yl)imidazo[1,2-a]pyrazin-6-yl]-2-pyridyl]oxy]-N,N-dimethyl-propan-1-amine, 3-[6-(3-ethoxyphenyl)imidazo[1,2-a]pyrazin-3-yl]phenol, 3-(1,3-benzodioxol-5-yl)-6-[4-(4-methylpiperazin-1-yl)phenyl]imidazo[1,2-a]pyrazine, 3-[6-(3-thienyl)imidazo[1,2-a]pyrazin-3-yl]phenol, 3-[6-[4-(4-methylpiperazin-1-yl)phenyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 4-[3-(4-chlorophenyl)imidazo[1,2-a]pyrazin-6-yl]-N-[3-(dimethylamino)propyl]benzamide, 4-[3-(1,3-benzodioxol-5-yl)imidazo[1,2-a]pyrazin-6-yl]-N-(2-dimethylaminoethyl)benzamide, 3-[6-(6-amino-3-pyridyl)imidazo[1,2-a]pyrazin-3-yl]phenol, N-(2-dimethylaminoethyl)-4-[3-(3-hydroxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 4-[3-(4-chlorophenyl)imidazo[1,2-a]pyrazin-6-yl]-N-(2-dimethylaminoethyl)benzamide, 3-[6-[6-(2-morpholinoethylamino)-3-pyridyl]imidazo[1,2-a]pyrazin-3-yl]phenol, N-[3-(dimethylamino)propyl]-4-[3-(3-hydroxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, N-(2-hydroxyethyl)-4-[3-(3-hydroxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 4-[3-(1,3-benzodioxol-5-yl)imidazo[1,2-a]pyrazin-6-yl]-N-[3-(dimethylamino)propyl]benzamide, 6-[6-(4-methylpiperazin-1-yl)-3-pyridyl]-3-phenyl-imidazo[1,2-a]pyrazine, 3-[6-[4-(4-isopropylpiperazin-1-yl)phenyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 5-[3-(1,3-benzodioxol-5-yl)imidazo[1,2-a]pyrazin-6-yl]pyridin-2-amine, 4-[6-[6-[3-(dimethylamino)propoxy]-3-pyridyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 4-[6-[6-(2-morpholinoethylamino)-3-pyridyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 4-[6-[6-(4-methylpiperazin-1-yl)-3-pyridyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 3-[2-(cyclohexylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-N,N-dimethyl-benzamide, N-[2-(dimethylamino)ethyl]-4-[3-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, N-[2-(dimethylamino)ethyl]-4-[3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, N-[3-(dimethylamino)propyl]-4-[3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, N-[2-(dimethylamino)ethyl]-4-[3-(4-hydroxy-3-methoxy-phenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, and 4-[6-[[(1S)-1-(hydroxymethyl)-2-methyl-propyl]amino]imidazo[1,2-b]pyridazin-3-yl]-2-methoxy-phenol.
 7. A method for inhibiting activity of Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being represented by the structural formula (III):

wherein: R1 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate, and R2 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate.
 8. A method of treating, or slowing progression of, a disease associated with Fyn kinase, said method comprising administering a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being represented by the structural formula (III):

wherein: R1 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate, and R2 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate.
 9. A compound of formula (III) selected from the group consisting of N-[4-[3-(4-hydroxy-3-methoxy-phenyl)imidazo[1,2-b]pyridazin-6-yl]phenyl]acetamide, N-[3-[6-(1,3-benzodioxol-5-yl)imidazo[,2-b]pyridazin-3-yl]phenyl]acetamide, N-[3-[3-(1,3-benzodioxol-5-yl)imidazo[1,2-b]pyridazin-6-yl]phenyl]acetamide, N-[3-[6-[3-(trifluoromethoxy)phenyl]imidazo[1,2-b]pyridazin-3-yl]phenyl]acetamide, 1-[3-[6-(3,4-dimethoxyphenyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]ethanone, N-[3-[6-(4-methylsulfonylphenyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]acetamide, N-[3-[3-(3-acetamidophenyl)imidazo[1,2-b]pyridazin-6-yl]phenyl]acetamide, N-[3-[3-(3-acetylphenyl)imidazo[1,2-b]pyridazin-6-yl]phenyl] acetamide, 4-[3-(3-acetamidophenyl)imidazo[1,2-b]pyridazin-6-yl]benzamide, N-[4-[3-(3-hydroxyphenyl)imidazo[1,2-b]pyridazin-6-yl]phenyl]acetamide, N-[3-[3-[3-(hydroxymethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]phenyl]acetamide, N-[3-[6-(4-dimethylaminophenyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]acetamide, N-[3-[3-(4-hydroxy-3-methoxy-phenyl)imidazo[1,2-b]pyridazin-6-yl]phenyl]acetamide, N-[3-[3-[4-(hydroxymethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]phenyl]methanesulfonamide, 1-[3-[6-(3-hydroxyphenyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]ethanone, [4-[3-[3-(hydroxymethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]phenyl]methanol, 4-[3-[3-(hydroxymethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]benzamide, N-(2-dimethylaminoethyl)-3-[6-[4-(hydroxymethyl)phenyl]imidazo[1,2-b]pyridazin-3-yl]benzamide, 3-[3-(3-hydroxyphenyl)imidazo[1,2-b]pyridazin-6-yl]benzamide, 4-[3-[4-(hydroxymethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]-2-methoxy-phenol, [3-[6-(3-pyridyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]methanol, [3-[6-[(4-fluorophenyl)methyl]imidazo[1,2-b]pyridazin-3-yl]phenyl]methanol, [3-[6-(3-methoxyphenyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]methanol, N-[3-[3-(4-pyridyl)imidazo[1,2-b]pyridazin-6-yl]phenyl]methanesulfonamide, 6-(2-methoxyphenyl)-3-(4-pyridyl)imidazo[1,2-b]pyridazine, 3-[3-(4-pyridyl)imidazo[1,2-b]pyridazin-6-yl]benzamide, N-[3-(6-phenylimidazo[1,2-b]pyridazin-3-yl)phenyl] acetamide, N-[3-[6-(3-hydroxyphenyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]acetamide, 3-(3,4-dimethoxyphenyl)-6-(3-fluorophenyl)imidazo[1,2-b]pyridazine, N-[3-[6-[4-(hydroxymethyl)phenyl] imidazo[1,2-b]pyridazin-3-yl]phenyl]acetamide, [3-(6-phenylimidazo[1,2-b]pyridazin-3-yl)phenyl]methanol, 6-(3-chlorophenyl)-3-(4-pyridyl)imidazo[1,2-b]pyridazine, 4-[3-(3,4-dimethoxyphenyl)imidazo[1,2-b]pyridazin-6-yl]-2-methoxy-phenol, N-[3-[6-(2-methoxyphenyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]acetamide, N-[3-[6-[3-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-3-yl]phenyl] acetamide, [3-[6-(2-methoxyphenyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]methanol, 4-[3-[3-(hydroxymethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]-2-methoxy-phenol, 3-phenyl-6-(4-pyridyl)imidazo[1,2-b]pyridazine, 3-[3-(4-pyridyl)imidazo[1,2-b]pyridazin-6-yl]phenol, 3-(3,4-dimethoxyphenyl)-6-phenyl-imidazo[1,2-b]pyridazine, 3-(3,4-dimethoxyphenyl)-6-(4-fluorophenyl)imidazo[1,2-b]pyridazine, N-[3-[6-(3,4,5-trimethoxyphenyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]acetamide, N-[3-[6-(4-hydroxy-3-methoxy-phenyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]acetamide, 3-phenyl-6-(3-pyridyl)imidazo[1,2-b]pyridazine, [4-[3-(4-pyridyl)imidazo[1,2-b]pyridazin-6-yl]phenyl]methanol, 3-(3,4-dimethoxyphenyl)-6-(2-methoxyphenyl)imidazo[1,2-b]pyridazine, 3-(3,4-dimethoxyphenyl)-6-(3-furyl)imidazo[1,2-b]pyridazine, N-[3-[6-(3-furyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]acetamide, [3-[6-(3-furyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]methanol, N,N-dimethyl-4-[3-(4-pyridyl)imidazo[1,2-b]pyridazin-6-yl]aniline, [3-[6-(4-methylsulfonylphenyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]methanol, N-[3-(3-phenylimidazo[1,2-b]pyridazin-6-yl)phenyl]acetamide, 6-phenyl-3-(4-pyridyl)imidazo[1,2-b]pyridazine, 6-(3-fluorophenyl)-3-(4-pyridyl)imidazo[1,2-b]pyridazine, 3-(3,4-dimethoxyphenyl)-6-(3-methoxyphenyl)imidazo[1,2-b]pyridazine, N-[3-[6-(5-methoxy-3-pyridyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]acetamide, [3-[6-(5-methoxy-3-pyridyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]methanol, 6-(1,3-benzodioxol-5-yl)-3-(4-pyridyl)imidazo[1,2-b]pyridazine, 6-(3-furyl)-3-(4-pyridyl)imidazo[,2-b]pyridazine, N-[3-[6-(3-chlorophenyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]acetamide, N-[3-[6-(3-methoxyphenyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]acetamide, 3-[3-[3-(hydroxymethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]phenol, 4-(3-phenylimidazo[1,2-b]pyridazin-6-yl)benzamide, 3-[3-(1,3-benzodioxol-5-yl)imidazo[1,2-b]pyridazin-6-yl]phenol, 6-phenyl-3-(3-pyridyl)imidazo[1,2-b]pyridazine, 3-(3-pyridyl)-6-(2-thienyl)imidazo[1,2-b]pyridazine, N-[3-[6-(3-acetylphenyl)imidazo[1,2-b]pyridazin-3-yl]phenyl] acetamide, 3-[6-(3-methoxyphenyl)imidazo[1,2-b]pyridazin-3-yl]phenol, 4-[6-(3,4-dimethoxyphenyl)imidazo[1,2-b]pyridazin-3-yl]-2-methoxy-phenol, 1-[3-[6-(2-methoxyphenyl)imidazo[1,2-b]pyridazin-3-yl]phenyl] ethanone, 1-[3-[6-(1-methylpyrazol-4-yl)imidazo[1,2-b]pyridazin-3-yl]phenyl]ethanone, N-[3-[3-(2-thienyl)imidazo[1,2-b]pyridazin-6-yl]phenyl]methanesulfonamide, 3-(1,3-benzodioxol-5-yl)-6-(3-pyridyl)imidazo[1,2-b]pyridazine, [4-[3-(3-pyridyl)imidazo[1,2-b]pyridazin-6-yl]phenyl]methanol, 6-benzyl-3-(3,4-dimethoxyphenyl)imidazo[1,2-b]pyridazine, 3-[6-[4-(hydroxymethyl)phenyl]imidazo[1,2-b]pyridazin-3-yl]phenol, [4-[6-(2-methoxyphenyl)imidazo[1,2-b]pyridazin-3-yl]phenyl] methanol, [4-[6-(3-methoxyphenyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]methanol, 2-methoxy-4-[6-(3-methoxyphenyl)imidazo[1,2-b]pyridazin-3-yl]phenol, 1-[3-[6-(3-furyl)imidazo[1,2-b]pyridazin-3-yl]phenyl] ethanone, 4-[3-(2-thienyl)imidazo[1,2-b]pyridazin-6-yl]benzamide, 3-[3-(1,3-benzodioxol-5-yl)imidazo[1,2-b]pyridazin-6-yl]-N-(2-hydroxyethyl)benzamide, [3-[3-(1,3-benzodioxol-5-yl)imidazo[1,2-b]pyridazin-6-yl]phenyl] methanol, N-[3-[6-(2-thienyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]acetamide, 3-(6-phenylimidazo[1,2-b]pyridazin-3-yl)phenol, 1-[3-[3-(3-hydroxyphenyl)imidazo[1,2-b]pyridazin-6-yl]phenyl] ethanone, [4-[6-(3-fluorophenyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]methanol, 1-[3-[3-[3-(hydroxymethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]phenyl]ethanone, 1-[3-[6-[3-(dimethylamino)phenyl]imidazo[1,2-b]pyridazin-3-yl]phenyl]ethanone, 1-[3-[6-(6-amino-3-pyridyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]ethanone, [4-[3-(2-thienyl)imidazo[1,2-b]pyridazin-6-yl]phenyl] methanol, N-[3-[3-(3,4-dimethoxyphenyl)imidazo[1,2-b]pyridazin-6-yl]phenyl]methanesulfonamide, 3-[3-(3-acetylphenyl)imidazo[1,2-b]pyridazin-6-yl]benzamide, N-[3-[3-(3-pyridyl)imidazo[1,2-b]pyridazin-6-yl]phenyl]methanesulfonamide, 3-[6-(4-pyridyl)imidazo[1,2-b]pyridazin-3-yl]phenol, 3-[6-(5-quinolyl)imidazo[1,2-b]pyridazin-3-yl]phenol, N-[3-[3-[3-(hydroxymethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]phenyl]methanesulfonamide, 2-methoxy-4-[6-(2-methoxyphenyl)imidazo[1,2-b]pyridazin-3-yl]phenol, 3-[3-(3-acetylphenyl)imidazo[1,2-b]pyridazin-6-yl]-N-methyl-benzamide, [3-[3-(2-thienyl)imidazo[1,2-b]pyridazin-6-yl]phenyl]methanol, 6-(1-methylpyrazol-4-yl)-3-(2-thienyl)imidazo[1,2-b]pyridazine, 3-[3-(3,4-dimethoxyphenyl)imidazo[1,2-b]pyridazin-6-yl]-N-(2-hydroxyethyl)benzamide, 3-(1,3-benzodioxol-5-yl)-6-(1-methylpyrazol-4-yl)imidazo[1,2-b]pyridazine, 3-(3,4-dimethoxyphenyl)-6-(1-methylpyrazol-4-yl)imidazo[1,2-b]pyridazine, 3-[6-(3-fluorophenyl)imidazo[1,2-b]pyridazin-3-yl]phenol, 1-[3-[6-(3-aminophenyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]ethanone, 6-(2-methoxyphenyl)-3-(3-pyridyl)imidazo[1,2-b]pyridazine, 3-(3,4-dimethoxyphenyl)-6-(4-pyridyl)imidazo[1,2-b]pyridazine, 3-[6-(3-pyridyl)imidazo[1,2-b]pyridazin-3-yl]phenol, 3-[6-(1-methylpyrazol-4-yl)imidazo[1,2-b]pyridazin-3-yl]phenol, [4-[6-(4-fluorophenyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]methanol, 4-[6-(3-hydroxyphenyl)imidazo[1,2-b]pyridazin-3-yl]-2-methoxy-phenol, 6-(3,4-dimethoxyphenyl)-3-(4-pyridyl)imidazo[1,2-b]pyridazine, 6-(4-fluorophenyl)-3-(3-pyridyl)imidazo[1,2-b]pyridazine, [3-[3-(3-chlorophenyl)imidazo[1,2-b]pyridazin-6-yl]phenyl]methanol, 3-[6-(4-fluorophenyl)imidazo[1,2-b]pyridazin-3-yl]phenol, 3-phenyl-6-(2-thienyl)imidazo[1,2-b]pyridazine, 3-(3,4-dimethoxyphenyl)-6-(3-pyridyl)imidazo[1,2-b]pyridazine, N-[3-[3-(3-hydroxyphenyl)imidazo[1,2-b]pyridazin-6-yl]phenyl]acetamide, 4-[6-[4-(hydroxymethyl)phenyl]imidazo[1,2-b]pyridazin-3-yl]-2-methoxy-phenol, 3-[3-(3,4-dimethoxyphenyl)imidazo[1,2-b]pyridazin-6-yl]-N-methyl-benzamide, N-[3-[3-(4-pyridyl)imidazo[1,2-b]pyridazin-6-yl]phenyl] acetamide, 6-(3-furyl)-3-(3-pyridyl)imidazo[1,2-b]pyridazine, N-[3-[6-(3,4-dimethoxyphenyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]acetamide, 3-[6-(3-furyl)imidazo[1,2-b]pyridazin-3-yl]phenol, 1-[3-[6-(4-pyridyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]ethanone, 6-(m-tolylmethyl)-3-(4-pyridyl)imidazo[1,2-b]pyridazine, 3-(1,3-benzodioxol-5-yl)-6-(4-fluorophenyl)imidazo[1,2-b]pyridazine, 3,6-bis(3,4-dimethoxyphenyl)imidazo[1,2-b]pyridazine, 3-[6-(2-methoxyphenyl)imidazo[1,2-b]pyridazin-3-yl]phenol, [4-(6-phenylimidazo[1,2-b]pyridazin-3-yl)phenyl] methanol, N-[4-[3-[4-(hydroxymethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]phenyl]acetamide, 4-[6-[3-(hydroxymethyl)phenyl]imidazo[1,2-b]pyridazin-3-yl]-2-methoxy-phenol, 1-[3-[6-[3-(hydroxymethyl)phenyl]imidazo[1,2-b]pyridazin-3-yl]phenyl]ethanone, 6-(4-pyridyl)-3-(2-thienyl)imidazo[1,2-b]pyridazine, 2-methoxy-4-[3-(2-thienyl)imidazo[1,2-b]pyridazin-6-yl]phenol, N-(2-hydroxyethyl)-3-(3-phenylimidazo[1,2-b]pyridazin-6-yl)benzamide, 6-benzyl-3-(4-pyridyl)imidazo[1,2-b]pyridazine, 4-[3-(3-pyridyl)imidazo[1,2-b]pyridazin-6-yl]benzamide, 1-[3-[6-(3-pyridyl)imidazo[1,2-b]pyridazin-3-yl]phenyl] ethanone, 1-[3-[6-(3-methoxyphenyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]ethanone, 6-[(4-fluorophenyl)methyl]-3-(4-pyridyl)imidazo[1,2-b]pyridazine, 3-[3-(1,3-benzodioxol-5-yl)imidazo[1,2-b]pyridazin-6-yl]aniline, 3-(1,3-benzodioxol-5-yl)-6-(3-furyl)imidazo[1,2-b]pyridazine, [4-[6-(3,4-dimethoxyphenyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]methanol, 3-[3-(1,3-benzodioxol-5-yl)imidazo[1,2-b]pyridazin-6-yl]-N-(2-dimethylaminoethyl)benzamide, N-[3-[6-(3-chloro-4-fluoro-phenyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]acetamide, 3-[3-[4-(hydroxymethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]phenol, [3-[6-(3,4-dimethoxyphenyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]methanol, 1-[3-[3-(3-acetylphenyl)imidazo[1,2-b]pyridazin-6-yl]phenyl] ethanone, N-(2-dimethylaminoethyl)-3-[3-(2-thienyl)imidazo[1,2-b]pyridazin-6-yl]benzamide, 3-(1,3-benzodioxol-5-yl)-6-phenyl-imidazo[1,2-b]pyridazine, 3-[3-(3-pyridyl)imidazo[1,2-b]pyridazin-6-yl]phenol, 3-(3,4-dimethoxyphenyl)-6-(2-thienyl)imidazo[1,2-b]pyridazine, 3-[3-(3-hydroxyphenyl)imidazo[1,2-b]pyridazin-6-yl]phenol, N-[3-[3-[4-(hydroxymethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]phenyl]acetamide, 1-[3-[6-(4-fluorophenyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]ethanone, 3-[3-(3-acetamidophenyl)imidazo[1,2-b]pyridazin-6-yl]-N-methyl-benzamide, [3-(3-phenylimidazo[1,2-b]pyridazin-6-yl)phenyl]methanol, 6-(1-methylpyrazol-4-yl)-3-(4-pyridyl)imidazo[1,2-b]pyridazine, N-(2-dimethylaminoethyl)-3-[3-[3-(trifluoromethoxy)phenyl]imidazo[1,2-b]pyridazin-6-yl]benzamide, [4-[3-[4-(hydroxymethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]phenyl]methanol, 4-[6-(1,3-benzodioxol-5-yl)imidazo[1,2-b]pyridazin-3-yl]-2-methoxy-phenol, 1-[3-[6-(2-thienyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]ethanone, 6-(5-methoxy-3-pyridyl)-3-(2-thienyl)imidazo[1,2-b]pyridazine, 3,6-bis(2-thienyl)imidazo[1,2-b]pyridazine, N-(2-dimethylaminoethyl)-3-[6-(1-methylpyrazol-4-yl)imidazo[1,2-b]pyridazin-3-yl]benzamide, 3-[6-(1,3-benzodioxol-5-yl)imidazo[1,2-b]pyridazin-3-yl]-N-(2-dimethylaminoethyl)benzamide, 3-[3-[3-(2-dimethylaminoethylcarbamoyl)phenyl] imidazo[1,2-b]pyridazin-6-yl]benzamide, N-(2-hydroxyethyl)-3-[3-(3-hydroxyphenyl)imidazo[1,2-b]pyridazin-6-yl]benzamide, 2-methoxy-4-[6-(3,4,5-trimethoxyphenyl)imidazo[1,2-b]pyridazin-3-yl]phenol, [3-[3-(3-furyl)imidazo[1,2-b]pyridazin-6-yl]phenyl]methanol, 4-(6-benzylimidazo[1,2-b]pyridazin-3-yl)benzamide, 3-[6-(4-acetamidophenyl)imidazo[1,2-b]pyridazin-3-yl]-N-(2-dimethylaminoethyl)benzamide, 2-methoxy-4-[6-[3-(trifluoromethoxy)phenyl]imidazo[1,2-b]pyridazin-3-yl]phenol, N-(2-dimethylaminoethyl)-3-[6-[3-(hydroxymethyl)phenyl] imidazo[1,2-b]pyridazin-3-yl]benzamide, 4-[6-[(3,4-difluorophenyl)methyl]imidazo[1,2-b]pyridazin-3-yl]benzamide, 3-[6-(3-acetamidophenyl)imidazo[1,2-b]pyridazin-3-yl]-N-(2-dimethylaminoethyl)benzamide, 2-methoxy-4-[6-[3-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-3-yl]phenol, 6-benzyl-3-(5-methoxy-3-pyridyl)imidazo[1,2-b]pyridazine, 4-[6-(m-tolylmethyl)imidazo[1,2-b]pyridazin-3-yl]benzamide, N-(2-dimethylaminoethyl)-3-[6-(2-methoxyphenyl)imidazo[1,2-b]pyridazin-3-yl]benzamide, N-(2-dimethylaminoethyl)-3-[6-(3-phenoxyphenyl)imidazo[1,2-b] pyridazin-3-yl] benzamide, 3-(6-cyclopropylimidazo[1,2-b]pyridazin-3-yl)phenol, 4-[6-(3-fluorophenyl)imidazo[1,2-b]pyridazin-3-yl]-2-methoxy-phenol, 6-[(4-fluorophenyl)methyl]-3-(5-methoxy-3-pyridyl)imidazo[1,2-b]pyridazine, 4-[6-[(4-fluorophenyl)methyl]imidazo[1,2-b]pyridazin-3-yl]benzamide, N-(2-hydroxyethyl)-3-[3-[4-(hydroxymethyl)phenyl] imidazo[1,2-b]pyridazin-6-yl]benzamide, 3-[3-(4-hydroxy-3-methoxy-phenyl)imidazo[1,2-b]pyridazin-6-yl]benzamide, 3-(1-methylpyrazol-4-yl)-6-(m-tolylmethyl)imidazo[1,2-b]pyridazine, 3-[3-(3-acetylphenyl)imidazo[1,2-b]pyridazin-6-yl]-N-(2-hydroxyethyl)benzamide, [4-(6-benzylimidazo[1,2-b]pyridazin-3-yl)phenyl]methanol, 4-[6-[(4-fluorophenyl)methyl]imidazo[1,2-b]pyridazin-3-yl]-2-methoxy-phenol, -[(4-fluorophenyl)methyl]-3-(1-methylpyrazol-4-yl)imidazo[1,2-b]pyridazine, N-(2-dimethylaminoethyl)-3-[6-(4-fluorophenyl)imidazo[1,2-b]pyridazin-3-yl]benzamide, 3-[3-(3-chlorophenyl)imidazo[1,2-b]pyridazin-6-yl]-N-(2-hydroxyethyl)benzamide, 3-[6-(m-tolylmethyl)imidazo[1,2-b]pyridazin-3-yl]benzamide, 1-[3-(6-benzylimidazo[1,2-b]pyridazin-3-yl)phenyl] ethanone, 5-(6-benzylimidazo[1,2-b]pyridazin-3-yl)pyridin-2-amine, N-(2-dimethylaminoethyl)-3-[6-(3-furyl)imidazo[1,2-b]pyridazin-3-yl]benzamide, 3-[3-[4-(hydroxymethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]-N-methyl-benzamide, 2-methoxy-4-[6-(propylamino)imidazo[1,2-b]pyridazin-3-yl]phenol, 3-(4-pyridyl)-N-(2-thienylmethyl)imidazo[1,2-b]pyridazin-6-amine, 2-methoxy-4-[6-(tetrahydropyran-4-ylamino)imidazo[1,2-b]pyridazin-3-yl]phenol, 2-methoxy-4-[6-(2-thienylmethylamino)imidazo[1,2-b]pyridazin-3-yl]phenol, N-propyl-3-(4-pyridyl)imidazo[1,2-b]pyridazin-6-amine, 2-methoxy-4-[6-(2-pyridylmethylamino)imidazo[1,2-b]pyridazin-3-yl]phenol, 3-(4-pyridyl)-N-tetrahydropyran-4-yl-imidazo[1,2-b]pyridazin-6-amine, 3-(3,4-dimethoxyphenyl)-N-propyl-imidazo[1,2-b]pyridazin-6-amine, 4-[6-[[(1S)-1-(hydroxymethyl)-2-methyl-propyl]amino] imidazo[1,2-b]pyridazin-3-yl]-2-methoxy-phenol, 3-(3,4-dimethoxyphenyl)-N-(2-pyridylmethyl)imidazo[1,2-b]pyridazin-6-amine, 3-[[3-(4-pyridyl)imidazo[1,2-b]pyridazin-6-yl]amino]propan-1-ol, (2S)-3-methyl-2-[[3-(4-pyridyl)imidazo[1,2-b]pyridazin-6-yl]amino]butan-1-ol, 1-[3-[6-(3-hydroxypropylamino)imidazo[1,2-b]pyridazin-3-yl]phenyl]ethanone, 3-(3,4-dimethoxyphenyl)-N-(2-thienylmethyl)imidazo[1,2-b]pyridazin-6-amine, 3-[[3-(3,4-dimethoxyphenyl)imidazo[1,2-b]pyridazin-6-yl]amino]propan-1-ol, N-[3-[6-(4-pyridyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]acetamide, 4-[6-(1,3-benzodioxol-5-ylmethylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methoxy-phenol, 1-[3-[6-(1,3-benzodioxol-5-ylmethylamino)imidazo[1,2-b]pyridazin-3-yl]phenyl] ethanone, N-(1,3-benzodioxol-5-ylmethyl)-3-(3,4-dimethoxyphenyl)imidazo[1,2-b]pyridazin-6-amine, [3-[6-(4-pyridyl)imidazo[1,2-b]pyridazin-3-yl]phenyl]methanol, 2-methoxy-4-[6-(4-pyridyl)imidazo[1,2-b]pyridazin-3-yl]phenol, 3-(4-pyridyl)-N-(2-pyridylmethyl)imidazo[1,2-b]pyridazin-6-amine, 4-[3-(4-hydroxy-3-methoxy-phenyl)imidazo[1,2-b]pyridazin-6-yl]-2-methoxy-phenol, [3-[3-[3-(hydroxymethyl)phenyl] imidazo[1,2-b]pyridazin-6-yl]phenyl]methanol, N-[3-[6-[3-(hydroxymethyl)phenyl]imidazo[1,2-b]pyridazin-3-yl]phenyl]acetamide, 3-(4-fluorophenyl)-N-methyl-imidazo[1,2-b]pyridazin-6-amine, 3-(4-methoxyphenyl)-N-methyl-imidazo[11,2-b]pyridazin-6-amine, 2-[6-(methylamino)imidazo[1,2-b]pyridazin-3-yl]phenol, N-methyl-3-(3-thienyl)imidazo[1,2-b]pyridazin-6-amine, 3-[6-(methylamino)imidazo[1,2-b]pyridazin-3-yl]phenol, 3-(3,4-dimethoxyphenyl)-N-methyl-imidazo[1,2-b]pyridazin-6-amine, N,N-dimethyl-3-[6-(methylamino)imidazo[1,2-b]pyridazin-3-yl]benzamide, N-methyl-3-(1-methylpyrazol-4-yl)imidazo[1,2-b]pyridazin-6-amine, N-[3-[6-(methylamino)imidazo[1,2-b]pyridazin-3-yl]phenyl]acetamide, 3-(6-methoxy-3-pyridyl)-N-methyl-imidazo[1,2-b]pyridazin-6-amine, and (Z)-5-[6-(methylamino)imidazo[1,2-b]pyridazin-3-yl]pent-4-en-1-ol.
 10. A method for inhibiting activity of Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being represented by the structural formula (IV):

wherein: R1 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate, and R2 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate.
 11. A method of treating, or slowing progression of, a disease associated with Fyn kinase, said method comprising administering a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being represented by the structural formula (IV):

wherein: R1 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate, and R2 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate.
 12. A compound of formula (IV) selected from the group consisting of 3-[2-(cyclohexylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-N,N-dimethyl-benzamide, N,N-dimethyl-3-[2-[2-(4-sulfamoylphenyl)ethylamino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzamide, 3-[2-[(4-hydroxycyclohexyl)amino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-N,N-dimethyl-benzamide, 1-[3-[2-[(4-hydroxycyclohexyl)amino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]ethanone, N-[3-[2-(2-furylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]acetamide, 3-[2-(cyclopropylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-N,N-dimethyl-benzamide, 3-[2-(isobutylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-N,N-dimethyl-benzamide, 3-[2-[(4-fluorophenyl)methylamino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-N,N-dimethyl-benzamide, N-[3-[2-(2-thienylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl] acetamide, 4-[2-[[5-(1-methylpyrazol-4-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl]amino] ethyl]benzenesulfonamide, 4-[[5-[3-(dimethylamino)phenyl] imidazo[2,1-b][1,3,4] thiadiazol-2-yl]amino]cyclohexanol, N-[3-[2-(isobutylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]methanesulfonamide, 3-[2-(3-hydroxypropylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzamide, 4-[2-[(4-hydroxycyclohexyl)amino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenol, 3-[2-(2-furylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzamide, 4-[2-[[5-(6-methoxy-3-pyridyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl]amino] ethyl]benzenesulfonamide, N,N-dimethyl-3-[2-(tetrahydropyran-4-ylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzamide, N,N-dimethyl-3-[2-(o-tolylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzamide, N-isobutyl-5-(5-methoxy-3-pyridyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, N-(1,3-benzodioxol-5-ylmethyl)-5-(5-methoxy-3-pyridyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, 3-[2-[(4-methoxyphenyl)methylamino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-N,N-dimethyl-benzamide, N-[2-(4-pyridyl)ethyl]-5-(3,4,5-trimethoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, 3-[2-(benzylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-N,N-dimethyl-benzamide, 5-(6-methoxy-3-pyridyl)-N-(4-pyridylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, 3-[2-(2-furylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-N,N-dimethyl-benzamide, 2-methoxy-4-[2-(tetrahydropyran-4-ylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenol, 5-(5-methoxy-3-pyridyl)-N-(4-pyridylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, 4-[[5-(3-chloro-4-fluoro-phenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl]amino]cyclohexanol, 4-[2-[[5-(3,4-dimethoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl]amino] ethyl]benzenesulfonamide, 5-(3,4-dimethoxyphenyl)-N-[2-(4-pyridyl)ethyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine, 5-(4-pyridyl)-N-(4-pyridylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, 5-(6-methoxy-3-pyridyl)-N-[2-(4-pyridyl)ethyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine, 4-[2-[[5-(3-pyridyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl]amino]ethyl]benzenesulfonamide, 5-(4-morpholinophenyl)-N-(2-thienylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, [4-[2-[(4-methoxyphenyl)methylamino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]methanol, 5-(4-chlorophenyl)-N-(3-pyridylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, N-[3-[2-[2-(4-pyridyl)ethylamino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl] acetamide, N,N-dimethyl-3-[2-[2-(4-pyridyl)ethylamino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzamide, 2-methoxy-4-[2-[(4-methoxyphenyl)methylamino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenol, 5-(6-methoxy-3-pyridyl)-N-(3-pyridylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, 5-(3-chloro-4-fluoro-phenyl)-N-(2-morpholinoethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, 5-(4-pyridyl)-N-[2-(4-pyridyl)ethyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine, 4-[[5-(6-methoxy-3-pyridyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl]amino]cyclohexanol, 1-[5-[2-(2-morpholinoethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-2-thienyl]ethanone, 5-(4-pyridyl)-N-(2-thienylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, N-[3-[2-(cyclohexylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]methanesulfonamide, 3-[2-(isobutylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzamide, 3-[2-(cyclopropylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzamide, 4-[[5-(3-fluorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl]amino]cyclohexanol, 4-[[5-(3,4-dimethoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl]amino]cyclohexanol, 5-(3-pyridyl)-N-(2-thienylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, 5-(3,4-dimethoxyphenyl)-N-(4-pyridylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, N-cyclohexyl-5-(3-fluorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, N-(2-furylmethyl)-5-(3-pyridyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, N-(2-furylmethyl)-5-(1-methylpyrazol-4-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, 5-(5-methoxy-3-pyridyl)-N-(2-thienylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, 5-(3,4-dimethoxyphenyl)-N-isobutyl-imidazo[2,1-b][1,3,4]thiadiazol-2-amine, 1-[3-[2-(isobutylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl] ethanone, N-benzyl-5-(3-pyridyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, N-benzyl-5-(5-methoxy-3-pyridyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, 5-(3-pyridyl)-N-(tetrahydropyran-4-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, 5-(5-methoxy-3-pyridyl)-N-(tetrahydropyran-4-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, N-[(4-methoxyphenyl)methyl]-5-(5-methoxy-3-pyridyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, N-(o-tolylmethyl)-5-(3-pyridyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, 4-[[5-(5-methoxy-3-pyridyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl]amino]cyclohexanol, 3-[2-(1,3-benzodioxol-5-ylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-N,N-dimethyl-benzamide, and 5-(3,4-dimethoxyphenyl)-N-(tetrahydropyran-4-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine.
 13. A method for inhibiting activity of Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being represented by the structural formula (V):

wherein: R1 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate, and R2 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate.
 14. A method of treating, or slowing progression of, a disease associated with Fyn kinase, said method comprising administering a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being represented by the structural formula (V):

wherein: R1 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate, and R2 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate.
 15. A compound of formula (V) selected from the group consisting of 4-[4-[3-(2-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]phenyl]morpholine, 4-(3-chloro-4-fluoro-phenyl)-3-(2-methoxyphenyl)-1H-pyrazolo [3,4-b]pyridine, 3-(2-methoxyphenyl)-4-(6-methoxy-3-pyridyl)-1H-pyrazolo [3,4-b]pyridine, 3-(2-methoxyphenyl)-4-(2-methoxypyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridine, 4-[3-(3-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-N,N-dimethyl-benzamide, N,N-dimethyl-4-[3-(3-thienyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]benzamide, N-[4-(3-cyclopropyl-1H-pyrazolo [3,4-b]pyridin-4-yl)phenyl]acetamide, 3-[3-(4-pyridyl)-1H-pyrazolo[3,4-b]pyridin-4-yl] aniline, [4-[3-(3-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]phenyl]methanol, 3-(2-methoxyphenyl)-4-(3-thienyl)-1H-pyrazolo[3,4-b]pyridine, N-[4-[3-(3,4,5-trimethoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]phenyl]acetamide, 3-(2-methoxyphenyl)-4-[(E)-styryl]-1H-pyrazolo[3,4-b]pyridine, 4-(3-fluorophenyl)-3-(2-methoxyphenyl)-1H-pyrazolo [3,4-b]pyridine, 4-[3-(2-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]benzamide, [4-(3-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)phenyl]methanol, 3-phenyl-4-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine, 4-(4-isopropylphenyl)-3-(3,4,5-trimethoxyphenyl)-1H-pyrazolo[3,4-b]pyridine, 4-(3-chlorophenyl)-3-cyclopropyl-1H-pyrazolo[3,4-b]pyridine, N-(2-dimethylaminoethyl)-3-[3-(2-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]benzamide, [3-[3-(2-methoxyphenyl)-1H-pyrazolo [3,4-b]pyridin-4-yl]phenyl]methanol, 4-[3-(3-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]benzamide, 4-[3-(4-chlorophenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]benzamide, 3-[3-(3,4,5-trimethoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]phenol, 1-[3-[3-(4-piperidyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]phenyl]ethanone, N-[4-[3-(3-thienyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]phenyl]acetamide, 2-methoxy-4-[3-(4-piperidyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]phenol, N-[3-[3-(3,4,5-trimethoxyphenyl)-1H-pyrazolo [3,4-b]pyridin-4-yl]phenyl]methanesulfonamide, 4-(3-furyl)-3-(2-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridine, 3-[3-(1,3-benzodioxol-5-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]phenol, 4-(3-furyl)-3-(3-pyridyl)-1H-pyrazolo [3,4-b]pyridine, [4-[3-(3,4,5-trimethoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]phenyl]methanol, 4-(3-methoxyphenyl)-3-(4-piperidyl)-1H-pyrazolo [3,4-b]pyridine, 4-[3-(2-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]benzonitrile, N,N-dimethyl-4-[3-(3,4,5-trimethoxyphenyl)-1H-pyrazolo [3,4-b]pyridin-4-yl]benzamide, [4-[3-(1,3-benzodioxol-5-yl)-1H-pyrazolo [3,4-b]pyridin-4-yl]phenyl]methanol, 4-(5-fluoro-2-methoxy-phenyl)-3-(4-piperidyl)-1H-pyrazolo[3,4-b]pyridine, 4-(4-methylsulfonylphenyl)-3-(3,4,5-trimethoxyphenyl)-1H-pyrazolo[3,4-b]pyridine, [4-[3-(3-chlorophenyl)-1H-pyrazolo [3,4-b]pyridin-4-yl]phenyl] methanol, [3-[3-(1,3-benzodioxol-5-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]phenyl]methanol, 4-(3-furyl)-3-phenyl-1H-pyrazolo[3,4-b]pyridine, 4-(6-methoxy-3-pyridyl)-3-(3,4,5-trimethoxyphenyl)-1H-pyrazolo [3,4-b]pyridine, 3-cyclopropyl-4-(2-furyl)-1H-pyrazolo [3,4-b]pyridine, 4-(2-furyl)-3-(2-methoxyphenyl)-1H-pyrazolo [3,4-b]pyridine, [4-[3-(2-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]phenyl]methanol, 1-[3-[3-(2-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]phenyl]ethanone, 4-(3-furyl)-3-(4-pyridyl)-1H-pyrazolo[3,4-b]pyridine, 3-[3-(3-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]aniline, 3-(3-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)benzamide, 3-[3-(3,4,5-trimethoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]aniline, and 4-(3-fluorophenyl)-3-(3,4,5-trimethoxyphenyl)-1H-pyrazolo [3,4-b]pyridine.
 16. A method for inhibiting activity of Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being represented by the structural formula (VI):

wherein: R1 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate, and R2 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate.
 17. A method of treating, or slowing progression of, a disease associated with Fyn kinase, said method comprising administering a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being represented by the structural formula (VI):

wherein: R1 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate, and R2 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate.
 18. A compound of formula (VI) selected from the group consisting of N-(2-methoxyethyl)-3-(3-thienyl)imidazo[1,2-b]pyridazin-6-amine, 3-(3,4-dimethoxyphenyl)-N-(2-methoxyethyl)imidazo[1,2-b]pyridazin-6-amine, 3-(4-fluorophenyl)-N-(2-methoxyethyl)imidazo[1,2-b]pyridazin-6-amine, 4-[6-(2-furylmethylamino)imidazo[1,2-b]pyridazin-3-yl]benzoic acid, N-(2-furylmethyl)-3-(4-methoxyphenyl)imidazo[1,2-b]pyridazin-6-amine, [4-[6-(2-furylmethylamino)imidazo[1,2-b]pyridazin-3-yl]phenyl]methanol, [3-[6-(2-furylmethylamino)imidazo[1,2-b]pyridazin-3-yl]phenyl]methanol, 1-[3-[6-(2-furylmethylamino)imidazo[1,2-b]pyridazin-3-yl]phenyl]ethanone, [4-[6-(2-thienylmethylamino)imidazo[1,2-b]pyridazin-3-yl]phenyl]methanol 3-(4-aminophenyl)-N-(2-thienylmethyl)imidazo[1,2-b]pyridazin-6-amine, 3-(4-fluorophenyl)-N-(2-thienylmethyl)imidazo[1,2-b]pyridazin-6-amine, 3-(3-methoxyphenyl)-N-(2-thienylmethyl)imidazo[1,2-b]pyridazin-6-amine, 1-[3-[6-(2-thienylmethylamino)imidazo[1,2-b]pyridazin-3-yl]phenyl]ethanone, 2-[[3-(3,4,5-trimethoxyphenyl)imidazo[1,2-b]pyridazin-6-yl]amino]butan-1-ol, 2-[[3-(4-methoxyphenyl)imidazo[1,2-b]pyridazin-6-yl]amino]butan-1-ol, 2-[[3-[4-(hydroxymethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]amino]butan-1-ol, 2-[[3-(6-methoxy-3-pyridyl)imidazo[1,2-b]pyridazin-6-yl]amino]butan-1-ol, 2-[[3-(3-methoxyphenyl)imidazo[1,2-b]pyridazin-6-yl]amino]butan-1-ol, [3-[6-[(3-chlorophenyl)methylamino] imidazo[1,2-b]pyridazin-3-yl]phenyl] methanol, 3-(4-aminophenyl)-N-[(3-chlorophenyl)methyl] imidazo[1,2-b]pyridazin-6-amine, [4-[6-[(4-fluorophenyl)methylamino]imidazo[1,2-b]pyridazin-3-yl]phenyl]methanol, N-(1,3-benzodioxol-5-ylmethyl)-3-(4-pyridyl) imidazo[1,2-b]pyridazin-6-amine, 4-[6-(1,3-benzodioxol-5-ylmethylamino)imidazo[1,2-b]pyridazin-3-yl]phenol, 3-(benzofuran-2-yl)-N-(4-pyridylmethyl)imidazo[1,2-b] pyridazin-6-amine, 3-(3-aminophenyl)-N-tetrahydropyran-4-yl-imidazo[1,2-b]pyridazin-6-amine, 3-(3,4-dimethoxyphenyl)-N-tetrahydropyran-4-yl-imidazo[1,2-b]pyridazin-6-amine, N-[3-[6-(tetrahydropyran-4-ylamino)imidazo[1,2-b]pyridazin-3-yl]phenyl]acetamide, N-tetrahydropyran-4-yl-3-(3,4,5-trimethoxyphenyl)imidazo[1,2-b]pyridazin-6-amine, 3-(1H-indol-5-yl)-N-tetrahydropyran-4-yl-imidazo[1,2-b]pyridazin-6-amine, 3-(3-methoxyphenyl)-N-tetrahydropyran-4-yl-imidazo[1,2-b]pyridazin-6-amine, 2-methoxy-4-[6-[(4-methoxyphenyl)methylamino]imidazo[1,2-b]pyridazin-3-yl]phenol, 3-[[3-(1,3-benzodioxol-5-yl)imidazo[1,2-b]pyridazin-6-yl]amino]propan-1-ol, 3-[[3-(1H-indol-5-yl)imidazo[1,2-b]pyridazin-6-yl]amino]propan-1-ol, 3-[[3-[3-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]amino]propan-1-ol, 4-[6-(3-hydroxypropylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methoxy-phenol, 3-[[3-(4-phenoxyphenyl)imidazo[1,2-b]pyridazin-6-yl]amino]propan-1-ol, (2S)-2-[[3-(3-aminophenyl)imidazo[1,2-b]pyridazin-6-yl]amino]-3-methyl-butan-1-ol, (2S)-2-[[3-(1,3-benzodioxol-5-yl)imidazo[1,2-b]pyridazin-6-yl]amino]-3-methyl-butan-1-ol, (2S)-2-[[3-(3,4-dimethoxyphenyl)imidazo[1,2-b]pyridazin-6-yl]amino]-3-methyl-butan-1-ol, N-[3-[6-[[(1S)-1-(hydroxymethyl)-2-methyl-propyl]amino] imidazo[1,2-b]pyridazin-3-yl]phenyl] acetamide, 4-[6-[[(1S)-1-(hydroxymethyl)-2-methyl-propyl]amino]imidazo[1,2-b]pyridazin-3-yl]benzonitrile, (2S)-2-[[3-(4-aminophenyl)imidazo[1,2-b]pyridazin-6-yl]amino]-3-methyl-butan-1-ol, 3-(1,3-benzodioxol-5-yl)-N-(2-pyridylmethyl)imidazo[1,2-b]pyridazin-6-amine, N-(cyclopropylmethyl)-3-(3-methoxyphenyl)imidazo[1,2-b]pyridazin-6-amine, N-(2-furylmethyl)-3-phenyl-imidazo[1,2-b]pyridazin-6-amine, N-(2-furylmethyl)-3-(3,4,5-trimethoxyphenyl)imidazo[1,2-b]pyridazin-6-amine, 3-(3-aminophenyl)-N-(2-thienylmethyl)imidazo[1,2-b]pyridazin-6-amine, N-(2-thienylmethyl)-3-(3,4,5-trimethoxyphenyl)imidazo[1,2-b]pyridazin-6-amine, 3-(4-methoxyphenyl)-N-(2-thienylmethyl)imidazo[1,2-b]pyridazin-6-amine, 3-[6-(2-thienylmethylamino)imidazo[1,2-b]pyridazin-3-yl]phenol, 2-[[3-(2-thienyl)imidazo[1,2-b]pyridazin-6-yl]amino]butan-1-ol, N-[(3-chlorophenyl)methyl]-3-(4-methoxyphenyl)imidazo[1,2-b]pyridazin-6-amine, N-[(3-chlorophenyl)methyl]-3-(6-methoxy-3-pyridyl)imidazo[1,2-b]pyridazin-6-amine, 4-[6-[(3-chlorophenyl)methylamino]imidazo[1,2-b]pyridazin-3-yl]-2-methoxy-phenol, 3-(3-aminophenyl)-N-propyl-imidazo[1,2-b]pyridazin-6-amine, 3-(1,3-benzodioxol-5-yl)-N-propyl-imidazo[1,2-b]pyridazin-6-amine, N-propyl-3-(3-thienyl)imidazo[1,2-b]pyridazin-6-amine, 3-(3,4-dimethoxyphenyl)-N-propyl-imidazo[1,2-b]pyridazin-6-amine, N-[3-[6-(propylamino)imidazo[1,2-b]pyridazin-3-yl]phenyl]acetamide, 4-[6-(propylamino)imidazo[1,2-b]pyridazin-3-yl]benzoic acid, 3-(4-methoxyphenyl)-N-propyl-imidazo[1,2-b]pyridazin-6-amine, 3-[6-(propylamino)imidazo[1,2-b]pyridazin-3-yl]phenol, 3-(3-methoxyphenyl)-N-propyl-imidazo[1,2-b]pyridazin-6-amine, 1-[3-[6-(propylamino)imidazo[1,2-b]pyridazin-3-yl]phenyl]ethanone, 4-[6-[(3,4-dichlorophenyl)methylamino]imidazo[1,2-b]pyridazin-3-yl]benzoic acid, 3-phenyl-N-(4-pyridylmethyl)imidazo[1,2-b]pyridazin-6-amine, 3-(4-aminophenyl)-N-tetrahydropyran-4-yl-imidazo[1,2-b]pyridazin-6-amine, and 4-[6-[(2,4-dimethylphenyl)methylamino]imidazo[1,2-b]pyridazin-3-yl]-2-methoxy-phenol.
 19. A method for inhibiting activity of Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound selected from the group consisting of N-[3-[6-(2-furylmethylamino)pyrazin-2-yl]phenyl]acetamide, 4-[6-[1-(hydroxymethyl)propylamino]pyrazin-2-yl]phenol, 2-[[6-(5-isopropyl-2-methoxy-phenyl)pyrazin-2-yl]amino]butan-1-ol, 6-(3-aminophenyl)-N-benzyl-pyrazin-2-amine, 2-[[6-(4-aminophenyl)pyrazin-2-yl]amino]butan-1-ol, N-[3-(dimethylamino)propyl]-3-[6-(4-methoxyphenyl)pyrazin-2-yl]benzamide, 2-methoxy-4-[6-(4-methoxyphenyl)pyrazin-2-yl]phenol, N-[3-[6-(4-methoxyphenyl)pyrazin-2-yl]phenyl]acetamide, N-[3-[6-(3-hydroxyphenyl)pyrazin-2-yl]phenyl]acetamide, 3-[5-(3-furylmethylamino)-3-pyridyl]phenol, N-[3-[5-(3,4,5-trimethoxyanilino)-3-pyridyl]phenyl] acetamide, 3-[(3-methoxyphenyl)methyl]-5-(3,4,5-trimethoxyphenyl)-1H-imidazo[4,5-b]pyrazin-2-one, N,N-dimethyl-3-[2-oxo-3-[(1 S)-1-phenylethyl]-1H-imidazo[4,5-b]pyrazin-5-yl]benzamide, 5-[3-(dimethylamino)phenyl]-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine, 3-[5-[(6-methoxy-3-pyridyl)amino]pyrazolo [1,5-a]pyrimidin-3-yl]phenol, 3-(3-methoxyphenyl)-N-(6-methoxy-3-pyridyl)pyrazolo [1,5-a]pyrimidin-5-amine, 1-[3-[5-[(6-methoxy-3-pyridyl)amino]pyrazolo[1,5-a]pyrimidin-3-yl]phenyl]ethanone, N-[5-[[3-(3-hydroxyphenyl)pyrazolo[1,5-a]pyrimidin-5-yl]amino]-2-methyl-phenyl]methanesulfonamide, 3-(3,4-dimethoxyphenyl)-N-(3-pyridylmethyl)pyrazolo[1,5-a]pyrimidin-5-amine, N-(3-pyridylmethyl)-3-(3,4,5-trimethoxyphenyl)pyrazolo[1,5-a]pyrimidin-5-amine, N-(4-isopropylphenyl)-3-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-5-amine, 3-(5-methoxy-3-pyridyl)-N-(4-morpholinophenyl)pyrazolo[1,5-a]pyrimidin-5-amine, 3-(3-aminophenyl)-N-(3-pyridylmethyl)pyrazolo [1,5-a]pyrimidin-5-amine, 3-(2-methoxyphenyl)-N-(3-pyridylmethyl)pyrazolo[1,5-a]pyrimidin-5-amine, (E)-3-[3-[5-(3-pyridylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl]phenyl]prop-2-enoic acid, N-[3-(dimethylamino)propyl]-4-[6-(2-fluoro-3-methoxy-phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]benzamide, 6-(1H-indol-5-yl)-N-methyl-pyrazin-2-amine, N-ethyl-2-(3,4,5-trimethoxyanilino)-7,8-dihydro-5H-pyrido [4,3-d]pyrimidine-6-carboxamide, 6-propyl-N-(3,4,5-trimethoxyphenyl)-7,8-dihydro-5H-pyrido [4,3-d]pyrimidin-2-amine, [2-[3-(dimethylamino)anilino]-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl]-(2-methoxyphenyl)methanone, N-[3-(4-fluorophenyl)-6-[4-(morpholine-4-carbonyl)phenyl]imidazo[1,2-a]pyridin-8-yl]formamide, N-[3-(3-acetylphenyl)-6-[4-(morpholine-4-carbonyl)phenyl]imidazo[1,2-a]pyridin-8-yl]formamide, N-[3-(3-chloro-4-fluoro-phenyl)-6-[3-(methanesulfonamido)phenyl]imidazo[1,2-a]pyridin-8-yl]formamide, N-[3-(4-fluorophenyl)-6-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyridin-8-yl] formamide, 1-methyl-N-[4-(4-methylpiperazin-1-yl)phenyl]-2-[3-(trifluoromethyl)phenyl]pyrrolo[3,2-c]pyridin-6-amine, 1-methyl-N-pyrimidin-4-yl-2-[3-(trifluoromethyl)phenyl]pyrrolo[3,2-c]pyridin-6-amine, 2-(3-fluorophenyl)-1-methyl-N-[4-(4-methylpiperazin-1-yl)phenyl]pyrrolo[3,2-c]pyridin-6-amine, 2-(3-fluorophenyl)-1-methyl-N-pyrimidin-4-yl-pyrrolo[3,2-c]pyridin-6-amine, 1-benzyl-N-[4-(4-methylpiperazin-1-yl)phenyl]-2-(3-pyridyl)pyrrolo[3,2-c]pyridin-6-amine, 2-(1H-pyrazol-4-yl)-N-(2-pyridyl)-1H-pyrrolo[3,2-c]pyridin-6-amine, N-(4-methylsulfonylphenyl)-2-(1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridin-6-amine, 1-benzyl-2-(3-pyridyl)-N-pyrimidin-4-yl-pyrrolo[3,2-c]pyridin-6-amine, N-(3-methoxyphenyl)-2-(1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridin-6-amine, N-(3,4-dimethoxyphenyl)-2-(1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridin-6-amine, 1-benzyl-N-[4-(4-methylpiperazin-1-yl)phenyl]-2-phenyl-pyrrolo[3,2-c]pyridin-6-amine, N-[3-[8-acetamido-3-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyridin-6-yl]phenyl] acetamide, N-[3-(3-acetylphenyl)-6-(3-methoxyphenyl)imidazo[1,2-a]pyridin-8-yl]acetamide, N-[3-(3-acetylphenyl)-6-(2,4-dimethoxyphenyl)imidazo[1,2-a]pyridin-8-yl] acetamide, N-[3-(3-acetylphenyl)-6-(2-methoxyphenyl)imidazo[1,2-a]pyridin-8-yl]acetamide, N-[6-(4-aminophenyl)-3-(4-fluorophenyl)imidazo[1,2-a]pyridin-8-yl]acetamide, N-[3-(3-acetylphenyl)-6-[4-(morpholine-4-carbonyl)phenyl] imidazo[1,2-a]pyridin-8-yl] acetamide, N,N-dimethyl-4-[4-[4-(4-methylpiperazin-1-yl)anilino]-1H-pyrrolo[3,2-c]pyridin-2-yl]benzamide, 4-[2-(3,5-dimethoxyphenyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]morpholine, N-[4-[[2-(2-methoxyphenyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]amino]phenyl] acetamide, 2-(2-methoxyphenyl)-1-methyl-N-[3-(trifluoromethyl)phenyl]pyrrolo[3,2-c]pyridin-4-amine, 6-(3-chlorophenyl)-3-(3,4-dimethoxyphenyl)pyrazolo[1,5-a]pyrimidin-7-amine, 5-amino-4-(1H-benzimidazol-2-yl)-1-(1,3-benzodioxol-5-yl)-2H-pyrrol-3-one, 8-(2,5-dimethoxyphenyl)-7-(4-fluorophenyl)-1-methyl-3H-imidazo[1,2-g]purine-2,4-dione, methyl 2-amino-1-(3-hydroxyphenyl)pyrrolo[3,2-b] quinoxaline-3-carboxylate, 2-(3,4-dimethoxyphenyl)-6-hydroxy-chromen-4-one, 2-amino-1-(3-methoxyphenyl)pyrrolo[3,2-b] quinoxaline-3-carboxamide.
 20. A method of treating, or slowing progression of, a disease associated with Fyn kinase, said method comprising administering a therapeutically effective amount of at least one compound of claim 19, or pharmaceutically acceptable salt or solvate of such compound to a patient in need thereof.
 21. A compound capable of inhibiting binding of ATP to Fyn kinase, selected from the group consisting of compounds comprising the pharmacores described in Table
 2. 22. An inhibitor of de-phosphorylation of bound ATP by Fyn kinase, wherein the compound is selected from the group consisting of compounds comprising the pharmacores described in Table
 2. 23. A method for inhibiting activity of Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, wherein the compound is selected from the group consisting of compounds comprising the pharmacores described in Table
 2. 24. A method of ameliorating or preventing a disorder associated with Fyn kinase, said method comprising administering a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, wherein the compound is selected from the group consisting of compounds comprising the pharmacores described in Table
 2. 25. The method of claim 24, wherein the disease associated with Fyn kinase is selected from the group of disorders consisting of Type I diabetes, Type II diabetes, pre-diabetes, breast cancer, prostate cancer, pancreatic cancer, esophageal cancer, gastric cancer, liver cancer, bowel cancer, melanoma, Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease.
 26. A method for ameliorating and improving physiologic functions associated with Fyn kinase, said method comprising administering an effective amount of at least one compound, or pharmaceutically acceptable salt or solvate of the compound to a subject in need thereof, wherein the compound is selected from the group consisting of compounds comprising the pharmacores described in Table
 2. 27. The method of claim 26, wherein the physiologic function associated with Fyn kinase is selected from the group consisting of general weight loss, obesity, lean muscle mass, exercise recovery, stress recovery, and physical endurance.
 28. The method of claim 26, wherein the physiologic function associated with Fyn kinase is selected from the group consisting of improved recovery from head or spinal trauma. 